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Metabolic syndrome is a cluster of risk factors that increases an individual’s risk to 
diabetes and cardiovascular diseases. Given the personal, social and economic 
consequences and the growing impacts of these wide spread chronic diseases, 
sufficient and accurate knowledge around metabolic syndrome plays a key role to 
define effective prevention and intervention programs. Despite many studies having 
been undertaken globally and offering various definitions for metabolic syndrome, 
there is still no general consensus about accurate definitions and their diagnostic 
criteria, in particular among different ethnic groups. Given this gap, we undertook a 
cross-sectional study investigating overall health condition and metabolic syndrome 
risk factors amongst three ethnic groups living in Western Australia as well as the 
effects of ethnicity on metabolic syndrome components.  
 
The study population consisted of adult immigrants with European, Indian and 
Iranian origin who had lived in Australia for at least 5 years, and had an acceptable 
knowledge of written and spoken English. They had also one or more criteria 
including: body mass index (BMI) ≥ 25, waist circumference ≥ 94 cm for males and 
≥ 80 cm for females, blood pressure≥ 130/85 mmHg (or taking medication), 
dyslipidemia (or taking medication) and diabetes mellitus. Participants were 
recruited from the community through different methods. Individuals with major 
systematic illness such as cancer and liver or renal failure, and women who were 
pregnant or lactating were excluded from this study.  
 
After a primary screening, eligible volunteers received overall information about the 
study via phone conversation and email. Participants were also instructed to fast 
overnight between 10-14 hours before attending in out-patient clinic at Curtin 
University for clinical assessment. The variables of interest for the current study 
were anthropometric measurements, fasting blood glucose, fasting insulin, lipid 
profile, hs-CRP; systolic and diastolic blood pressure, and endothelial markers of 
VCAM-1, Adiponectin and E-selectin. The participants’ dietary habits and the level 




To examine the main objectives, data from 97 participants (49 males and 48 females) 
with BMI 29.95±3.8 (kg/m
2
) and aged 46.2±13.7 years were analysed. These 
participants included 35 Europeans (Males: 11, Females: 24), 29 Indians (Males: 16, 
Females: 13) and 33 Iranians (Males: 22, Females, 11), living in Western Australia.  
 
According to the results, the highest overall prevalence of metabolic syndrome was 
shown by IDF definition (32%, Males: 30.6%, Females: 33.3%), followed by ATP 
III (28.9%, Males: 26.5%, Females: 31.3%), WHO (24.7%, Males: 18.4%, Females: 
31.3%)) and EGIR (21.6%, Males: 18.4%, Females: 25%). The WHO definition 
aligns with the metabolic syndrome defined by ATPIII and IDF. In this study, the 
percentage of participants assessed as having metabolic syndrome risk factors by the 
WHO was lower than those with metabolic syndrome based on ATP III guidelines 
and IDF measures (see above); however, the highest percentage of participants with 
insulin resistance was identified by the WHO definition (66.7%).   
 
The results highlighted that the Indian group tended to have the highest total body fat 
percentage among three ethnic groups after adjustment for age and BMI (European: 
36.09±0.7%, Indian: 38.5±0.7%, Iranians: 36.9±0.7%). Similarly, for a given age and 
WC, the Indian group had the highest estimated mean percentage of truncal fat 
compared to two other groups (European: 39.5±1.0 %, Indian: 42.7±1.0 %, Iranian: 
39.5±0.9%).  Also, the results documented that for all ethnicities, in the same BMI, 
men had a lower total body fat, but a higher truncal fat compared to women. The 
results of comparing the adjusted measurements of total and truncal fatness in men 
and women of three ethnic groups suggest that the reference range of BMI and WC 
for detecting metabolic syndrome in both Indian men and women would be lower 
than those in the same gender of two other groups. Also, the cut-off points of BMI 
and WC in European women would be lower than that in Iranians women; however 
higher cut-off points need to be applied for European men compared to Iranian men.   
 
According to the raw data, European and Iranian individuals participating in this 
study had the highest and the lowest mean values of total and truncal fatness, serum 
glucose, insulin and lipids, HOMA and blood pressure, respectively. These results 
were compatible with hs-CRP and E-selectin data analyses, indicating that Europeans 
may be at higher risk of cardiovascular events based on these biomarkers. 
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Subsequently, the initial patterns observed for most risk factors reformed when data 
were adjusted for potential confounders. Namely, Indian participants had the highest 
degrees of total and truncal fatness and insulin resistance (indicated by HOMA), and 
systolic and diastolic blood pressure in new analysis. However, there was no 
difference between the patterns observed for hs-CRP and E-selectin before or after 
adjustment for these variables. It was also found that the degree of associations 
between different cardiovascular risk factors and the biomarkers evaluated vary 
between ethnic groups. This may cause bias in predicting the risk of cardiovascular 
events in populations having a specific risk factor dominantly.  
 
The current study indicated that different components of metabolic syndrome 
including general and central obesity, insulin resistance, dyslipidaemia and 
hypertension as well as serum biomarkers of hs-CRP, E-selectin and adiponectin can 
be affected by ethnicity. These findings support the hypothesis that ethnicity plays a 
significant role in developing metabolic syndrome risk factors. This also suggests 
that biomarkers of cardiovascular diseases may have different levels of accuracy 
across ethnic groups. This important point should be considered when these 
biomarkers are used to compare the risk of cardiovascular diseases among ethnic 











Metabolic syndrome is a cluster of risk factors that increases an individual’s risk to 
diabetes, stroke and cardiovascular diseases that are important subgroups of chronic 
diseases. In turn, chronic diseases are responsible for main proportion of mortality 
and morbidity; and its human and financial related costs over the world. So, 
establishing related prevention programs is vital to decrease personal, social and 
economic consequences of a wide range of chronic diseases such as diabetes and 
cardiovascular diseases. In this way, sufficient and accurate knowledge around 
metabolic syndrome plays a key role to define effective prevention programs 
(Zimmet, McCarty, and de Courten 1997; Bonow and Gheorghiade 2004; Gu et al. 
2005). 
 
Despite many studies having been undertaken globally and providing five definitions 
for metabolic syndrome, there is still no general consensus about accurate definition 
and their diagnosis criteria. The primary research defining metabolic syndrome 
criteria and their cut off points have been mainly conducted in Western countries, 
particularly in Europe. However, the implementation of these criteria in different 
countries showed that they may be inappropriate for other regions (Bonow and 
Gheorghiade 2004; Bhardwaj et al. 2011). Current studies indicate variances not only 
in the criteria and their diagnosis range in different nations but also on the same 
ethnic groups in the different countries (Bonow and Gheorghiade 2004; Bhardwaj et 
al. 2011). These controversies cause more complexities for health care strategists 
particularly in countries receiving emigrants from different countries and ethnic 
groups. This evidence highlights a big gap that needs addressing.  
 
Australia is an immigrant nation with a variety of ethnic groups and cultures that 
come together from five continents over the world. Given the limited comprehensive 
studies regarding to ethnicity and metabolic syndrome in Australia, this condition 
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made the best opportunity for this purpose. The current study was designed to 
evaluate overall health condition and metabolic syndrome risk factors amongst some 
ethnic groups as well as the effects of ethnicity on metabolic syndrome in Australia.  
 
Given the importance of the personal and financial consequences of metabolic 
syndrome risk factors, the results of the study reveal important facts in regards to 
metabolic syndrome and also assist scientists and health strategists to define more 




Ethnicity plays a significant role in developing metabolic syndrome components 
including general and central obesity, hypertension, dyslipidaemia, high blood 




The main objective of this study was to investigate the effects of ethnicity on 
metabolic syndrome risk factors in overweight and obese subjects. The aim was to 
clarify whether ethnicity may be a major factor responsible for the overall health 




1. To compare metabolic syndrome criteria among a cross-section of immigrants 
from three ethnic groups in Western Australia using four common 
international definitions of metabolic syndrome 
2. To describe the effects of ethnicity on the endothelial dysfunction in the 
ethnic groups under study,  
3. To investigate the impact of diet on metabolic syndrome among the three 
ethnic groups,  
4. To explore the correlation between adiponectin and different components of 




This thesis consists of six chapters. After the introduction, the second chapter 
presents a literature review addressing different aspects involved in the metabolic 
syndrome. The chapter provides information on the results of previous studies 
investigating the impact of ethnicity on cardiovascular diseases and metabolic 
syndrome components. Chapter three provides an overview of the research methods 
used to test the hypothesis and address the objectives. The fourth chapter presents the 
results of this study. The findings of the study are discussed in chapter five. And, the 
final chapter presents an overall summary of the research, the significance of the 







2.1 Chronic diseases 
 
Chronic disease is irreversible, progressive and accrual illness leading to future 
functional impairment or disability. It is generally specified by a prolonged course of 
illness with complex and unknown aetiology and various risk factors; and a long 
latency period (Bull et al. 2004). Almost all international health organizations and 
institutes linked to public health such as World Health Organization use this term to 
encompass disease and disorders including:  
 
 Cardiovascular diseases  like heart disease, stroke and hypertension;  
 Diabetes and its complications such as kidney diseases;  
 Cancers;  
 Chronic lung diseases;  
 Chronic musculoskeletal disease eg Arthritis; and Chronic neurological 
disorders (Prevention 2009).  
 
2.1.1 Worldwide prevalence of chronic disease 
Chronic diseases make up a large proportion of non-communicable diseases (NCDs)  
and its prevalence has now reached to epidemic proportions worldwide causing more 
than 36 million deaths (63% of global deaths) in 2008 (WHO 2011c) and are 
projected to reach 52 million in 2030 (WHO 2013). Over 50% of NCDs deaths were 
caused by cardiovascular disease (17 million deaths) and diabetes (1.3 million 
deaths). More than 25% of these deaths occurred below 60 years which were mostly 
preventable. Premature death from non-communicable diseases were responsible for 
22% and 35% of men and women mortality in low-income countries, comparing to 
the 8% and 10% among men and women in high-income courtiers respectively 




2.1.2 Prevalence of chronic diseases in Australia 
According to a national survey carried in 2005, among the variety of chronic 
diseases, 30% of respondents had cardiovascular problems including uncomplicated 
hypertension and ischemic heart disease and 8.3% suffered from diabetes with a type 
2 dominancy (Knox et al. 2008). In 2011, 21513 Australians died of coronary heart 
diseases representing more than one fifth of all deaths in Australia and it still remains 
the most important cause of death in this country (Australian Institute of Health and 
Welfare 2014). Reports released by the Australian Bureau Statistics (ABS) indicate 
that CVD had the most contribution to the burden of disease in Australia after cancer 
in 2007 (Australian Bureau of Statistics 2010). 
 
2.2 Metabolic syndrome  
Insulin resistance has been suggested as the most important aetiology of diabetes 
mellitus and cardiovascular diseases (Reaven 1988). It is established that the health 
consequences of insulin resistance are more dangerous when it is accompanied with 
a cluster of its associated metabolic disorders including obesity, hyperglycaemia, 
hyperlipidaemia, hypertension and proteinuria, now known as “metabolic 
syndrome”. In the other words, the term of metabolic syndrome, described also with 
other names such as insulin resistance syndrome, cardiometabolic syndrome, 
dysmetabolic syndrome and syndrome X (Govindarajan et al. 2005; Onat et al. 2007; 
Gautier et al. 2010), refers to a collection of metabolic disorders associated with 
insulin resistance syndrome (Grundy 2004a).     
 
2.2.1 Current definitions and position statement for metabolic syndrome 
There are four global definitions for metabolic syndrome. In all definitions except 
one, providers have defined a core component as well as a collection of other minor 
variables. The American Association of Clinical Endocrinologist has also issued a 
position statement which modifies other definitions according to the clinical 




2.2.1.1 World Health Organization (WHO) Definition 
According to the first definition provided by World Health Organization in 1998, 
Diabetes, impaired glucose tolerance or insulin resistance are mentioned as one of 
the fixed components marking metabolic syndrome for individuals (Table 1). Also, 
adiposity index with waist hip ratio >0.9  for male and 0.85 for female or obesity 
with Body Mass Index (BMI) more than 30 kg/m
2
 has been defined as one of the 
variable criteria. Additionally, the measurement for dyslipidaemia, as the second 
variable criterion, followed by triglycerides (TG) ≥1.69 mmol/L and /or high-density 
lipoprotein cholesterol (HDL-C) <0.90 mmol/L for men and <1.01 mmol/L for 
women.  
 
Hypertension, like diabetes, is both a disease and risk factor and is measured by 
Systolic Blood Pressure (SBP) ≥140 mmHg and Diastolic Blood Pressure (DBP) ≥90 
mmHg indicating another criterion for metabolic syndrome. Excretion of albumin in 
urine (microalbuminuria) by ≥2.5mg/mmol creatinine for men and ≥3.5mg/mmol 
creatinine for women is the last variable component mentioned in WHO’s definition. 
To be labelled metabolic syndrome, one of the fixed components and at least two 
variable criteria should be linked together (World Health Organization 1999). 
 
Table 1: The clinical criteria for metabolic syndrome defined by WHO  
 
Insulin resistance identified by one of the following 
 Type 2 diabetes 
 Impaired fasting glucose (IFG) 
 Impaired glucose tolerance (IGT) 
Or for those with normal fasting glucose levels (110 mg/dL), glucose uptake 
below the lowest quartile for background population under investigation 
under hyperinsulinemia, euglycemic conditions 
Plus any two of the following factors: 
 BMI > 30kg/m2 and/or Waist: Hip ratio > 0.9 in males & >0.85 in females 
 Antihypertensive medication and/or high blood pressure (≥140 mmHg 
systolic or ≥ 90mmHg diastolic) 
 Triglycerides ≥ 150mg/dL 
 HDL cholesterol < 35 mg/dL in males & < 39 mg/dL in females 




2.2.1.2 European Group for the Study of Insulin Resistance (EGIR) Definition 
At the same time, the EGIR suggested a new definition of metabolic syndrome that 
cases need two or more criteria including central obesity, dyslipidaemia, 
hypertension and blood pressure as well as insulin resistance or hyperinsulinemia in 
only non-diabetic subjects. Central obesity has been determined by waist 
circumference ≥94cm for male and ≥80cm for female in current classification. Also 
dyslipidaemia is considered by TG>2mmlo/L or HDL-C<1mmol/L, and like WHO’s 
definition, hypertension is defined by BP ≥140/90mmHg. Since, insulin resistance 
plays a key role in this definition; fasting blood glucose ≥ 6.1mmol/L is counted as 
another minor criterion. The same as WHO’s definition, a combination of at least 
two changeable components is necessary for diagnosis of metabolic syndrome 
(Balkau et al. 2002). 
 







2.2.1.3 National Cholesterol Education Program-Adult Treatment Panel III 
(ATP III) Definition 
Scientists found that LDL plays a significant role in Coronary Heart Disease (CHD) 
compared to other components (Hulthe and Fagerberg 2002). Also, other clinical 
findings reveal significant co-relation between treatment of high levels of LDL and 
reducing CHD incidence (Austin et al. 1988). So, they modified the criteria for 
metabolic syndrome and have announced a third world-wide definition for it by 
reducing the diagnostic threshold of the WHO definition for certain criteria like 
HDL-C and hypertension. According to the new definition, central obesity has been 
defined by waist circumference >102 cm for male and >88cm for females.  
 
Although, hyperinsulinemia and insulin resistance have been removed for the new 
classification, comparisons of both to previous definitions; and fasting plasma 
glucose level remained the same. With the strict strategy in reducing the diagnostic 
threshold of the WHO definition, triglyceride level ≥ 1.7 mmol/L for both gender; 
and low HDL-C <1.03 mmol/L and <1.29 mmol/L for male and female respectively 
have been agreed for dyslipidaemia criteria. In addition, metabolic syndrome is 
marked when three or more of five components that exist together in cases (Expert 
Panel on Detection and Treatment of High Blood Cholesterol in 2001).The following 
are the details of criteria suggested for clinical diagnosis of metabolic syndrome 
[Table 2]. 
 
2.2.1.4 American Association of Clinical Endocrinologist (AACE) Definition 
Clinicians as first contact line to individuals and patients have been faced with 
unclear points and questions around diagnosis and treatment (Alberti, Zimmet, and 
Shaw 2006). Their most important questions are categorized in below:  
 Is there any proof for treatment of the insulin resistance beyond treating 
individual components, e.g. dyslipidaemia and high blood pressure?  
 Should the cut point for treatment of individual component be lesser while 
they are known as insulin resistance cases?  
 Would treatment approaches for individual components be different when 




Therefore, the AACE to ensure consistency among endocrinologists, proposed 
solutions offering a means of understanding insulin resistance and feasible clinical 
attitude to recognize and deal with persons at risk by reviewing experts’ experience 
and opinion. AACE eventually submitted definite differences to diagnose individuals 
with insulin resistance. Also, in parallel, they accepted the blood pressure and lipid 
criteria according to the ATP III guidelines. These summarized differences are as 
follows: 
 
1. The Insulin Resistance Syndrome refers to a collection of metabolic disorders 
occurring mainly in individuals with hyperinsulinemia or insulin resistance. 
2. Insulin resistance syndrome is different to diabetes. 
3. While, BMI and WC are accepted as indices of obesity, they must be defined 
specifically in different ethnic groups.  
4. Ethnicity is known as an important risk factor for insulin resistance and some 
non-Caucasian ancestries (e.g., Latino/ Hispanic American, African American, 
Native American, Asian American, Pacific Islander) are at higher risk of the 
Insulin Resistance Syndrome.    
5. Other factors including hypertension, family history of diabetes type 2, CVD and 
a history of CVD, gestational diabetes, polycystic ovarian syndrome and 
acanthosis nigricans have been accepted that enhance the risk of developing the 
insulin resistance syndrome. 
6. Individuals with diabetes type 2 usually are diagnosed by fasting blood glucose 
concentration; however the glucose level in plasma two hours after 75 gram oral 
glucose load is recognized as a more reliable test of risk for insulin resistance 
syndrome.  
 
Given the mentioned process, unlike the three early definitions, the AACE 
intentionally provided a position statement instead of specific new definition for 
metabolic syndrome in order to rely on clinical judgment for diagnosis and treatment 
(Einhorn et al. 2003). 
 
2.2.1.5 International Diabetes Federation (IDF) Definition 
Experts in International Diabetes Federation (IDF) produced a new definition based 
on the essence of the ATP III definition. They defined waist circumference as an 
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index for adiposity according to ethnicity, instead of a general measurement for all 
populations [Table 3]; and changed fasting glucose by ≥5.6 mmol/L. Other criteria 
like abnormal high blood pressure and triglycerides have remained the same at ≥ 
130/85 mmHg and ≥ 1.7 mmol/L, respectively. Also,  high-density lipoprotein 
cholesterol (HDL-C) was determined by <1.03 mmol/L for men and < 1.29 mmol/L 
for women (Alberti, Zimmet, and Shaw 2006).   
 
 
Table 3: Waist Circumference values according to Ethnicity/Country using in IDF definition 
for metabolic Syndrome  






















South & Central Americans  Using South Asian data till specific data 
Sub-Saharan Africans  Using European data till specific data 






2.2.2 Prevalence of metabolic syndrome 
2.2.2.1 Worldwide prevalence of metabolic syndrome 
A large number of studies carried out across the five continents, tried to define 
prevalence of metabolic syndrome particularly during last decade. Some of them 
have been done by Cameron et al. (2007) in Australia, Balasubramanyam et al. 
(2008), Ford et al. (2002), Lin et al. (2007) and Karve et al. (2010) in United States, 
Hu et al. (2004) in Finland, Okafor (2012) in Africa and Gupta et al. (2004) in India.  
 
The majority of early studies applied National Cholesterol Education Program 
(NCEP ATPIII) definition, mentioned in section 2.2.1.3, however later research 
focused mainly on IDF definition or a comparison to other current criteria. The 
prevalence of metabolic syndrome is high worldwide (International Diabetes 
Federation 2006); however its rates vary, because of different definitions and criteria 
being administrated (Cameron et al. 2007). In-addition, a rising trend in prevalence 
of metabolic syndrome is reported by several studies (James et al. 2004; Beltran-
Sanchez et al. 2013). Likewise, studies indicate a parallel increase in prevalence of 
obesity confirming strong correlation between metabolic syndrome and obesity as its 
important driver(Alberti, Zimmet, and Shaw 2006).  
 
In other words, while direct estimation for prevalence of metabolic syndrome is 
limited due to the necessary significant clinical work,  obesity may, as a  simpler 
criterion, be used as a reliable estimation for metabolic syndrome prevalence (Park et 
al. 2003; Daniels et al. 2005; Grundy et al. 2005; Bray and Bellanger 2006; Hossain, 
Kawar, and El Nahas 2007; Grundy 2008). According to a study undertaken in the 
US, one fourth of the population in the United States met the criteria for metabolic 
syndrome diagnosis. Also, the results show the prevalence of metabolic syndrome 
has been increased from 27.9% to 34.1% between 1994 and 2006 (Mozumdar and 
Liguori 2011). This trend has been confirmed with similar results presented by other 
studies carried out in other countries (Ford, Giles, and Mokdad 2004; Esteghamati et 
al. 2010)  
 
2.2.2.2 Prevalence of metabolic syndrome in Australia 
One of the first population based studies to determine the prevalence of metabolic 
syndrome in Australia revealed the prevalence of metabolic syndrome using IDF 
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definition was 30.7% (27.1-34.3). This rate was 21.7% (19.0-24.3), 22.1% (18.8-
25.4), and 13.4% (11.8-14.9) when the data was adjusted to the WHO, ATPIII and 
EGIR criteria for metabolic syndrome, respectively (Cameron et al. 2007). Although, 
the prevalence rates are different due to specification of current definitions, the 
results indicate significant rise in the prevalence of metabolic syndrome in Australia 
as a more important point.  
 
Based on IDF criteria, 30% of Australians aged 25 and over are known as metabolic 
syndrome cases (Cameron et al. 2007). Moreover, in the all definitions, the 
prevalence of metabolic syndrome increased with rising age in both genders, 
however it was clearly higher among men than women in the oldest age category. 
Namely, the prevalence of metabolic syndrome according to the WHO, ATPIII, 
EGIR and IDF among males and females were 25.4% versus 18.2%, 24.4% versus 
19.9%, 15.6% versus 11.3% and 34.4% versus 27.2% (P<0.001) respectively. In 
addition, the study documented that participants had been diagnosed as Insulin 
resistant cases by 50.9%, 56.1%, 69.7% and 91.1% on the basis of IDF, ATPIII, 
WHO and EGIR definitions (Cameron et al. 2007).  
 
2.2.3 Components of metabolic syndrome 
2.2.3.1 Insulin resistance or hyperinsulinemia 
According to definitions and guidelines for metabolic syndrome, insulin resistance is 
a condition in which insulin is produced more than normal, but it does not work 
properly in the body. Several studies indicate that insulin resistance develops into 
type 2 diabetes in individuals who have been involved with it for more than 10 years 
(Lillioja et al. 1988; Warram et al. 1990; Shulman 2000). Moreover, according to 
consistent findings it has been known as the best indicator to predict whether or not a 
person will become a diabetic in the future (DeFronzo 1988; Haffner et al. 1990; 
Bonora et al. 2004; Kumashiro et al. 2011).  
 
2.2.3.1.1 Prevalence of insulin resistance 
Despite useful research around insulin resistance, lack of comprehensive statistical 
data, probably due to diagnosis of insulin resistance which usually is secondary to 
other disorders like hypertension and hyperglycaemia, still remains (Bonora et al. 
1998). According to several worldwide studies, presenting a powerful correlation 
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between insulin resistance and the numerous components of metabolic syndrome, 
prevalence of insulin resistance reportedly, ranges from 3-16% for white populations, 
while Japanese ethnicity received a rate of less 2% in comparison  to the whites 
(Olatunbosun and Schade 2002). 
 
2.2.3.1.2 Pathophysiology of insulin resistance 
Insulin, as the fundamental anabolic hormone, is produced by the β cells in pancreas 
and plays an important role in growth, tissue developments as well as promotes 
glucose uptake into cells. Insulin is secreted when plasma glucose rises after a meal 
and maintains glucose homeostasis in numerous tissues (Shulman 2000; Sesti 2006). 
The severity of responses to insulin stimulation for glucose uptake along with the 
applied compensation methods for hyperglycaemia by individuals are two important 
factors playing a key role in insulin resistance’s regulations and developing 
associated diseases in future.  
 
Several studies suggest defects in pancreatic β cells results in inadequate 
compensatory secretion of insulin to combat the decreased tissue sensitivity, and thus 
leading to development of non-insulin dependent diabetes mellitus (NIDDM) among 
insulin–resistance subjects. However, evidences indicate that the combination of 
insulin resistance and hyperinsulinemia compensatory makes a vicious cycle which 
eventually predisposes conditions to develop some diseases and disorders like 
hypertension, several amounts of increase in glucose tolerance as well as increasing 
in triglycerides, a decrease in high density lipoprotein cholesterol (HDL-C), smaller 
denser low-density lipoprotein (LDL-C), and higher concentration of plasminogen 
activator inhibitor 1 (PAI-1) (Reaven 2011). Other than pancreatic β cells, there are 
also three major sites involved in maintenance of glucose homeostasis including 
muscles, adipose tissue and liver. 
 
A. Pathophysiology of insulin resistance in muscles 
Skeletal muscle is the major site of glucose disposal. After glucose is entered into the 
cells, it is transformed to glucose-6-phosphate by hexokinase II. Subsequently, about 
20-25% of all glucose-6-phosphate is directed to the glycolysis pathway, while the 
remaining 75-80 % is converted to glycogen. The process of glycogen synthesis 
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which is regulated by the enzyme glycogen synthase occurs mainly in the skeletal 
muscles (DeFronzo and Tripathy 2009). In the pathogenesis of type 2 diabetes 
mellitus, impaired glycogen synthesis in muscle has been demonstrated as the main 
and initial detected defect accounting for insulin resistance (DeFronzo 2004). It is 
known that insulin plays key roles not only in the glucose transport system but also 
in different enzymatic steps involved in glucose disposal mechanisms. As a result, 
any defect in systems contributing to the entrance of glucose into the muscle cells, its 
phosphorylation, or glycogen synthesis may have a role in developing insulin 
resistance and the subsequent hyperglycaemia.   
 
Although, exclusive mechanisms underlying these alternations have not been 
completely elucidated yet, evidence indicates that increased levels of plasma fatty 
acids has a key role in this regard (Roden 2004). Several specific mechnisms have 
been proposed to be involved in fatty acids-induced muscle insulin resistance, such 
as Randle cycle, inhibition of insulin signalling pathway, alternation in gene 
expression, increase in ROS, inflammation and mitochondrial dysfunction (Martins 
et al. 2012). Investigators employing nuclear magnetic resonance (NMR) 
spectroscopy technique suggested that saturated fatty acids may induce skeletal 
muscle insulin resistance through inhibiting glucose transportation or hexokinase II 













Figure 2: Proposed alternative mechanism for fatty acid–induced insulin resistance in 
human skeletal muscle (Shulman 2000) 
 
Figure 2 shows another proposed mechanism for fatty acid-induced insulin 
resistance. In this process, intracellular fatty acid metabolites such as diacylglycerol, 
fatty acyl CoA and ceramides are increased due to increasing delivery of fatty acids 
to the muscles or a decreasing in intracellular fatty acid metabolism. Then, 
metabolites activate a cascade of seine/threonine kinase on insulin receptors 1 and 2 
(IRS1 and IRS 2) which eventually reduces the capability of the insulin receptor 
substrates to active PI 3-kinase. Subsequently, it reduces glucose transport activity 
and inhibits insulin signalling (Shulman 2000; Sesti 2006; Martins et al. 2012).  
 
Primarily, scientists suggested the failure in insulin-stimulating is limited to NIDDM 
cases, however later studies presented this defect involves both diabetics and normal 
individuals (Sesti 2006; Kumashiro et al. 2011).  
 
B. Pathophysiology of insulin resistance in adipose tissue  
As discussed above, increased levels of plasma FFA impairs action of insulin in the 
main insulin-target tissues. Given that adipose tissue is the primary source of plasma 
FFA, it has been considered as a major mediator of insulin resistance (Ruan and 
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Lodish 2003). Insulin is the main hormone in the body regulating systemic energy 
homeostasis by enhancing overall energy storage and suppressing energy 
mobilisation. Insulin plays its role in adipose tissue, through increasing glucose 
uptake, glycogen synthesis, fatty acid synthesis and de novo triglyceride synthesis, 
but reducing the release of FFA, in part by suppressing hormone- sensitive lipase 
activity (Belfrage et al. 1985; Chen et al. 1987; Stralfors and Honnor 1989; Ruan and 
Lodish 2003). In addition, insulin promotes lipoprotein lipase activity in adipose 
tissue, resulting in increasing the clearance of triglyceride-rich lipoproteins from 
plasma (Sadur and Eckel 1982). Accordingly, in the presence of adipose tissue 
insulin resistance, other tissues become exposed to increased levels of glucose and 
FFA.          
 
Adipose tissue has been shown to secret a variety of factors, such as tumour necrosis 
factor-α (TNF- α), leptin, IL-6, adipocyte complement related protein of 30kDa 
(Acrp 30, adiponectin) and resistance contributing to the pathogenesis of obesity-
associated insulin resistance. These adipose tissues-derived factors have been 
indicated to induce systemic insulin resistance in part by stimulating lipolysis in 
adipocytes resulting in increased FFA release (Ruan and Lodish 2003).  
   
Independent of overall adiposity, abdominal or visceral adipose tissue (VAT) has a 
significant role to develop insulin resistance (Kelley et al. 2000b). Whereas, the thigh 
subcutaneous adipose tissue (TSAT) plays a different role compare to visceral 
adipose tissue as it has protective and more favourable inflammation profile in 
metabolic syndrome (Koster et al. 2010; Amati et al. 2012). As it shown in Figure 3, 
the subjects with high VAT have a negative correlation with insulin sensitivity 
compare to others with low amount of VAT (Koster et al. 2010). 
 
Also, several experimental confirmed that the visceral adiposity is significant 
correlated with higher cytokines and inflammatory markers like IL-6, CRP and PAI-
1 leads to a  unhealthy metabolic condition in obese individuals (Karelis et al. 2005; 
Kintscher et al. 2008; Koster et al. 2010; Amati et al. 2012). In addition, infiltration 
of pro-inflammatory T-lymphocytes in visceral adiposity tissues after 5 days high fat 
diet highlighted that it may contributes in local inflammatory cell activation and 






Figure 3: Insulin sensitivity (Rd) distribution by phenotype group. Box plots and means (Black 
Square). LBM, Lean Body Mass; Rd, Glucose Disposal; TSAT, Thigh Subcutaneous Adipose Tissue 
and VAT, Visceral Adipose Tissue (Koster et al. 2010) 
 
C. Pathophysiology of insulin resistance in liver  
 
Despite extensive evidence indicating the liver as a major organ involved in systemic 
insulin- resistance, underling mechanisms are less clear. As mentioned in previous 
section, insulin plays an essential role in regulating systemic energy homeostasis 
through promoting overall energy storage and reducing energy mobilisation. Insulin 
fulfils its role in the liver by inhibition of gluconeogenesis and glycogenolysis, as 
well as by stimulating glycogen synthesis, resulting in an overall decrease in hepatic 
glucose production (Ruan and Lodish 2003; Rui 2014). Accordingly, hyperglycaemia 
as the major consequence of insulin resistance can occurs mainly due to the failure of 
insulin to reduce hepatic glucose production.  
 
According to several studies, FFAs have been also implicated as a significant 
contributing cause of hepatic insulin resistance. At early stage, Williamson and et al 
in 1966 presented promotion of gluconeogenesis due to increasing FFAs 
concentration in rat liver (Williamson, Kreisberg, and Felts 1966). It has been then 
shown that excess plasma FFA enhances substrate availability for hepatic 
triglyceride synthesis and gluconeogenesis, resulting in increased triglyceride-rich 
lipoproteins, such as VLDL, and hepatic glucose production (Staehr et al. 2003; 
Nagle, Klett, and Coleman 2009; Rui 2014).    
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2.2.3.2 Diabetes Mellitus 
Diabetes Mellitus (DM) is a chronic metabolic disease characterized by prolonged 
hyperglycaemia secondary to insulin resistance or failure in insulin secretion or both 
of the conditions. Diagnosis of diabetes usually is accompanied with high blood 
glucose concentration with or without symptoms experienced by individuals who 
have advanced diabetes like excessive thirst, polyuria, hunger, lethargy and weight 
loss (in type 1), particularly in early stages. However, the pathological and functional 
damages to various organs mostly are happened in the silent progress period of 
diabetes mellitus before its clinical diagnosis (Alberti and Zimmet 1998b; WHO 
1999). 
 
2.2.3.2.1 Prevalence of diabetes mellitus 
Prevalence of diabetes is rising dramatically over the world. The early estimations 
projected that the prevalence of diabetes will increase from 4% to 5.4% between 
1995 and 2025. This involves eventually 300 million people compare to 135 million 
at the start point of this period. The higher increase in the number of people with 
diabetes is predicted to be in developing countries by 170% (from 84 to 228 million), 
compare to a 42% increase (from 51 to 72 million) occurring in developed countries 
(King, Aubert, and Herman 1998).  
 
The number of diabetic cases increased from 153 million in 1980 to 347 million in 
2008 over the world (Danaei et al. 2011). In addition, WHO has estimated diabetes 
will be the 7th leading cause of death in 2030 (WHO 2011a). On the other hand, 
recent analysis considered 133 studies from 91 countries and revealed the increasing 
speed of prevalence of diabetes is much faster than early estimations. According to 
the analysis, the world prevalence of diabetes and the number of affected people 
aged more than 20 will increase from 6.4% by 285 million in 2010, to 7.7% and 439 
million in 2030 respectively (Shaw, Sicree, and Zimmet 2010).  
 
Australian Diabetes, Obesity and Lifestyle Study (AusDiab) as a population-based 
survey has been conducted on a national sample population of 11247 Australian 
adults including a range of normal, overweight and obese participants between 1999 
and 2000. According to the AusDiab carried out by blood taking, the prevalence of 
diabetes has been estimated at 7.4% among adults aged more than 25 (Dunstan et al. 
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2001). Moreover, there was an accelerated trend in prevalence of diabetes between 
1995 and 2008, with Australians self-reporting in a National Health Survey (NHS), 
which was conducted by the Australian Bureau Statistics (ABS) in 2006. Data 
indicate that the number of population diagnosed as diabetic, using clinical methods, 
significantly increased from 2.4% to 4.0% during 12 years(ABS 2006; Australian 
Institute of Health and Welfare 2011).    
 
2.2.3.2.2 Pathophysiology of diabetes mellitus 
Diabetes is classified into two major categories. The early classification divided 
diabetes to Insulin Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent 
Diabetes Mellitus (NIDDM). However, latest grouping replaced this style to Type 1 
and Type 2, which were closer to IDDM and NIDDM respectively, since the primary 
nomination was confusing and diabetes needs to be treated by external insulin in 
different stages(World Health Organization 1980, 1985).  
 
A. Type 1 
The term Type 1 diabetes mellitus is used to describe hyperglycaemia at diagnostic 
level which results from destruction of pancreatic islet beta-cell. In this type of 
diabetes, beta-cell destruction may be due to an autoimmune mediated process, 
identified by presence of anti-glutamic acid decarboxylase, islet cell or insulin 
antibodies, or an unknown aetiology. It does not include other forms of β cell 
destruction or failure arising from unknown specific causes, such as mitochondrial 
defects and cystic fibrosis. Type 1 diabetes, named juvenile-onset diabetes in primary 
classification, may present at any age, from childhood to the latest decades of life; 
however the peak of incidence is during childhood and adolescence (Molbak et al. 
1994). Some individuals with type 1 diabetes are metabolically normal before 
presenting with a disease. However, as a result of the β cell destruction process, they 
eventually become dependent on insulin for survival and prevention of 
hyperglycaemia and its consequences like ketoacidosis, with a relatively different 
rate and level of destruction of the  cells in the pancreas.  
 
This rate represents the rapid or slow progress and a range of narrow to extensive 
destruction signifies the level of damage of  cells. The rapidly progressive form 
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mainly occurs in children and adolescence with autoimmune diabetes mellitus 
(World Health Organization 1999). In these patients, ketoacidosis may the first sign 
of disease, however in others, particularly adults; remaining normal β cells are 
usually adequate to prevent ketoacidosis for many years (Zimmet 1995). Although, 
diabetic patients categorised in type 1 are not usually obese, obesity may be 
presented in this type as well. 
 
B. Type 2 
Type 2 is a multifactorial and multi-organ disorder characterised mainly by insulin 
resistance in the liver and peripheral tissues, β cell dysfunction; and accompanied 
with elevated concentration of free fatty acids and inflammatory mediators (Zinman 
2011). It also is the most prevalent form of diabetes mellitus. In addition, the β cell 
dysfunction eventually also results in a relative lack of insulin. Patients in this 
category do not usually need to be treated by insulin, at least not in the initial phase; 
rather  it is linked to defective insulin action or insulin resistance (Alberti and 
Zimmet 1998b). Accordingly, in some type 2 diabetic patients may have a normal or 
even elevated insulin circulatory level. 
 
In contrast to type 1, type 2 diabetes mellitus has a more insidious onset, and the 
metabolic changes, (including hyperglycaemia) may not be sufficiently exaggerated 
level to cause the more obvious symptom and signs. Also, they usually do not 
experienced ketoacidosis other than under severe hyperglycaemia, or under the 
exacerbating influence of acute infection, trauma or similar stressful situation 
(Banerji et al. 1994; Umpierrez et al. 1995; Smiley, Chandra, and Umpierrez 2011). 
As a result, patients with type 2 diabetes may develop chronic consequences of 
hyperglycaemia silently for many years before identification (Harris 1993; Mooy et 
al. 1995). This type of diabetes is mainly linked to overweight and obesity, in 
particular central obesity. It has been suggested that central fat deposition is an 
important contributing or aggravating factor for insulin resistance (Kissebah et al. 






C. Gestational diabetes 
Gestational diabetes is defined as severity of glucose intolerance first arising or 
diagnosed during (American Diabetes Association 2006). Women with diabetes 
mellitus onset before pregnancy are not categorised in this classification. Diabetic 
patients in this group should continue their treatment during pregnancy like before. 
Although, the worldwide prevalence of gestational diabetes is unclear, emerging 
evidence suggest an increased frequency affecting 1% to 14% of all pregnancies in 
United States depending on the particular population in question (Jovanovic and 
Pettitt 2001).  A standard diagnostic tool, Oral Glucose Tolerance Test (OGTT) is 
used for diagnosis of gestational diabetes performed typically between weeks of 24 
and 28 of pregnancy. However, they are advised to have additional follow-up  by 
undertaking an OGTT six weeks after deliver (Alberti and Zimmet 1998b; Madarász 
et al. 2009). 
 
D. Other specific types 
Other specific types of diabetes mellitus mainly refer to some genetics and metabolic 
disorder with variety of aetiology. These diseases and disorders are classified in 
below briefly. 
 Genetic defects of β cell function 
 Genetic failure in insulin action  
 Chemical induced diabetes due to cross-hormonal influence with some agents 
such as  glucocorticoids  
 Diabetes due to some infections such as mumps and congenital rubella 
 Defects due to some endocrinopathies such as Pheochromocytoma and 
Cushing syndrome  
 Diseases due to exocrine pancreas including infection and pancreatic 
carcinoma (Pak et al. 1988; Taylor 1992; Fabris et al. 1992; Assan et al. 
1995; Byrne et al. 1996; Clement et al. 1996; Esposti, Ngo, and Myers 1996).  
 
Although, all types of diabetes mellitus are considerable by themselves, this thesis is 
focusing on type 2 diabetes mellitus because of its prevalence and effect on 




2.2.3.2.3 Diagnosis of diabetes mellitus 
Diagnosis of diabetes mellitus is commonly based on three different laboratory 
approaches; importantly and as indicated previously some individuals may have not 
any symptoms and signs during physical examination. These methods include fasting 
blood glucose, random blood glucose and oral glucose tolerance test (OGTT) to 
determine the extent of hyperglycaemia which mainly categorised to the milder 
forms of impaired fasting tolerance (IFG) or impaired glucose tolerance (IGT) and 
diabetes mellitus (Seino et al. 2010). Moreover, to measure blood glucose 
concentration, samples may be taken from venous plasma, venous whole blood or 
capillary whole blood. However, the extent of hyperglycaemia is defined by different 
level of glucose concentration in each laboratory method [Table 4]. 
 
Since, accurate and early diagnosis play a vital role in  preventing life-long 
consequences of diabetes mellitus, it is very important to prevent mismeasurement 
and misdiagnosis which may happen in some provisional hyperglycaemias due to 
surgery, trauma, infection and other similar stressful condition. In this way, fasting 
plasma glucose (FPG) and 2-h OGTT are known as the more reliable diagnosis test 








Table 4: Values for diagnosis of diabetes mellitus and other specific classification of 
hyperglycaemia (Alberti and Zimmet 1998b) 
 
 Glucose concentration, mmol/l (mg/dl) 
             Whole blood Plasma 













2-h post glucose load 
or both 
≥10.0 (≥180) ≥11.1 (≥200) ≥11.1 (≥200) 
 
Impaired Glucose Tolerance 
(IGT): 














2-h post glucose load ≥6.7 (≥120) and 
<10.0 (<180) 
≥7.8 (≥140) and 
<11.1 (<200) 

















≥6.1 (≥110) and 
<7.0 (<126) 
and (if measured) 









The Australian diabetes society recommended venous plasma glucose as standard 
laboratory method to determine hyperglycaemic conditions. In addition, consensus 
findings insist samples should be analysed by accredited laboratories and the glucose 
meter is unreliable for conclusive diagnosis, since generally its imprecision remains 
high.(Poirier et al. 1998; National Health and Medical Research Council 2001; 
Diabetes Australia Western Australia 2005).  
 
Standard glucose concentration for the diagnosis of diabetes mellitus is based on 
values mentioned in Table 4; however the diagnosis process is different according to 
magnitude of glucose concentration in different individuals. So that, single fasting 
plasma glucose value of 7mmol/l and above or a 2-h post-challenging value of 
11.1mmol/l and greater is sufficient to diagnosis diabetes in symptomatic 
individuals. However, asymptomatic patients’ need to at least two higher than normal 
results performed in different days to be marked as diabetic case (Alberti and 
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Zimmet 1998a; Reaven 2004; Diabetes Australia Western Australia 2005; World 
Health Organization 2006). Additionally, people with unverified hyperglycaemia are 
advised to repeat related tests periodically (Diabetes Australia Western Australia 
2005). 
 
The International Diabetes Federation (IDF) has established a clear protocol, 
consistent with the WHO framework (International Diabetes Federation 1999). 
Subsequently, a practical diagnostic algorithm has been produced by Lamb and Day 











2.2.3.3 Impaired glucose regulation 
Impaired glucose regulation is referred to an intermediate stage of abnormal glucose 
metabolism resulting in blood glucose levels, between that for the normal range and 
diabetes (Alberti and Zimmet 1998a). This glucose metabolism disorder may be 
represented in the fasting state or in the post-prandial condition.     
 
Impaired glucose tolerance (IGT) is distinguished form impaired fasting glucose 
(IFG) by post glucose load. Prevalence of IGT is in wide-ranging between <3% and 
20% among populations over the world. Early studies used raw WHO data for more 
than 150,000 persons from 75 countries and classified it in low (<3%), moderate (3-
10%) and high (11-20%) prevalence group which was observed in many population 
globally. However, recent estimation pronounced an average worldwide prevalence 
of 6.4% and predicted to arise to 7.1% by 2030 (King and Rewers 1993; 
International Diabetes Federation 2011). The AusDiab study revealed 16.4% of adult 
Australian aged 25 and over had impaired glucose regulation. This rate includes 
prevalence of IGT and IFG by 10.6% and 5.8% respectively, and varies  by gender, 
being 9.2% and 11.2% for male and female respectively (Dunstan et al. 2001). 
 
The OGTT is based upon measurement the glucose concentration after 2-h loading of 
75g oral glucose. Subjects with glucose concentration more than normal 
(7.8mmol/L), but lower the diabetic range (11.1mmol/L) are classified as 
IGT(Alberti and Zimmet 1998a). However, IDF recommended the mean of two 
OGTT is necessary to makes reliable criterion to diagnosis of IGT, since values of 
glucose circulatory may be different day to day (Dunstan et al. 2001). In addition, 
diagnosed IGT cases are at greater risk than metabolic syndrome individuals without 
increased fasting glucose. Because many with IGT are undiagnosed, they are not 
taking part in prevention programs such as lifestyle modification or pharmacological 
intervention (Karve and Hayward 2010). Although, many people with diagnosed 
diabetes do develop cardiovascular,  on a population level, IGT may play a stronger 
role because of its higher prevalence and long silent period before diagnosis 
(DECODE Study Group 1999). The risk factors for IGT are similar to diabetes and 
rises due to age, stressful condition, overweight and obesity, family history of 
hypertension, dyslipidaemia and diabetes; and  physical inactivity (Banerji et al. 





Obesity is one of the most important and critical factors that play a key role in 
metabolic syndrome. The significant role of obesity mainly refers to its powerful 
effect in predisposing to hyperglycaemia, diabetes and cardiovascular diseases 
(CVD) as well as wide range of their complications, morbidities and mortality, as 
discussed below (Kip et al. 2004). The rapid increase in prevalence worldwide 
results in significant population burdens in morbidity and premature mortality (Kelly 
et al. 2008; Reilly and Kelly 2010).  
 
2.2.3.4.1 Definition of obesity, measurement and weight classification 
Obesity is an atypical increase of body fat in proportion to body size. Although, 
obesity principally is considered in proportion of whole body fat, evidence shows a 
stronger correlation between fat accumulation in abdomen and trunk (central 
obesity); and associated complication compared to general obesity (i.e. affecting 
subcutaneous fat). Obesity usually depends on age, sex, and ethnic group. It 
substantially increases morbidity and mortality due to a wide range of diseases 
including: diabetes, CVD, stroke, respiratory disorders and gallbladder diseases as 
well as a variety of cancers like oesophagus, breast (postmenopausal), endometrium, 
colon and rectum, and kidney (Expert panel on the identification evaluation and 
treatment of overweight in adults 1998; Ogden et al. 2010; Purnell 2011). 
 
Despite difficulties to measure body fat, accurate measurement to evaluate the risk of 
obesity is necessary. Body mass index (BMI) traditionally is used to evaluate obesity 
by anthropometric measurement of weight (kg)/ height (m
2
). The WHO classification 
has been developed among individuals with European ethnicities that were at higher 
risk of diabetes, CVD and hypertension. Then, persons with BMI=19-24.9; 25-29.9; 
and ≥30 kg/m
2
 are categorised in normal, overweight and obese range respectively 
[Table 5] (Expert panel on the identification evaluation and treatment of overweight 
in adults 1998; Pi-Sunyer 2000). Other measurement tools like magnetic resonance 
imaging, computer-assist tomography scanning and underwater weighing are 
accurate, but using these applications is expensive and or impractical for routine use.   
However, Dual Energy X-ray Absorptiometry (DEXA) as another accurate 




Obesity has the highest and fastest growing prevalence of the risk factors of 
metabolic syndrome. Its incidence has made it a global pandemic causing major 
problems for health systems. Although, it seems the increasing prevalence rate 
emerged first in high income countries, this trend is now also apparent in most 
middle and many low income countries particularly in their urban regions (Kimokoti 
and Millen 2011; Swinburn et al. 2011; Raban, Dandona, and Dandona 2012). The 
world health organization estimates 1.5 billion adults aged 20 and over were 
overweight and obese in 2008 by using classification mentioned in table 5 (WHO 
2011d).   
 
Table 5: Classification of Overweight and Obesity by BMI 
BMI (kg/m
2
) Obesity Class Defined as 
<18.5  Underweight 
18.5-24.9  Normal 
25-29.9  Overweight 
30-34.9 I Obesity 
35-39.9 II  
40 III Extreme Obesity 
Source: (Expert panel on the identification evaluation and treatment of overweight in adults 
1998) 
 
According to the WHO statistics, more than 200 million men and approximately 300 
million women were placed in the obese range. In addition, in 2010, about 35 and 8 
million children were obese in developing and developed countries respectively 
(Pereira et al. 2002; Azadbakht, Mirmiran, Esmaillzadeh, and Azizi 2005; WHO 
2011d; Swinburn et al. 2011). The prevalence of obesity can however vary 
substantially by country, ranging between 0.46% in Vietnam and 78.5% in Nauru 
which apparently is due to differences in socioeconomic features and specific living 
conditions related to each country, region or ethnic group (WHO 2012).  
 
A population-based national survey in Australia (AusDiab) showed that in 1999-
2000, 19.3% of men and 22.2% of women were classified in the obese group. The 
AudDiab study indicated this rate was 2.5 folds higher than in 1980 and the peak of 
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this prevalence was particularly high (17.4%)  in young adult males aged between 25 
and 34 (Cameron et al. 2003; Seidell 2010). Another Australian study undertaken in 
2004-2005, illustrated that 62% of men and 45% of women were classified as 
overweight or obese and this classification peaked in the age group of 55-64 years 
with 72% of men and 58% of women affected respectively. Moreover, these 
proportions have significantly increased during the last ten years from 52% to 62% 
for men and from 37% to 45% for women (Snijder et al. 2007). Recent 
epidemiologic study projected using the results of AusDiab survey and estimated the 
future prevalence in Australia. According to their analysis, an estimate 64.9% of the 
normal weight 25-29-year-olds in 2000 will be overweight or obese at age 60-64 
years. The study’s finding also estimates prevalence of obesity will increase to 70% 
in the coming decade among Australian adults unless effective prevention programs 
change this pattern (Walls et al. 2011).  
 
A meta-analysis used the standard BMI criteria and studied on relevant publication 
performed between 1990 and 2008 in European countries. The results indicated the 
range from 4% to 28% of men and from 6.2% to 36.5% of women were obese by 
direct measurement (Berghofer et al. 2008). Despite some discrepancies, there was 
no considerable difference between direct measurement and self-reported methods 
when the results were compared to each other. Another study indicates the overall 
prevalence of obesity in India is 50.1% (Bhardwaj et al. 2011). However, this study 
used different criteria to the WHO’s international classification and considered 
obesity range to be BMI≥25kg/m
2
. The current research also indicated a prevalence 
of 68.9% for obesity where waist circumference is assessed instead of BMI. 
 
In addition, similar to many countries, the prevalence of obesity among Iranians aged 
25 to 64 years with a 2.5 times growth, significantly increased from 13.6% to 22.3% 
between 1999 and 2007. This pattern was statistically significant among urban and 
rural area, in both genders and all age groups. Also, the increasing trend in BMI was 
significant (P<0.001) from 25.03±0.05 in 1999 to 26.14±0.05 and 26.47±0.015 in 
2005 and 2007 respectively (Esteghamati et al. 2010). The major underlying cause of 
obesity is an imbalance between energy intake and metabolism. This is explained by 
an excess intake of highly available and inexpensive energy-dense, high-calorie 
foods on the one hand, and a low level of physical activity, resulting from propensity 
46 
 
to sedentary lifestyle, on the other (Grundy 2004b; Hossain, Kawar, and El Nahas 
2007; WHO 2009; Esteghamati et al. 2010). 
 
2.2.3.4.3 Central obesity 
A number of investigations (Shiwaku et al. 2005; Eckel, Grundy, and Zimmet 2005; 
Enkhmaa et al. 2005) found WHO definition (Section 2.2.1.1) inappropriate to be 
considered for all regions and ethnic groups. Some of them suggested the cut-off for 
BMI should be different among of ethnic groups whereas other studies concluded 
central obesity is a more reliable criterion than BMI for diagnosis of metabolic 
syndrome (Expert Panel on Detection and Treatment of High Blood Cholesterol in 
2001; Balkau et al. 2002; Cameron et al. 2003). Sufficient evidence has emerged 
during the last decade showing a direct correlation between central obesity and the 
consequences of metabolic syndrome particularly insulin resistance and diabetes 
(Brunner et al. 1997; Isomaa et al. 2001; Ritchie and Connell 2007; Yang et al. 
2010).  
 
It has been shown that total and regional fat mass are extensively under influence of 
genetic factors (Malis et al. 2005). Many studies confirmed a strong association 
between BMI and the percentage of body fat (PBF) (Goh et al. 2004; Mehdad et al. 
2012), however it was shown that this relationship is completely ethnic-specific 
(Deurenberg-Yap et al. 2000; Deurenberg, Deurenberg-Yap, and Guricci 2002). 
Similarly, the findings of Hughes et al. in Singapore showed that the BMI and WHR 
were significantly different in their correlations with obesity among diverse ethnic 
groups. For instance, both genders in Indians were predominantly prone to develop 
central obesity (measured by WHR), while Malays mainly tend to develop general 
obesity (measured by BMI) (Hughes et al. 1997). Accordingly, a principal research 
investigating the relations between BMI, total body fat and PBF as main indices of 
general obesity or between those reflecting central adiposity (e.g. truncal fat mass, 








2.2.3.4.4 Relationship between obesity and other cardiovascular risk factors     
Obesity influences on other components of the metabolic syndrome causing 
substantial aggravation on related consequences.  Significant association between 
increased body fat and insulin resistance has been demonstrated in many studies 
(Kahn, Hull, and Utzschneider 2006; Qatanani and Lazar 2007). It is now known that 
in individuals with obesity, adipose tissue releases increased amount of various 
factors, such as non-esterified fatty acids (NEFAs), glycerol, hormones and pro-
inflammatory cytokines which all contribute to the development of insulin resistance 
(Kahn, Hull, and Utzschneider 2006).    
 
It was shown that obesity is also associated with increased risks for hypertension and 
hyperlipidaemia (Kotsis et al. 2010; Repas 2011). While the exact mechanisms  by 
which obesity can directly cause hypertension have not been fully understood, 
activation of sympathetic nervous system, activation of the renin-angiotensin system 
and sodium retention have been proposed as the main alternations (Engeli, Negrel, 
and Sharma 2000; Re 2009). Additionally, it has been suggested that obesity-induced 
inflammation may also have an important role in promoting vascular dysfunction and 
subsequent hypertension (Kotsis et al. 2010). This was supported with the findings of  
a multi ethnic study on atherosclerosis, showing that obese individuals with 
CRP≥3mg/L were at higher risk for developing hypertension (twofold) compared to 
those with CRP<1mg/L. Meanwhile, a moderate effect of inflammation alone has 






















Abbreviations: HTN, hypertension; BMI, body mass index; CRP, C-reactive 




High blood pressure as a major component of metabolic syndrome is defined as the 
prolonged elevation of the systemic arterial pressure. Hypertension is a strong 
contributor in development of metabolic syndrome and its consequences, such as 
chronic heart disease (CHD), stroke and renal failure (Chobanian et al. 2003; Grundy 
2004b). Clinically, a systolic blood pressure (SBP) equal or higher than 140 mmHg 
or diastolic blood pressure (DBP) equal or higher than 90 mmHg or being under 
antihypertensive medication is defined as hypertension. 
 
Currently, and on the global scale, one billion people over the world suffer from high 
blood pressure; and statistics predict 1.56 billion adults will be affected by 
hypertension in 2025 (Kearney et al. 2005). Nearly, two-third of hypertensive cases 
are in developing countries and this trend apparently will be continued in the future 
without effective prevention programs. In addition, hypertension as “silent killer” 
claims almost 7.5 million or 13% of all deaths every year globally (van Vark et al. 
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2012), because particularly in pre-hypertension or early stages, individuals are often 
unaware of its presence. As mentioned, high blood pressure is highly associated with 
cardiovascular diseases and approximately 60% of diabetic patients suffer from 
hypertension as well (WHO 2011b). Table 6 shows the diagnostic classification of 
blood pressure in adults according to the National Cholesterol Education Program 
Expert Panel(NCEP 2002). 
 




2.2.3.5.1 Pathophysiology of hypertension  
Particularly during last decade, studies on CVD have increasingly explored the 
interplay between hypertension, inflammation and cardiovascular events (Bautista 
2003; Boos and Lip 2005). It is proposed hypertension causes a sequence initiating 
secretion of different mediators like IL-6 and C-reactive protein (CRP). Then this 
process is followed by failure to produce vasodilating endothelial factors especially 
nitric oxide (NO) and prostacyclin (PGI2), resulting endothelial dysfunction and 
eventually hypertension (Bautista 2003; Lakoski et al. 2010). On the other hand, 
increasing blood pressure consequently harms the arterial walls and this round 
develops a vicious cycle aggravating the primary inflammation. The experimental 
evidence shows the degree of endothelial dysfunction is associated with severity of 
blood pressure directly (Brasier, Recinos, and Eledrisi 2002). 
 
2.2.3.5.2 Hypertension, mediators and markers 
C-reactive protein, as one of the general acute phase reactants, is produced in 
response to the inflammation. Although, it was traditionally revealed it is mainly 






Normal <120 and <80 
Pre-hypertension 120-139 or 80-89 
Hypertension Stage 1 140-159 or 90-99 
Hypertension Stage 2 ≥160 or ≥100 
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respiratory tract and kidney epithelium under certain conditions (Gould and Weiser 
2001; Jabs et al. 2003; Jialal, Devaraj, and Venugopal 2004). In addition, Calabro et 
al showed that human coronary artery smooth muscles cell as well as adipocytes can 
synthesize CRP following stimulation by inflammatory cytokines (Calabró, 
Willerson, and Yeh 2003; Calabro et al. 2005; Yeh 2005). Likewise, the RAS has 
long recognized as another contributing factor leading to hypertension(Lakoski et al. 
2010).  Angiotensin II (Ang II) produced via the RAS, can increase blood pressure 
directly since it plays not only in increase renal sodium and water retention, but it 
also has a vasoconstrictor role. Additionally, it has confirmed Ang II induces the 
expression of endothelial pro-inflammatory cytokines like IL-6 and vascular cell 
adhesion molecules type 1 (VCAM-1). Moreover, Ang II can promote the 
intracellular production of H2O2 in endothelial cells and smooth muscle cells.  This, 
in turn, increases inflammatory cytokines production and subsequently the risk of 
atherosclerosis via pro-inflammatory effects (Hernandez-Presa et al. 1997; 
Kranzhofer et al. 1999; Tummala et al. 1999; Pueyo et al. 2000). 
 
2.2.3.6 Dyslipidaemia 
Dyslipidaemia is diagnosed by increased LDL-cholesterol and triglycerides, and low 
concentration of HDL-cholesterol, which occur commonly in combination to each 
other. However, isolate low HDL-cholesterol may be found in some cases 
occasionally (Grundy et al. 2004; Wyszynski et al. 2005). Dyslipidaemia is a main 
contributor in developing atherosclerosis and CVD. 
 
2.2.3.6.1 Lipoproteins and atherogenicity 
Lipoproteins predominantly are constituted by two main components: lipids 
including triglyceride, cholesterol and phospholipids; and protein or apoproteins. The 
function of lipoproteins is to transport lipids in plasma.  Low density lipoprotein 
(LDL) for example transports cholesterol and  individuals cholesterol esters to 
peripheral tissues  (Murtola et al. 2011). Lipoproteins are traditionally classified into 
five main groups according to their densities, and a sixth and more recently described 
member, lipoprotein (a) is often also now included. These groups are lipoprotein (a), 
high density lipoproteins (HDL), low density lipoproteins (LDL), intermediate 
density lipoproteins (IDL), very low density lipoproteins (VLDL) and chylomicrons 
(CM) [Table 7]. The higher density lipoproteins have higher percentage of protein 
51 
 
relative to lipid as well as an inverse association to the size (Garrett and Grisham 
1995; Gennest and Libby 2011). 
 
Another classification categorises lipoproteins according to their surface proteins 
called apolipoproteins.  Apolipoprotein A (apo A) and apolipoprotein (apo B) with 
two subclasses including apoB100 and apoB48 are two important features in this 
classification (Chahil and Ginsberg 2006). All apo B-lipoproteins are able to harm 
the endothelial layer and activate the inflammatory atherogenic process through the 
injured blood vessels. However, HDL as the major apo A – containing lipoprotein 
has anti-atherogenic activity, which is mainly due to its principal role in reverse 
cholesterol transport (RCT). During RCT process, apo A lipoprotein accepts the 
cholesterol accumulated in  peripheral cells (e.g. macrophages present in 
atherosclerosis lesions)  are return them to the liver to be subsequently excreted into 
the bile (Chahil and Ginsberg 2006; Cavigiolio et al. 2008; Rader et al. 2009; 
Rothblat and Phillips 2010).  
 
Table 7: Plasma Lipoproteins composition in fasting state (Gennest and Libby 2011) 












CM Intestine <0.95 100-
1000 
1-2 0.0 0 B48 
VLDL Liver <1.006 40-50 10 0.1-0.4 0.2-1.2 B100 
IDL VLDL 1.006-
1.019 




20-25 25 1.5-3.5 0.2-0.4 B100 




6-10 40-55 0.9-1.6 0.1-0.2 AI AII, 
LP (a) Liver  1.051-
1.082 
25 30-50   B100, 
(a) 
Apo: apolipoproteins; CM: Chylomicrons ; HDL: high-density lipoprotein; IDL: intermediate-density 
lipoprotein; LDL: low-density lipoprotein; LP : lipoprotein ; VLDL: very-low-density lipoprotein. 















Atherosclerosis is a chronic and progressive inflammatory disease involving blood 
vessels almost in all sizes (Gornik and Beckman 2005). It usually starts from the 
early years of life and the clinical signs manifest in middle to late adulthood. This 
disorder takes place through three main processes. These stages and processes are:  
1. proliferation of endothelial smooth muscles cells (SMC) by the mutual action 
with inflammatory cellular elements;  
2. formation by the accumulated smooth muscle cells in a layer of collagen-rich 
matrix and elastin fibres;  
3. and uptake and accumulation of lipids, predominantly as cholesterol esters 
and free cholesterol formats.  
 
Among several hypotheses explaining the factors that trigger atherosclerosis, two 
theories predominate: these include “oxidation” and “response to injury”, with the 
latter widely accepted at this time (Ross 1993). According to the “response to injury” 
theory, atherosclerosis process starts with the injury to the arterial wall which 
triggers inflammatory reactions, participating in atherosclerotic plaque formation.     
 
In normal conditions, arterial endothelium plays a considerable role in controlling 
homeostasis of the cardiovascular system by releasing vasodilator nitric oxide (NO) 
as well as antithrombotic and fibrinolytic factors. However, in response to injury, NO 
and acetylcholine present an inverted effect causing vasoconstriction in damaged 
endothelium by releasing agents such as  thromboxane A2 and prostaglandins. In 
parallel, abnormal intracellular signalling increases the intracellular Ca
2+
 which leads 
to extra vasoconstriction (Mallika, Goswami, and Rajappa 2007; Sherwood 2009).  
In addition, pro-inflammatory cytokines such as tumour necrosis factor (TNF-α) or 
interleukin-1β (IL-1β) stimulate the endothelial cells to express vascular cell 
adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) 
causing an aggression and adhesion of platelets and monocytes on the site of damage 







Figure 6: Interplay between endothelial cell dysfunction and endothelial cell activation 
(a) 
Cytokines and oxidized LDL stimulate 
endothelial cell permeability and NF-κB-
dependent inflammatory gene expression. 
ROS appear to play a central role mediating 









In addition to its vasodilatory properties, NO 
promotes barrier stability, limits 
inflammation, inhibits platelet aggregation, 
and limits SMC proliferation. Loss of these 
protective properties in endothelial cell 
dysfunction therefore perpetuates endothelial 





As a consequence of inflammation, monocytes enter into the intima which, in turn, 
increases endothelial permeability (Figure 6). Subsequently, plasma atherogenic 
lipoproteins, particularly LDL, are able to move through the endothelial layer and 
mediate or contribute to form a visible “fatty steak”, a hallmark of atherosclerosis in 
early stage. The lipoprotein accumulation causes that the layer of vessels to bulge 
into arterial lumen gradually. By continued inflammation and monocyte invasion as 
well as increased herniation, the lumens of blood vessel are reduced. Both 
biochemical and mechanical changes exacerbate oxidative stress and cause arterial 
damage in a vicious cycle (Figure 7) (Woywodt et al. 2002; Boon NA 2002; Hayashi 






Figure 7: Stages of atherosclerotic plaque formation. Early apoB-containing lipoprotein 
accumulation and monocyte binding drive the early stages of plaque development forming 
fatty streaks in the vessel wall. While these processes continue in advanced atherosclerosis, 
monocyte cell death, smooth muscle recruitment, and matrix deposition are hallmarks of 
atheroma formation.(Funk, Yurdagul, and Orr 2012) 
 
 
The “fatty streak” lesion can occur in infants and young children, while it develops 
into a “fibrous plaque” with age as an advanced lesion is formed (Figure 7) (Mallika, 
Goswami, and Rajappa 2007; Maziere and Maziere 2009). 
 
2.3.1 Atherosclerosis risk factors 
Risk factors of atherosclerosis encompass a collection of variety of factors which can 
be categorised in three main groups.  
 
The first modifiable group can be controlled by changing in lifestyle and include 
obesity, physical inactivity and smoking. Risk factors such as hypertension, diabetes 
mellitus, insulin resistance and dyslipidaemia can be modified by both lifestyle 
modification or through medication. In contrast, risk factors including age, gender 
and ethnic or familiar specification are classified under unmodifiable group (Fleming 
1999; Fauci, Braunwald, and Isselbacher 2003).  
 
Metabolic syndrome and its components can accelerate the atherosclerosis process 
through pro-inflammatory and inflammatory stages. Adipose tissue can continue to 
increased production of cytokines which consequently causes reductions in insulin 
sensitivity and establishes a systemic pro-inflammatory state. The influence of 
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dyslipidaemia, particularly increased level of LDL, is well known in both lesion 
commencement and progression in atherosclerosis as is the role of various 
forms/modifications of LDL. For example, LDL oxidation synergises atherogenisity 
of lipoproteins, and dense and small LDL particles play more significant atherogenic 
role than buoyant and large LDL particles(Lamarche et al. 2001; Blake et al. 2002; 
Hulthe and Fagerberg 2002; Vakkilainen et al. 2003). The triglyceride-rich particles 
and their remnants are, like LDL, also considered to contribute to plaque 
development.  
 
Chylomicron remnants, which are present particularly in the postprandial state, are 
considered to be particular atherogenic. Triglyceride-rich particles can accumulate 
due to increased production or impaired clearance, for example due to lack or 
inhibition of lipoprotein lipase. Similarly, chronic hyperglycaemia in diabetic 
patients speeds up the production of advanced glycation end products (AGEs) which 
in turn activate extra parallel processes for arterial inflammation (Schmidt et al. 
1999). Other features involved in metabolic syndrome such as increased PAI-1 and 
hyper-fibrinogenemia contribute in inflammatory phenomenon as well (Sorrentino 
2005). 
 
Endothelial dysfunction subsequent to imbalance between vasodilator and 
vasoconstrictor’s action, such as NO and angiotensin II, presents its role as risk 
factor in atherosclerosis via increasing circumferential wall tension (CWT). 
Endothelial damage initiates and intensifies atherosclerosis due to defect in 
production and dysfunction of nitric oxide (Davignon and Ganz 2004; Funk, 
Yurdagul, and Orr 2012). 
 
2.3.2 Atherosclerosis and inflammatory biomarkers 
Many studies over last decade have attempted to find a variety of biomarkers in 
relation to atherosclerosis as well as to determine how their modulation influences its 
development or prevention. Most experimental studies on metabolic syndrome have 
focused more on acute phase reactants, e.g. C- reactive protein (CRP), plasminogen 
activator inhibitor-1 (PAI-1) and cellular adhesion molecules (CAMs) such as 




CRP is known as the strongest non lipid biomarker to predict the risk of 
cardiovascular events compared to other predictors (Ridker et al. 2013). It is a 
marker of inflammation synthetized primarily by the liver following microbial 
infection, autoimmune reactions and tissue injury. Additionally, it was shown that 
CRP can be produced by renal cortical tubular epithelial cells in response to 
inflammatory stimuli (Jabs et al. 2003). It has also been detected in atherosclerotic 
lesions of human arterial wall (Yasojima et al. 2001), which could be the result of its 
participation in vascular inflammation. Several studies confirm its role in myocardial 
infarction, cardiac sudden death, stroke, diabetes mellitus and peripheral artery 
diseases (Ridker et al. 2000; Albert et al. 2002; Ridker et al. 2002; Linnemann et al. 
2006; Ridker et al. 2008). Also, increased levels of CRP are associated positively 
with body weight in both men and women (Linnemann et al. 2006; Zuliani et al. 
2009). Moreover, a number of studies reveal that some medications (e.g 
statins/aspirin) which reduce the risk of atherosclerosis have been shown to modify 
CRP circulatory levels in parallel of their treatment effects (Fisher et al. 2008; Ridker 
et al. 2008) 
 
In addition to the above mentioned clinical roles, serum CRP is an important marker 
predicting metabolic syndrome (Anand et al. 2004). Compared to other biomarker 
predictors for cardiovascular events and metabolic syndrome, CRP has a long life 
and a lower diurnal and seasonal variation in circulatory systems (Packard and Libby 
2008). Furthermore, CRP is a well validated screening test for conventional risk 
factors and other inflammatory markers; and it is simply analysed by standardized 
high sensitive immunoassay method which is relatively inexpensive and widely 
available (Pearson et al. 2003; Anand et al. 2004; Packard and Libby 2008). 
Additionally, detectability of CRP in early stages of atherosclerosis is another 
advantage compare to the other biomarkers predicting the risk of cardiovascular 








Figure 8: Inflammatory Biomarkers and the progression of atherosclerosis. The 
progression of atherosclerosis involves various inflammatory biomarkers that can be 




The American Heart Association has identified a highly sensitive technique used for 
the measurement of CRP (hs-CRP) as an independent inflammatory marker 
predicting the risk of coronary diseases (Pearson et al. 2003).  Serum CRP 
concentration usually rise up to 100 – 200 mg/L during an acute phase reaction. 
However, just a small elevation in CRP levels is thought to be useful for predicting 
CVD risk. The current guideline for cardiovascular risk assessment categorized the 
variety of risks according to the different levels of hs-CRP. Accordingly, the 
classified groups of low, intermediate and high risk are defined by the levels of 0 to 
<1mg/L, 1-3mg/L, >3-10 mg/L respectively, however the CRP levels > 10mg/L is 
recognized as unspecific elevation. In individuals with CRP concentration more than 
10 mg/L, the test should be repeated at a late time to rule out infection, malignancy 
or autoimmune diseases (Yeh and Willerson 2003). In contrast, there are few 
controversies around the role of CRP to develop cardiovascular events and metabolic 
syndrome. Without denying this overall role, they commonly emphasize that the 
occurrence of CVD is multifactorial and CRP plays a  role along with other risk 
factors including genetics (Lin et al. 2012).  
 
PAI-1, along with other inflammatory cytokines including TNF and IL-6, can be 
released by adipose tissue. The production of these inflammatory agents depends on  
the number of adipocytes; however insulin reduces their production through the 
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suppression of lipolysis (Grundy 2006). PAI-1 as anti-fibrinolytic factor contributes 
to the shift of balance from antithrombotic to pro-thrombotic statues (Landmesser, 
Hornig, and Drexler 2004). An early study exploring a population with high 
prevalence of coronary heart disease showed an increased PAI-1 production during 
the first acute myocardial infarction (AMI) in both men and women (Thogersen et al. 
1998). Evidence suggested elevated PAI-1 concentration may be influenced by 
cardiovascular risk factors such as genetic susceptibility, insulin resistance and 
obesity (Brown et al. 1998; Grundy et al. 2004). Also, the resulting thrombosis 
subsequent to rupture or erosion in the arterial wall, even in a small plaque, can be 
larger in person who is under a pro-thrombotic status. This pro-thrombotic condition 
causes the person to be at risk of major life-threatening cardiovascular events. 
Although, the exact mechanism is not yet understood, it is known that anti-platelet 
therapy or anti-coagulant therapy reduces the risk of cardiovascular events (Pearson 
et al. 2002; Grundy 2006). 
 
 
2.4 Diet and metabolic syndrome 
 
Although the metabolic syndrome is associated to dietary intake, the mechanism of 
how metabolic syndrome develops is not yet well understood (Esposito et al. 2004; 
Azadbakht, Mirmiran, Esmaillzadeh, Azizi, et al. 2005; Kimokoti and Millen 2011). 
Industrialization and technological advances cause a universal transition of 
nutritional behaviour with a shift from plant-based foods to high energy dense 
regime. There are many studies exploring the relationship between different 
nutritional patterns and incidence of metabolic syndrome, its components and 
cardiovascular disease (Sonnenberg et al. 2005; Esmaillzadeh et al. 2007; Azadbakht 
et al. 2007; Panagiotakos et al. 2007; Fogli-Cawley et al. 2007; Lutsey, Steffen, and 
Stevens 2008; Babio et al. 2009; Denova-Gutierrez et al. 2010; Kim and Jo 2011).  
 
Existing studies mainly attempt to classify food items into healthy, or prudent, 
patterns and fast energy or Western patterns, and the data analysed based on 
appropriate classification. Evidence from some of the studies, reveal a strong 
association between ten year incidence and death rates from coronary heart diseases 
and average intake dietary energy from saturated fatty acids. In addition, there was 
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no indication of association to death rates either from proteins or polyunsaturated fats 
in the diet (Keys et al. 1986). In 9 years observation, Lutsey et al. (2008) examined 
the association between the incidences of metabolic syndrome and two different 
dietary patterns.  
 
Fruits, cruciferous and carotenoid vegetables, poultry and fish were typified as 
prudent dietary whereas high consumption of processed meat, refined grains, fried 
foods and red meat were placed in western pattern in this study. Their results showed 
an association between a Western dietary pattern and an 18% higher risk of 
metabolic syndrome incidence which confirm previous similar correlation in other 
studies (Sonnenberg et al. 2005; Esmaillzadeh et al. 2007; Lutsey, Steffen, and 
Stevens 2008). 
 
Since the 1980s, the Mediterranean diet has been recognized as cardio-protective 
(Keys et al. 1986). This dietary pattern is characterised by high intake of 
monounsaturated fatty acids (mostly from olives), vegetables, nuts, whole grain 
cereals, legumes and white meat (poultry and fish) along with low/ moderate red 
meat and alcohol consumption. Evidence derived from a meta-analysis of 50 
countries including more than half million individuals confirmed a significant 
association between Mediterranean diet and low cardiovascular risk (Babio et al. 
2009). Also, other randomized controlled trials showed that consumption of healthy 
diets like Mediterranean patterns can improve metabolic syndrome components and 
subsequently reduce the incidence of metabolic syndrome among those who are 
diagnosed as metabolic syndrome cases (Esposito et al. 2004; Esmaillzadeh et al. 
2007).  
 
Additionally, a number of experimental trials show that whole grain and cereal fibre 
consumption is correlated to low incidence of metabolic syndrome risk factors 
(McKeown et al. 2004; Esmaillzadeh, Mirmiran, and Azizi 2005a; Sahyoun et al. 
2006). Furthermore, the risk of the hypertriglyceridemic waist (HW) phenotype (i.e., 
central obesity in combination with hypertriglyceridemia) was inversely correlated 
with high intake of whole grain; however the consumption of refined grains was 
significantly associated to the risk of HW phenotype (Esmaillzadeh, Mirmiran, and 
Azizi 2005b).  
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The role of dietary fibres in reduction of risk of chronic diseases like diabetes 
mellitus and CVD has been shown in many studies, however the biological 
mechanism resulting in these effects is  not completely understood yet (Barclay et al. 
2008; Ventura et al. 2009; He et al. 2010). Among all dietary fibres, legumes have 
characteristically low energy density whereas vegetable proteins have high dietary 
fibre and oligosaccharides. The results of dietary intervention studies indicate that 
consumption of legumes helps to improve glycaemic control. The legume intake is 
associated with lower incidence of type 2 diabetes (Villegas et al. 2008), better 
maintenance of blood glucose concentration (Venn and Mann 2004; Rotimi et al. 
2010), improvement in weight control and weight loss (Papanikolaou and Fulgoni 
2008; Hermsdorff et al. 2011), preventing inflammation and endothelial dysfunction, 
improvement in antioxidant status (Rotimi et al. 2010), reduced risk of coronary 
heart diseases and mortality rate due to cardiovascular cause (Bazzano et al. 2001; 
Nothlings et al. 2008). 
 
Evidence shows a significant reduction in total and LDL cholesterol concentration 
subsequent to a 14 day legume (kidney beans) intake, although there was no 
significant increase in the levels of HDL levels (Kolonel et al. 2000; Venn and Mann 
2004; Villegas et al. 2008; Trinidad et al. 2010). Similarly, the results from another 
research study undertaken among Iranian women show the consumption of legume is 
inversely correlated to serum concentration of CAMs and inflammatory biomarkers 
such as CRP, TNFα and IL-6 (Esmaillzadeh and Azadbakht 2012). 
 
2.5   Physical activity and metabolic syndrome 
 
Physical activity is one of the most effective components for regulating energy 
balance. Unlike the basal metabolic rate, physical activity is under voluntary control. 
Acknowledgment of the significance of physical activity has increased due to the 
epidemics of the westernised lifestyle and other related risk factors leading to 
metabolic syndrome such as obesity, and chronic disease. Physical inactivity causes 
greater risk of metabolic syndrome’s components and consequences like CVD and 
diabetes mellitus (Wannamethee et al. 1998; Helmrich et al. 1991; Dunstan et al. 
2005). Physical inactivity commonly develops metabolic syndrome through increase 
in the risk of obesity and prepare the conditions for insulin resistance and 
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dyslipidaemia (Jakes et al. 2003; Boparai, Davila, and Chandalia 2011; Cameron and 
Shaw 2011).   
 
Several studies carried out in different countries evaluated the relationship between 
physical activity or inactivity and metabolic syndrome. One of those findings show 
the odds ratio (OR) of having metabolic syndrome is directly related to leisure time 
activities including watching TV or video or using computer outside of work. 
Namely, OR with 95% confidence interval (CI) were 1.41, 1.37, 1.70 and 2.10 for 
one, two, three and four hours per day watching TV and using computer respectively 
when those compared with participants who were involved less than one hour of 
these behaviours. In contrast, individuals who were not involved in moderate or 
vigorous physical activity had higher ORs by two times compare to who had ≥150 
minutes per week of similar activity (Ford et al. 2005) 
 
As mentioned already (section 2.2.3.1), insulin resistance is one of the fundamental 
mechanisms that plays a key role in developing metabolic syndrome.  Attempts to 
determine the relationship between insulin resistance and physical activity among 
Iranian society revealed that decreasing physical activity in different levels is 
associated with increasing BMI, systolic blood pressure, waist circumference, fasting 
blood glucose and HOMA (homeostatic model assessment) score significantly. The 
results of this study also indicated the lower total physical activity score (TPA) and 
commuting have invert correlation with higher HOMA after adjustment for age, sex, 
BMI, smoking and residential region (P<0.01). This independent pattern was 
observed similarly when the duration of vigorous or moderate-intensity physical 
activity has been examined. Additionally, in association with all variety of physical 
activities and HOMA, work-time physical activity presented higher contribution 
compare to the moderate and recreation time physical activity. However, the 
prolonged sedentary behaviour significantly correlated to higher HOMA values 
(Esteghamati et al. 2009).     
 
Published results from another study accomplished in Australia showed lengthier TV 
watching more than 14 hours per week is positively associated with a greater risk of 
insulin resistance, dyslipidaemia and obesity in both sexes (Dunstan et al. 2005). 
Also, TV watching presented stronger association with metabolic syndrome in 
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women compared to men and this relationship was independent of all other factors. 
These findings were similar for the association with TV viewing when alternative 
metabolic syndrome criteria include NCEP and IDF were applied. Furthermore, the 
prevalence of metabolic syndrome was associated with each 1 hour increase in TV 
watching in men and women by 12% and 26% respectively.   
 
Other findings showed that the prevalence of insulin resistance and dyslipidaemia in 
both genders, and prevalence of obesity and hypertension in women are correlated to 
a total physical activity time of ≥2.5 hours per week. Woman who did not undertake 
the public health physical activity goal of ≥2.5 hours per week through walking and 
moderate physical activity were significantly more likely to have the metabolic 
syndrome compare to those who did not do any vigorous physical activity but still 
achieved the public health target. However, this level of moderate physical activity 
had no protective effect against metabolic syndrome in men. There was significant 
inverse correlation with metabolic syndrome in both sexes for between those who 
undertake ≥1 hour vigorous physical activity (see section 3.4.4) per week and those 
who participated in only <1 hour per week of the similar activity. The prevalence of 
metabolic syndrome reduction in man and women by 11% and 28% respectively has 
been associated with each 30 min increase in physical activity per day (Dunstan et al. 
2005).  
 
Several studies assessing physical activity behaviour among different ethnic groups 
revealed that Asian Indians are more inactive compare to white Caucasians (Zimmet 
1992; Jernigan et al. 2010; Misra et al. 2012). Also, the prevalence of metabolic 
syndrome is higher than most of other ethnic groups which were compared to Indians 
in several countries including United States, UK and Fiji. Similar to other studies, the 
prevalence of metabolic syndrome increased by age and it was more common among 
Indian women than men (Taylor et al. 1984; Ramachandran et al. 2003; Boparai, 
Davila, and Chandalia 2011; Brian et al. 2011; Williams et al. 2011).  
 
Moreover, it has been shown that the prevalence of impaired glucose tolerance and 
diabetes mellitus were significantly higher at the lower quartile of physical activity 
among sedentary, moderate heavy and heavy South Indian workers by 16.8%,13.2% 
and 11% respectively (Ramachandran et al. 2003; Misra et al. 2012). Evidence 
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confirms that prevention programmes encouraging decrease in amount of times spent 
for watching TV or using a computer, particularly along with increased physical 
activity decrease the prevalence of MS (Dunstan et al. 2005; Ford et al. 2005). 
 
2.6 Ethnicity and metabolic syndrome 
 
2.6.1 Genetic factors and metabolic syndrome 
It is now established that genetic factors have a powerful influence on the incidence 
of obesity and other components of metabolic syndrome (Reaven et al. 1967; Tobey 
et al. 1981; Nakamura et al. 1994; Bonora et al. 1998; Nesto 2003; Kristiansson et al. 
2012). During last decade, studies in different countries like Belgium, French and US 
have shown variations in the prevalence of metabolic syndrome risk factors. In 
addition, metabolic syndrome risk factor rates were different among various ethnic 
groups even in a society; and in this regard, other than environmental factors, genetic 
factors play a key role (Ferrannini et al. 1987; Shen et al. 1988; Bouchard and 
Perusse 1988; Korkeila et al. 1991).  
 
For example, evidence suggests that the accelerated rate of premature diabetes and 
CVD in South Asians immigrants is due to inherent insulin resistance as well as an 
increased susceptibility to the development of the metabolic syndrome in the 
framework of a Western lifestyle. It is suggested that a thrifty genotype involves 
insulin resistance and selective partitioning of excess calories into visceral stores in 
this ethnic group (Fabsitz, Carmelli, and Hewitt 1992; Cleland and Sattar 2005). 
However, Black male immigrants of African descent tend to display a different fat 
distribution phenotype, also resulting obesity and insulin resistance but with a 
paradoxically healthy lipid profile (hyperinsulinemia, low serum triglycerides and 
high HDL-cholesterol). The anti-atherogenic lipid profile found in African black 
males seems to have potentially a protective role against cardiac events, and is 
expected to modify the substantial effects of environmental factors increasing the 
risk of CVD in this ethnic group (Glueck et al. 1984; Herd et al. 2001; Kumar et al. 
2006; Veghari GR 2007).  
 
It is undoubtedly true that obesity is not simply a direct result of overeating, but it 
mainly results from a complex interaction of the environment and genetic factors. In 
64 
 
a small number of people, obesity may be developed because of a single-gene 
disorder, mainly defects in genes encoding leptin (Ob gene) or the leptin receptor 
(Zhang et al. 1994; Clement et al. 1998). Leptin is a hormone secreted primarily by 
adipose tissue, regulating fat mass in the body through profound effects on appetite 
and energy expenditure. Leptin deficiency is an autosomal recessive trait causing 
massive obesity in ob/ob mice and humans (Montague et al. 1997).  
  
In most cases, genetic factors contributing to obesity are not limited to a single-gene 
defect, but it results from a combination of various genes disorders. Recent studies 
have identified more than 300 genes and gene makers with potential influence 
(promoting or protective) on obesity (Chagnon et al. 2003). Involvement of this 
number of genes may cause many different types of obesity.  
 
 
2.6.2 Impact of ethnicity on metabolic syndrome components  
Over the last two decades, studies have investigated the impact of ethnicity on 
cardiovascular diseases and metabolic syndrome components among different ethnic 
groups particularly African and South Asian immigrants. The results of the studies 
among immigrants showed that ethnic groups with African ancestry had higher rates 
of obesity, insulin resistant, hypertension and diabetes type 2, but a lower rate of the 
metabolic syndrome when compared to Caucasians. The studies suggest that African 
diabetic individuals have not demonstrated the typical dyslipidaemia of the metabolic 
syndrome (Ferrannini et al. 1987; Herd et al. 2001; Kumar et al. 2006; Veghari GR 
2007).  
 
This pattern has been different from what has been found in South Asian immigrants.  
The finding of a large study conducted on Indians and Pakistanis living in London 
(the Southall study) indicated that after matching for age and BMI, South Asian men 
had higher waist: hip ratio, SBP, insulin levels after glucose load and serum 
triglyceride as well as lower HDL-C than Caucasians (McKeigue et al. 1993). Also, 
high prevalence of insulin resistance syndrome along with a tendency to central 




In addition, the prevalence of type 2 diabetes was 20% compared with 5% in the 
Caucasian subjects (McKeigue, Shah, and Marmot 1991). Consistent with the 
Southall study, in the another study, anthropometric measures of 73 South Asian and 
1287 Caucasian children aged 8–11 years were compared with their fasting and post-
glucose insulin concentrations (Sorensen and Stunkard 1994). Although, South Asian 
children had a lower ponderal index (weight/body surface area), there was no 
difference in waist circumference or waist: hip ratio, suggesting a predisposition to 
preferential accumulation of central adiposity. Also, although both their fasting and 
post-glucose-load glucose levels were similar, insulin levels were around 50% higher 
in South Asians than Caucasian. Moreover, fasting triglyceride levels were 12% 
higher in this ethnic minority (Sorensen and Stunkard 1994).  
 
It is not completely elucidated which key pathways in metabolism are involved in 
ethnic differences in metabolic and vascular functions. However some existing 
findings such as different concentrations of leptin (Glenday et al. 2006; Wu et al. 
2007), anti-inflammatory markers such as CRP (Dhawan et al. 1994; Deurenberg-
Yap et al. 2001; Chambers et al. 2001; Whincup et al. 2002; Misra and Vikram 2004; 
Anand et al. 2004; Kelley-Hedgepeth et al. 2008; Cushman et al. 2009), 
adipocytokinase like adiponectin and Plasminogen Activator Inhibitor-1 (Cappuccio 
1997; Misra and Vikram 2004; Kuller 2004), in some ethnic groups, particularly in 
South Asian population have been highlighted in this regard.  
 
There has been convincing evidence to indicate a higher prevalence of metabolic 
syndrome risk factors and diabetes among Asians compared with Caucasians, 
suggesting the use of lower anthropometric cut-points to indicate overweight among 
Asians (Meis et al. 2006). As mentioned above, the results of the Southall study as 
well as other studies in this field has accepted this fact among South Asian 
immigrants; and some of them suggest that familial factors apply a stronger impact 
than environmental factors causing a more powerful influence on developing obesity 
and its consequences (Korkeila et al. 1991; Guillaume et al. 1995). 
 
There are few studies comparing cardiovascular risk factors among Asian 
immigrants with different nationalities (Kuller 2004; Tillin et al. 2005). Similarly, 
limited studies exploring metabolic syndrome risk factors among immigrants in 
66 
 
Australia have been mainly focused on Caucasians (Ball et al. 2003). Accordingly, a 
multiethnic study investigating the impact of ethnicity on metabolic syndrome risk 
factors among Asian immigrants compared to those with European ancestry would 
provide interesting and new data. With this background in-depth review presented in 







As already mentioned (in sections 2.1.1, 2.2.2.1 and 2.2.2.2) the risk factors of 
metabolic syndrome may be influenced by different factors such as genetics, 
socioeconomics and cultural issues. Although many studies have been undertaken 
globally and offer various definitions for metabolic syndrome, there is still no 
general consensus about accurate definitions and their diagnostic criteria, in 
particular among different ethnic groups.  
 
Australians from a variety of ethnic groups and cultures come together from five 
continents over the world. Given the limited comprehensive studies on ethnicity and 
metabolic syndrome in Australia, this condition provided the best opportunity to 
explore some of the controversies around this issue. This current study was designed 
to evaluate overall health condition and metabolic syndrome risk factors amongst 
some ethnic groups as well as to study the effects of ethnicity on metabolic syndrome 
in Australia. It was hypothesized that ethnicity may play an important role in the 
development of the metabolic syndrome.  
 
3.1 Study design  
 
This was a cross-sectional, pilot study describing the possible impacts and 
fundamental relationship between ethnicity and metabolic syndrome components 
among West Australian immigrants. Also, this method was appropriate to examine 





Given the main hypothesis, it was rational that the current study would focus on 
some ethnic groups which may have the most impact on health in respect to the 
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metabolic syndrome. So, the chosen ethnic groups for this study needed to meet at 
least one criterion below: 
 That they were a major ethnic group in Australia which can thus have a 
significant impact on health nationally 
 That existing similar studies about migrants from those ethnic groups have 
been undertaken in the origin or other countries  
 
According to the released information of census carried out in 2013 by the Australian 
Bureau of Statistics (ABS), migrants from Europe, China and India made most 
population in Australia. According to the Australian census in 2011, European, 
Indian and Iranian ancestry have made proportions of 51.2%, 1.8% and 0.2% of 
Australians respectively. India was the main source of permanent additions in 2012-
13 with an increase of 28.4% compare to previous year. In addition, Indians and 
Iranians ancestry showed an increased by 66.5% and 53.4% in census 2011 
compared to census 2006, respectively (Australian Bureau of Statistics 2013). On the 
other hand, there were similar studies about European, Indian and Iranian in their 
home countries as well as the destination countries for migrants, over the world. 
Given the above facts, participants were chosen through three targeted ethnic groups 
in Western Australia that included Australians from European countries, Indians and 
Iranian. 
 
With respect the key role of body fat in relation to different components of MS, 
sample size was calculated based on an predicted 10% reduction in body fat 
percentage in Indian group relative to two other groups, assuming a standard 
deviation of 8.3% (Vasudev et al. 2004). Using a clinical trial formula (Jeyaseelan 
and Rao 1989), a sample of eighty four subjects (twenty eight subjects in each 
groups) could provide sufficient power (80%) to detect predicted difference at the 





3.2.1 Recruitment phase 
 
After receiving the ethics approval for the study from Curtin University (approval 
number HR 179/2008) and in order to recruit participants from the targeted ethnic 
groups, a wide range of methods was applied to recruit necessary participants for the 
study. The recruitment phase commenced through general and ethnic specific 
advertising in The West Australian, community newspapers, Curtin University radio 
and website, and multicultural broadcasting as well as direct contact to the ethnic 
associations and communities in Perth.  
 
In the first step, the following major government departments were contacted to 
source appropriate participants for the study: 
 
 Department of Immigration and Citizenship, DIAC 
 Australian Bureau of Statistics, ABS 
 Department of Health (data linkage system) 
 Department of Communities, WA 
 Office of Multicultural Interests, OMI 
 
However, the DIAC’s data was not accessible because of individuals’ privacy, as 
protected by government legislation. In addition, upon further consideration, the data 
from these departments were not considered optimal for this purpose as they could 
introduce considerable biases. For example, the data from department of health 
belonged only to those who have been admitted in hospitals as inpatients. 
 
In the next step, contact with some communities and advertising in the popular 
edition of The West Australian newspaper were undertaken twice. Although, we 
received a good response from European groups via these methods, the recruitment 






3.2.2 The second method of recruitment 
To find required participants particularly from ethnic groups other than European, a 
new method was established. In this method, the latest census information carried out 
by the Australian Bureau of Statistics (ABS) in 2006 was analysed. The online ABS 
data base was used to determine the number of resident for each ethnic group in 
different suburbs. Then, 28 of 78 suburbs with the highest targeted ethnic 
populations were chosen for recruitment.  
 
To recognize the targeted suburbs with the most concentration of the targeted ethnic 
groups, an influence index was defined for all 28 suburbs using the formula below: 
 
 
                    
                                             




The influence indexes were different and ranged from 15.3% to 79.8%. The 14 
suburbs in Perth were selected as final targeted areas according to the higher 
population and influence index. In the next step, the flyers [Appendix 1] were 
distributed in the selected suburbs.  
 
Inclusion criteria 
Volunteers were recruited according to the inclusion and exclusion criteria which 
was necessary to define as this study has focused on the metabolic syndrome criteria 
among three ethnic groups. The inclusion and exclusion criteria as well as the reason 
why those are selected are listed below: 
 Age 18 years and more  
 Parents of the volunteers must be from one of the European countries, India 
and Iran, since the study was aimed to evaluate the ethnicity effect on the 
metabolic syndrome 
 Participants have lived in Australia for at least 5 years, as the study’s goals 
need to reduce biases from the effects of environment as much as possible  
 Have working knowledge of written and spoken English in order to prevent 




Plus one or more criteria mentioned below: 
 Are overweight: Body Mass Index (Weight/Height2) of 25 or more 
 Waist circumference: 94 cm for Male and 80 cm for Female or more 
 Blood pressure 130/85 and higher or taking medication 
 Hypertriglyceridemia or hypercholesterolemia or taking medication 
 Diabetes 
 
The above inclusion criteria were selected as they are the basic conditions for 
metabolic syndrome diagnosis according to variety of its definitions and usually are 
detectable by individuals. Pregnant and breastfeeding women were excluded from 
the study, as participants need to be evaluated for body composition by Dual Energy 
X-Ray Absorptiometry (DEXA) test as well. 
 
A screening questionnaire 
Following recruitment, prospective volunteers were invited to fill out an online 
screening questionnaire uploaded on the Curtin University website. The information 
of potential volunteers who were not familiar with the online method or had no 
access to the internet was taken via telephone. Both online and telephone screening 
questionnaires included some questions related to the volunteers’ general 
demographic information such as age, sex, height, weight, background and medical 
history as well as the questions relating to the study’s inclusion criteria [Appendix 2].  
 
Table 8: Characteristics of the study subjects 
 European Indian Iranian Total 
Male 11 (31.4% ) 16 (55.2%) 22 (66.7%) 49 (50.5%) 
Female 24 (68.6%) 13 (44.8%) 11 (33.3%) 48 (49.5%) 
Total 35 (100%) 29 (100%) 33 (100%) 97 (100%) 
 
 A total of 97 volunteers were eligible to participate in the study (49 males and 48 
females).  In all, 35 participants (11 males and 24 females) were from European 
countries, 29 participants (16 males and 13 females) from India and 33 participants 
(22 males and 11 females) from Iran [Table 8]. The subject recruitment and 
















A total of 134 volunteers who responded to the 
recruitment were screened using an online 
questionnaire or phone conversation 
113 volunteers were invited 
to attend for clinical day 
21 volunteers were excluded 
following initial screening 
107 volunteers attended for 
clinical measurements 
  10 volunteers did not meet 
the study inclusion criteria 
97 volunteers were eligible 
to participate in the study 
6 volunteers dropped out 
before attending to the clinic 
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3.3 Materials used for data collection  
 
 Blood Collection Set 21G: (BD Vacutainer®, NJ, USA) 
 Body composition monitor: (Model  BC 541, Tanita corporation, China) 
 Citrate blood collection tube 4.5ml: (BD Vacutainer®, NJ, USA) 
 Dietary questionnaire: (Cancer Council, Victoria , Australia) 
 Examination gloves: (Labserv, Victoria, Australia)  
 Food frequency questionnaire: (Cancer Council of Victoria, Australia) 
 Human Adiponectin ELISA kit: (Life Research Pty Ltd, Victoria, Australia) 
 Human ELISA kit for Plasminogen Activator Inhibitor 1 (PAI1), Life Research Pty 
Ltd, Victoria, Australia  
 Human ELISA kit for Vascular Cell Adhesion Molecule 1 (VCAM1), Life Research 
Pty Ltd, Victoria, Australia 
 Human E-Selectin ELISA kit, Life Research Pty Ltd, Victoria, Australia  
 International physical activity questionnaire (IPAQ) 
 Laboratory centrifuge: Hettich zentrifugen, Germany 
 Lunar Prodigy Pro: General Electric Company, USA 
 Microcentrifuge tube 1.5 ml: Labserv, Victoria, Australia 
 Multiple sample luer adapter: BD Vacutainer®, NJ,USA 
 One Use Holder: BD Vacutainer®, New South Wales, NJ, USA 
 Plain plastic vial 5 ml:  Lomb Scientific Pty. Ltd., WA, Australia 
 Plastic transfer pipettes 1ml: Livingstone international Pty. Ltd. NSW, Australia 
 Portable stadiometer: Mentone Education Centre, design number 1013522, Victoria, 
Australia 
 Skin cleaning swabs saturated with 70% v/v Isopropyl Alcohol BP: BSN medical 
(Aust) Pty.Ltd., Victoria, Australia  
 Sphygmomanometer: empire® N - Stand model, Riester, Germany 
 SST™ II Advance blood collection tube 10ml: BD Vacutainer®, NJ, USA 






3.4 Methods of data collection 
 
A summary of different steps of data collection and the clinical assessment protocol 
used in this study is presented in Table 9. 
 
 
Table 9: Summary table describing different steps of data collection and clinical assessment 
protocols 
 
A. Introductory Phase 
1. Recruitment via different methods described in Section 3.2.1 
2. Screening of respondents via online screening questionnaire/ telephone 
3. Contact with eligible volunteers to arrange an appointment for clinical 
examination date, and to send food frequently questionnaire. 
 
B. Clinical assessment protocols  
1. On the morning of clinical examination date, participants attended at the 
Health Service Centre, Curtin University, following an overnight fast of 10-
14 hours 
2. Upon arrival, volunteers received the participant information sheet 
explaining the study’s procedures and protocols in details. The written 
consent form was then obtained. 
3. Participants were then asked to empty their bladder and collect a midstream 
urine sample. 
4. Anthropometric measurements were taken with volunteers dressed in light 
indoor clothing, without shoes and an empty bladder. 
5. Volunteers were then asked to take a rest of 15 minutes prior to blood 
pressure assessment and blood sampling. 
6. Systolic and diastolic blood pressures were taken using the blood pressure 
manometer with the appropriate adult cuff size. 
7. Blood samples were then taken through venepuncture. The separated plasma 
and serum were stored at -80º C. 
8. The Food frequency questionnaire and physical activity questionnaire 
completed by participants were then checked by investigators. 
9. Lastly, body composition assessment was done using the method of whole 
body dual energy x-ray absorptiometry (DEXA) available in the school of 





3.4.1 Introductory phone conversation 
After a primary screening, volunteers who met the inclusion criteria received overall 
information about the study via phone conversation and email. They also received 
answers to questions they had. Their questions were usually about the eligibility 
conditions, the time that they needed to allocate for their contribution in the study, 
their medical history as well as their appointment. Participants were also instructed to 
fast overnight between 10-14 hours before attending in out-patient clinic at Curtin 
University for clinical assessment explained in below. 
 
3.4.2 Clinical assessment protocols 
Clinical assessments including anthropometrical, biomedical, biophysical variables 
were conducted in outpatient clinic at the Health Service Centre; and the research 
room at Health Sciences Building, Curtin University, Bentley Campus, Western 
Australia. On presentation to the clinic, volunteers received the participant 
information sheet [Appendix 3] explaining the study’s procedures and protocols in 
details. Then, they completed a written consent form and signed it before clinical 
examination and phlebotomy [Appendix 4]. 
 
3.4.2.1 Anthropometrical measurement 
Anthropometric measurements were taken with volunteers dressed in light indoor 
clothing, without shoes and an empty bladder. Participants were weighed on a 
calibrated portable electronic scale to the nearest 0.1 kg. Height was measured with a 
portable stadiometer (Mentone Education Centre) to the nearest 0.5 cm with 
participants in stocked feet, standing straight against a wall. Body Mass Index (BMI) 




) and classified into normal weight 
(BMI<25), overweight (25≤BMI<30) and obesity (BMI ≥30). 
 
Waist circumference was measured twice in the standing position, halfway between 
the lateral lower margin of ribs and the iliac crest on hip bone, with abdomen 
relaxed, arms relaxed at the sides and feet collected together.  Hip circumference was 
measured at the widest horizontal point over the buttocks. The average of two 
measurements to the nearest 0.1 cm, using a plastic measuring-tape, was taken the 
final record. Waist circumference was measured according to the WHO 
recommendation and classification for different ethnic groups (Gibson 2005; WHO 
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2005). Waist hip ratio (WHR) was calculated as the ratio between waist and hip 
circumferences. 
 
3.4.2.2 Blood pressure measurement 
After the anthropometrical measurements, participants were asked to take a rest of 
about 15 minutes prior to blood pressure assessment to establish their systolic and 
diastolic pressures. Systolic (SBP) and diastolic (DBP) blood pressure were taken 
using the blood pressure manometer (Riester, Germany) with the appropriate adult cuff size. 
The average of three times measurements on the left arm with 5 minutes interval; and 
the subjects in supine position was recorded.  
 
3.4.2.3 Biomedical assessment 
Blood samples were taken through venepuncture into plasma and serum vacutainer 
tubes by qualified nurse in the Health Service Centre at Curtin University. Blood 
samples were centrifuged in the Laboratory centrifuge, [Hettich zentrifugen, 
Germany], at RCF 2000 g for 10 minutes for both plasma and serum tubes. However, 
serum tubes were left at the normal room temperature (18 - 25º C) for 15 to 30 
minutes in vertical position to be clotted prior to centrifugation. The separated 
plasma and serum were stored in 1.5 mL microcentrifuge tubes at -80º C. 
 
The fasting samples were analysed for glucose, insulin, hs-CRP, triglyceride, total 
cholesterol, LDL and HDL cholesterol, VCAM-1, Adiponectin and E-selectin.  
 
For urine samples, participants were asked to empty their bladder and take a 
midstream urine sample. Ten mL of each urine sample was stored in two separate 5 
mL plain vials at -80º C, until analysis for albumin and creatinine. 
 
Enzymatic colorimetric assays on a general chemistry analyser were used to 
determine the levels of serum glucose, triglyceride and total cholesterol levels. The 
concentration of serum HDL cholesterol was measured using an appropriate direct 
method (Ultra HDL assay). All of these analysis were performed using Abbott 
diagnostic kits (Abbott laboratories, IL, USA) with a between- and within-run 
coefficient of variation <4.3%. LDL cholesterol was calculated using a modified 
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version of the Friedewald equation (Friedewald, Levy, and Fredrickson 1972) with 
quantities in mmol/L. 
 
Insulin concentrations were measured by the Abbott Architect insulin assay. The 
derived concentration of fasting glucose and insulin were used to calculate the 
homeostatic model assessment (HOMA) score through the related equation below 
(Bonora et al. 2000). This method was defined and used for first time by Matthews 
and et al. in 1985 (Matthews et al. 1985). 
 
     
                (
   
 )                  (
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A score > 2.5 signifies low insulin sensitivity in adults (Keskin et al. 2005). 
 
Serum hs-CRP was assessed by nephelometry using a BNII analyser (Siemens 
Healthcare Diagnostic Inc. Newark, DE, USA) with between and within-run 
coefficient of variation of 8.4% and 5.7% respectively.  
 
The albumin and creatinine levels were assessed to determine albumin/creatinine 
ratio in the fasting spot urinary samples.  An albumin excretion ≥ 30 and < 300 mg/g 
creatinine was classified as microalbuminuria. Clinical albuminuria was detected in 
the present of an albumin creatinine ratio ≥300 mg/g (Molitch et al. 2004). The level 
of albumin in urine samples were assessed by the Abbott Micro-albumin assay, with 
between and within-run coefficient variation of 12.9% and 7.4% (Wako Pure 
Chemical Industries, Ltd. Osaka, Japan).     
 
ELISA assays were used to analyse VCAM-1 (USCN Life Science Inc., Houston, 
USA), Adiponectin (Assaypro Inc., Missouri, USA) and E-selectin (Cusabio, Hubei, 
China) respectively. All ELISA assays were done at Curtin University and the 





3.4.3 Dietary intake assessment 
Usual dietary habits over the 12 past months were assessed using the validated food 
frequency questionnaire developed by the Cancer Council of Victoria, Australia 
[Appendix 5] (Giles and Ireland 1996; Hodge et al. 2000). This semi-quantitative 
dietary questionnaire is established specifically for use in Australian adults; and 
includes 74 food items with 10 frequency response options extending from ‘Never’ 
to ‘3 or more times per day’.  
 
It also included 3 photographs of scaled portions for four foods (used to calculate a 
serving size calibrator), questions about the overall frequency of fruits and 
vegetables intake (used to calibrate the overestimation of these items in the food list), 
and questions on some food intakes like bread that do not fit into the frequency 
format simply.  
 
In addition, the 74 food items were categorized into four different groups:  
A) Cereal foods; sweets and snacks;  
B) Dairy products, meats and fish;  
C) Fruit and  
D) Vegetables.   
 
Moreover, the assessment of alcoholic beverages intake was covered by a set of 
separate questions. The output of the questionnaire comprised 35 nutrients such as 
total carbohydrate and fat, protein; and total saturated monounsaturated and 
polyunsaturated fatty acids (Cancer Council Victoria 2009).  
 
Participants received the dietary questionnaire and were instructed on how to 
complete it at home prior to attending the clinic on the clinical examination date (the 
day on which patient samples and anthropometric measurements were taken) in order 
to fill out it at a more convenient time. However, they given additional guidance 
during clinical examination, if they have had any questions or concerns. Then, the 
filled questionnaires were checked by the researcher to ensure they were completed 




Dietary questionnaires were analysed by the Cancer Council Victoria, Australia 
using the related software. The software calculates the weight of each food item 
according to the serving size recorded respond by individuals and multiplies with the 
frequency of consume.  The frequency scale used for the analysis of above 74 food 
items is shown in Table 10. 
 




Frequency Daily equivalent 
frequency 
1 Never 0 
2 Less than once per 
month 
0.02 
3 1-3 times per month 0.07 
4 Once per week 0.14 
5 Twice per week 0.28 
6 3-4 per week 0.5 
7 5-6 per week 0.78 
8 Once per day 1 
9 Twice per day 2 
10 3 or more per day 3 
Cancer Council Victoria (Giles and Ireland 1996) 
 
 
The final outcomes are classified in different formats including: 
1. Raw data  
2. Nutrients computed from food without alcoholic beverages (including 
carotenoids and fatty acids, glycaemic index and glycaemic load), 
3. Nutrients from alcoholic beverages, 
4. Nutrients from food intakes, and 
5. An error report 
 
All derived information classified in above categories show the total energy received 
from carbohydrate, protein and fat including total saturated fatty acids, 
monounsaturated fatty acids and polyunsaturated acids and other nutrients in every 
individual. The analysis outcomes also demonstrate the amount of the main minerals, 
vitamins and dietary fibres consumed by participants.   
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3.4.4 Physical activity 
Participants’ physical activity level was assessed using the short version of the self-
administrated international physical activity questionnaire (IPAQ). The validity and 
reliability of this questionnaire has been tested in over 12 countries, including 
Australia (Craig et al. 2003). The questionnaire assesses three specific types of 
activities including walking, moderate-intensity and vigorous-intensity activities 
(described through the questionnaire along with some examples [Appendix 6]) 
during a period of one week.  
 
They cover the activities undertaken through four comprehensive domains including:  
1) leisure time physical activity,  
2) domestic and yard activities,  
3) work-related physical activity,  
4) Transport-related physical activities.  
 
Data collected from the questionnaires were analysed in a continuous scoring format. 
Based on the level of intensity, each group of activities was assigned a metabolic 
equivalent score (METs) derived from the reliability study undertaken in 2000-2001. 
The Met score for walking, moderate-intensity and sever-intensity activities are 3.3, 
4.0 and 8.0, respectively (Craig et al. 2003). The score for each group of activities 
was calculated by multiplying the time spent on those activities (in minutes) by the 
assigned MET value. The total value for one week was the sum of the scores (MET-
minutes/week) calculated for each activity:  
 







 MET minutes/week scores: 
1. Walking MET-minutes/week = 3.3 * walking minutes * walking days/week 
2. Moderate MET-minutes/week = 4.0 * mod.-intensity activity min * moderate 
days/week 





3.4.5 Body composition 
Body composition assessment was the last clinical parameter which was measured, 
done through body scanning in the school of physiotherapy at Curtin University. For 
this purpose, the method of whole body dual energy x-ray absorptiometry (DEXA) 
was used [Lunar Prodigy (GE Corporation, USA)]. It is reliable, economical and safe 
method compared to other methods such as CT scan as it uses low dose x-ray of two 
different energy levels (Van Loan and Mayclin 1992). Female participants were 
rechecked to ensure they are not pregnant or breastfeeding. Then, they were 
informed about the scanning procedure in detail. Participants also were requested to 
change into a laboratory gown and remove all personal metal items like jewellery or 
watches prior to the scan. 
 
 
3.5 Statistical analysis 
 
SPSS statistics package for windows, version 21 (IBM Corporation, USA) was used 
for all statistical analysis. The analysis started with descriptive statistics. Cross-
tabulation analysis was used to obtain a frequency distribution of categorical 
variables, and to compare different definitions of metabolic syndrome. For 
continuous variables, including anthropometric, biomedical, dietary and physical 
activity measurements, data are presented as mean ± standard deviation (SD) (in the 
text and tables), and mean ± standard error of mean (SEM) (in charts). All 
continuous variables were also assessed for normality. Transformation or a 
nonparametric test, like Shapiro-Wilk, was used if the variable was not normally 
distributed. 
 
To assess variance equality, the Leven test was used between categorical and 
continuous variables. 
 
The level of agreement between different definitions of metabolic syndrome was 
assessed using the kappa coefficient. Kappa values lower than 0.40 were considered 
as a “poor” agreement beyond chance, values between 0.40 and 0.75 indicated as 
“fair” to “good” agreement beyond chance, and coefficients 0.75 and greater were 
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considered as “agreement” beyond chance (Landis and Koch 1977; Fleiss 1981), 
Independent t tests were used to compare anthropometrics with metabolic variables 
among genders. 
 
One way ANOVA with Tukey’s HSD adjustment was used to compare the 
categorical and all normal continuous variables which met other parametric 
conditions for this purpose. In addition, the association between continuous variables 
were evaluated using Pearson Correlation using SPSS software. Some variables, such 
as fasting blood glucose, which did not meet the parametric conditions were assessed 
by related non-parametric tests such as the Kruskal Wallis test.   
 
3.6 Ethical Considerations 
 
The study was conducted according to the guidelines laid down in the Helsinki 
declaration and the National Health and Medical Research Council Guidelines 
(NHMRC, 2007) and all protocols involving human subjects were approved by the 
Curtin University Human Research Ethics Committee (HR 179/2008). All 
participants participated voluntarily, provided informed consent and were made 
aware that they could withdraw at any time from the study. The results were also 
shared with the participants. 
 
Chapter 3 has provided an overview of the research methods used to test the 












This chapter provides the results in six sections including the overall characteristics 
of the study groups, comparison of the different definitions of metabolic syndrome, 
dietary configuration and physical activity levels, assessment the components of 
metabolic syndrome, the effects of ethnicity on endothelial dysfunction and 
assessment of adiponectin in three ethnic groups. Firstly, an overview of basic 
measures is given and then these are evaluated in relation to other derived indices 
and to features such as diet and physical activity.  
 
4.1 Overall characteristics 
 
One hundred and thirty-four individuals responded to the advertisements and 
invitation to participate in the study.  Initially, the potential volunteers were screened 
for the inclusion and exclusion criteria via telephone and email.  Of 106 volunteers 
who seemed suitable, 97 were considered eligible during final screening at the clinic 
by the investigator. All ninety-seven participants (49 males and 48 females) from 
three ethnic groups in Western Australia completed the assessments planned for this 
study. 
 
The participants ranged in age from 19 to 74 years (46.2±13.7). As shown in the 
Table 11, participants with a background from European countries had higher mean 
age than Indians (55.6±11.7 vs. 38.2±11.5 y; P<0.001) and Iranians (55.6±11.7 vs. 
43.2±12.5; P<0.001). Participants also had a mean weight of 84.8±13.9 kg. There 
was no significant difference in the mean weight of participants in three ethnic 
groups (Europeans: 86.6 ±14.2 kg, Indians: 80.1±12.7 kg, Iranians: 86.9±15.9 kg; All 








ranging from 25.0 to 41.1, with a higher, 
but not significant difference, in women than men, 30.1 (±4.2) and 29.8 (±3.4) 
respectively; (P=0.67). In all, 56.7% of the 97 participants were overweight, whereas 
43.3% of them were classified as obese cases.  
 
The mean WC, HC and WHR found were 99.4 ±11.0 cm, 106.1 ±9.3 cm and 0.09 
±0.1 respectively. Participants had mean total body fat percentage of 37.3 (±7.9), 
truncal body fat percentage 55.2 (±7.1) and total fat mass (g) / total lean mass (g) 
percentage 65.9 (±22.7). Also, they had mean SBP of 121.3 ±13.97 mmHg, DBP of 
79.44 ±1.13 mmHg, fasting plasma glucose of 5.23±0.11 mmol/L, serum triglyceride 
of 1.45±0.08 mmol/L, total cholesterol of 5.20±0.10 mmol/L, HDL-cholesterol of 





Table 11: Anthropometric and metabolic characteristics of participants in each ethnic group, unadjusted for age or sex   
 
 



























- groups   
P-value 
Mean (SD) Range Mean (SD) Range Mean (SD) Range 
Age (y) 55.6 (11.07) 21-74 38.2 (11.49) 24-64 43.2 (12.45) 18.5-70 <0.001 <0.001 0.220 <0.001 
Weight (kg) 86.6 (14.2) 58-112 80.14 (12.71) 55.5-96.9 86.92 (15.1) 57-134 0.149 0.995 0.130 0.10 




 30.78 (3.9) 25.0-41.1 29.02 (3.7) 25.2-41.0 29.88 (3.8) 25.1-40.5 0.137 0.572 0.618 0.16 
Waist circumference (cm)  102.3 (11.1) 84.0-132.0 96.1 (10.0) 72.0-121.0 99.2 (11.0) 78.0-129.0 0.062 0.460 0.502 0.08 
Hip circumference (cm)
b
 108.7 (10.7) 91.0-141.0 102.52 (8.1) 92.0-124.0 106.4 (8.0) 90.0-128.0 0.019 0.592 0.182 0.03 
Waist/Hip ratio 0.942(0.08) 0.77-1.08 0.937(0.07) 0.79-1.04 0.932(0.08) 0.76-1.07 0.957 0.831 0.959 0.84 




125.4 (15.2) 104-160 120.6 (14.2) 95-160 117.6 (11.5) 98-142 0.346 0.059 0.690 0.07 
Diastolic blood pressure 
(mmHg) 
83.0 (10.2) 64-103 80.2 (10.4) 50-105 75.06 (11.4) 56-94 0.554 0.008 0.152 0.01 
Fasting glucose (mmol/L)  5.6 (1.10) 4.7-9.8 5.22 (1.00) 4.3-8.7 4.85 (0.99) 3.8-9.7 0.017 <0.001 0.073 <0.001 
Fasting insulin (µIU/mL)  10.6 (5.65) 3.6-23.9 9.76 (4.22) 3.6-20.8 8.35 (5.98) 1.3-28.7 0.963 0.061 0.135 0.06 
hs-CRP (mg/L) 
b
  4.37 (5.34) 0.4-24.6 3.54 (3.66) 0.3-14.2 2.75 (3.09) 0.2-15.2 0.949 0.659 0.858 0.68 
Total cholesterol (mmol/L) 5.64 (0.81) 4.0-7.2 5.21 (1.04) 3.4-7.3 4.72 (0.81) 2.5-6.2 0.14 <0.001 0.08 <0.001 
LDL-chol (mmol/L) 3.55 (0.72) 1.6-5.0 3.38 (0.89) 1.2-5.4 3.00 (0.75) 1.4-4.2 0.661 0.014 0.150 0.02 
HDL-chol (mmol/L) 1.38 (0.32) 0.7-2.4 1.13 (0.24) 0.8-1.7 1.12 (0.29) 0.7-1.9 0.003 0.001 0.983 <0.001 
Triglycerides (mmol/L) 
b
 1.54 (0.84) 0.6-3.8 1.53 (0.67) 0.6-3.3 1.30 (0.74) 0.3-3.5 0.956 0.294 0.205 0.18 
HOMA score 
c
 2.78 (1.97) 0.83-9.45 2.30 (1.13) 0.7- 4.68 1.80 (1.27) 0.22-5.74 0.785 0.011 0.082 0.03 













0.535 0.063 0.494 0.20 
a. P1, P2 and P3 demonstrate P values between European and Indian, European and Iranian; and Indian and Iranian groups respectively; b. P-values were determined after 
the variable was log transformed; c. All P-values were determined using a one-way ANOVA with Tukey’s HSD test, except for fasting glucose, fasting Insulin, HOMA and 
physical activity which were determined using a nonparametric test (Kruskal Wallis);hs-CRP, high sensitive C - reactive protein; LDL-chol, low density lipoprotein 


































groups   
P-value 
Mean (SEM) 95% CI Mean (SEM) 95% CI Mean (SEM) 95% CI 





 30.72(0.787) 29.16-32.28 29.11(0.77) 27.58-30.64 29.92(0.721) 28.49-31.36 0.145 0.443 0.387 0.34 
WC (cm) 100.69(2.08) 96.55-104.83 97.75(2.04) 93.70-101.81 99.137(1.90) 95.34-102.93 0.352 0.595 0.614 0.65 
HC (cm)
b
 107.74(1.82) 104.12-111.37 102.59(1.78) 99.04-106.14 107.10(1.67) 103.78-110.42 0.061 0.856 0.051 0.09 
W/H 0.937(0.012) 0.914-0.960 0.952(0.011) 0.930-0.975 0.926(0.011) 0.905-0.947 0.399 0.490 0.090 0.24 
SBP (mmHg)
b
 120.53(2.62) 115.31-125.74 123.82(2.56) 118.71-128.92 117.92(2.40) 113.14-122.69 0.422 0.473 0.094 0.24 
DBP (mmHg) 80.75(2.09) 76.59-84.91 82.00(2.05) 77.93-86.07 75.17(1.91) 71.36(78.98) 0.692 0.059 0.014 0.03 
hs-CRP (mg/L)
b
 4.64(0.832) 2.99-6.29 3.50(0.814) 1.88-5.11 2.80(0.76) 1.28-4.31 0.825 0.645 0.812 0.90 
Total cholesterol 
(mmol/L) 
5.40(0.17) 5.06-5.74 5.24(0.168) 4.90-5.57 4.68(0.157) 4.37-4.99 0.525 0.003 0.015 0.005 
LDL-chol (mmol/L) 3.38(0.154) 3.07-3.68 3.37(0.15) 3.07-3.67 2.96(0.141) 2.68-3.24 0.980 0.055 0.044 0.06 
HDL-chol (mmol/L) 1.28(0.05) 1.18-1.38 1.16(0.049) 1.06-1.26 1.16(0.046) 1.07-1.25) 0.125 0.102 0.987 0.21 
Triglycerides (mmol/L)
b
 1.61(0.153) 1.31-1.91 1.52(0.15) 1.22-1.82 1.20(0.14) 0.92-1.48 0.98 0.037 0.028 0.04 
 
a. P1, P2 and P3 demonstrate within - groups P values between European and Indian, European and Iranian; and Indian and Iranian groups respectively 
b. P-values were determined after the variable was log transformed. All P-values were determined using a one-way ANOVA with Tukey’s HSD test. BMI, body mass index; 
WC, waist circumference; HC, hip circumference; W/C, Waist/Hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure, hs-CRP, high sensitive C - reactive 
protein; LDL-chol, low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol
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4.2 Comparison between the different definitions of metabolic 
syndrome 
 
According to the WHO classification [see Section 2.2.1.1, Table 1 & Table 4], 28.6% 
of participants in the European group, 27.6% of those in the Indian group and 18.2% 
of those in the Iranian group were identified as having metabolic syndrome. These 
percentages changed to 22.9%, 37.9% and 27.3% respectively, when ATPIII criteria 
[see Section 2.2.1.3] were used as the basis of classification [Table 13].  
 
Furthermore, there was an increased discrepancy when participants were classified 
with regard to EGIR and IDF criteria [see sections 2.2.1.2 & 2.2.1.5], namely 17.1%  
of European participants, 27.6% of Indians and 21.2% of Iranians according to EGIR 
definition, compared to 28.6%, 41.4% and 27.3%, respectively based on IDF 
definition. 
 
Table 13: Percentages of participants classified as having metabolic syndrome based on four 














Overall 28.6(10)  17.1(6)  22.9(8) 28.6(10) 
Male(11) 27.3(3) 9.1 (1) 27.3(3) 36.4 (4) 
Female(24) 29.2(7) 20.8 (5) 20.8(5) 25.0 (6) 
Indians  
(n=29) 
Overall  27.6(8) 27.6 (8) 37.9 (11) 41.4 (12) 
Male (16) 25(4) 25 (4) 31.3(5) 37.5 (6) 
Female (13) 30.8(4) 30.8 (4) 46.2(6) 46.2(6) 
Iranians 
(n=33) 
Overall 18.2(6) 21.2 (7) 27.3 (9) 27.3 (9) 
Male (22) 9.1(2) 18.2 (4) 22.7(5) 22.7(5) 
Female (11) 36.4(4) 27.3 (3) 36.4(4) 36.4(4) 
Total  
(n=97) 
Overall  24.7(24) 21.6 (21) 28.9 (28) 32 (31) 
Male (49) 18.4(9) 18.4(9) 26.5 (13) 30.6 (15) 






The total percentage of participants meeting metabolic syndrome criteria was the 
highest for the IDF (32%) followed by ATPIII (28.9%), WHO (24.7%) and EGIR 
(21.6%), Also, metabolic syndrome was more prevalent among female participants 
relative to males, using four definitions [Table 13]. 
 
Table 15 presents the level of agreement between metabolic syndrome defined by 
WHO, EGIR, ATPIII and IDF in three ethnic groups. Four definition of metabolic 
syndrome showed different levels of agreement in Europeans, Indians and Iranians. 
Overall, there was an excellent agreement (see Section 3.5) between IDF and ATPIII 
definitions (κ=0.83). IDF and ATPIII also showed the highest agreement in 
European (κ =0.851) and Iranian (κ =0.847) groups. However, in Indians the highest 
concordance was observed between WHO and EGIR (κ =0.827). WHO definition 
also showed a good agreement (see Section 3.5) with metabolic syndrome defined by 
ATPIII and IDF. 
 
Insulin resistance (based on the calculated HOMA score > 2.5) was identified in 
91.7%, 90.5%, 67.9% and 67.7% of participants classified as having metabolic 
syndrome based on WHO, EGIR, ATPIII and IDF criteria, respectively. Also, the 
highest percentage of participants with insulin resistance was discovered by WHO 
definition (66.7%), followed by IDF (63.6%).  However, ATPIII and EGIR failed to 
detect 42.4% of insulin resistant participants [Table 14]. 
  
 
Table 14: Number of participants with hyperglycaemia and insulin resistance classified as 




(n = 24) 
EGIR  
(n = 21) 
ATPIII  
(n = 28) 
IDF  
(n = 31) 
IR based on HOMA > 2.5 
(n=33) 
22 (66.7%) 19 (57.6%) 19 (57.6%) 21(63.6%) 
Diabetes mellitus  
(n= 6) 
5 (83.3%) 5 (83.3%) 5 (83.3%) 5 (83.3%) 
IFG  
(n= 5) 







Table 15: The level of agreement between metabolic syndrome defined by WHO, EGIR,    
ATPIII and IDF in three ethnic groups 
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The level of agreement was assessed using the kappa coefficient. WHO, world health organization; 
EGIR, European Group for the Study of Insulin Resistance; ATP III, Adult Treatment Panel III; IDF, 




4.3 Dietary characteristics and physical activity levels in three ethnic 
groups 
 
Increased risks of metabolic syndrome in different populations can be due to the 
factors related to health behaviours. Accordingly, individuals participating in this 
study were also evaluated for dietary habits, nutrients intake and levels of physical 
activity. Different components of metabolic syndrome were then assessed among the 
ethnic groups after controlling for these factors, as potential confounders. 
 
Overall, participants of this study had a mean (±SD) daily energy intake of 6708.08± 
2941.18 kJ/day, carbohydrate intake of 175.93±8.13, protein intake of 79.17± 4.23 
g/day and total fat intake of 62.39±3.15 g/day. 
 
Using ANOVA analysis, ethnicity was significantly associated with the intakes of 
bread & cereal foods (P= 0.03), meat & fish (P<0.001), vegetable & legumes 
(P<0.001), and fruit (P=0.001) as well as nutrients of protein (P<0.001), cholesterol 
(P=0.01), potassium (P= 0.007), sodium (P=0.01) and magnesium (P=0.04). 
 
Although, there was no significant difference between the amounts of carbohydrate 
taken by the three ethnic groups, they showed differences in regard to the intake of 
other nutrients [Table 16]. Namely, participants in Indian group had significantly 
lower intakes of protein (Indians: 55.2±37.6, Europeans: 83.5±31.4, Iranians: 
95.7±46.0 g/day), magnesium (Indians: 219.1± 97.8, Europeans: 276.2±99.4, 
Iranians: 289.1±132.2 mg/day) and sodium (Indians: 1505.3±853.6, Europeans: 
2103±851.0, Iranians: 2160.2±1037.3 mg/day) compared to Europeans and Iranians 
(all P-values between Indians vs. Europeans & Iranians <0.05).   
 
Indian participants also had significantly lower intake of total daily energy intake 
(Indians: 5732.2±2772.3, Iranians: 7527.3±3239.1 KJ/day, P=0.02) and dietary fat 






As to be expected, the lower intake of protein in Indians was associated with the 
lower consumptions of meat & fish, (Europeans: 156.1±96.0, Indians: 60.5±140.3, 
Iranians: 192.8±135.8 g/day), as the main source of this nutrient [Table 17]. The 
highest and lowest consumption of vegetables & legumes per day were consumed by 
Europeans and Indians, respectively (Europeans: 162.8±87.1, Indians: 58.5±35.1, 
Iranians: 79.2±39.6 g/day), while participants in Iranian group consumed the highest 
amounts of fruits (Europeans: 225.4±162.5, Indians: 243.0±170.2, Iranians: 
383.9±188.0 g/day) and breads & cereal foods (Europeans: 195.8±108.9, Indians: 
174.9±100.1, Iranians: 254.9±155.5 g/day) in comparison with Europeans and 
Indians. 
 
Correlation analysis showed a significant association between BMI and total fat 
intake (ρ=0.21, P= 0.04). We found no significant correlations between different 
energy/nutrients intakes and blood glucose and insulin, HOMA, SBP, DBP, serum 
total cholesterol and LDL-cholesterol. However, the levels of serum TG and HDL- 
cholesterol were significantly correlated with dietary intakes of total energy (TG: 
ρ=0.22 , P=0.03 ; HDL-C: ρ= - 0.25, P= 0.01 ), carbohydrate (TG: ρ= 0.21, P= 0.04; 
HDL-C: ρ= - 0.32 , P= 0.002), total fat (TG: ρ= 0.22, P=0.03 ; HDL-C: ρ= - 0.21, P= 
0.04 ) and saturated fat(TG: ρ= 0.23 , P=0.02 ; HDL-C: ρ= -0.24, P=0.02).   
 
As shown in Table 11, Iranian participants had non- significant trends to a higher 
mean physical activity levels relative to Europeans (P=0.06) and Indians (P=0.49). 
Meanwhile, there was a significant difference between mean physical activities 
levels determined in male and in female participants (M: 5667.3± 6241.3; F: 3216.1 
±4832.2, P = 0.01).  
 
In partial correlation analysis, we found no significant association between the levels 
of physical activity and blood glucose, insulin, insulin resistance (indicated by 
HOMA), serum lipid profile, or indices of obesity (BMI, WC, W/H), after 
controlling for age and gender.  
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Table 16: Characteristics of the dietary intake by three ethnic groups  
Ethnicity/ 
Nutrient 

























0.174 0.555 0.019 0.02 





83.46 (31.41) 33.4-163.1 55.2(37.6) 16.5-223.0 95.7(46.0) 31.05-279.5 <0.001 0.554 <0.001 <0.001 
Total Fat 
b 
(g/d) 65.36 (4.92) 26.0-130.3 52.7 (31.5) 19.5-169.7 67.7(31.6) 31.5-189.2 0.085 0.915 0.037 0.03 
Sat. Fat 
b
 (g/d)   26.21(11.39) 10.7-47.2 23.8 (14.0) 9.54-75.46 27.4 (13.5) 7.40-72.09 0.530 0.967 0.400 0.39 
Poly. Fat 
b (
g/d)   9.49 (5.77) 2.65-26.69 6.69 (4.51) 1.52-19.42 8.83 (4.86) 3.59-28.28 0.024 0.992 0.035 0.01 
Mono. Fat 
b
 (g/d) 23.76 (11.09) 8.91-53.57 17.42(11.57) 5.58-61.04 24.57(11.79) 11.11-71.45 0.008 0.907 0.003 0.002 
Cholesterol 
b 
(mg/d) 280.6(120.0) 123.4-605.0 201.7(177.3) 44.9-898.1 310.8(144.9) 76.2-730.8 0.001 0.819 <0.001 <0.001 
Fibre (g/day) 19.45(8.59) 2.72-35.50 15.80(8.67) 3.67-35.84 20.88(9.33) 7.23-49.71 0.235 0.784 0.068 0.08 
Calcium (mg/d) 848.53(280.5) 379.5-1397.6 743.79(320.2) 187.0-1321.2 878.54(311.3) 357.8-1895.8 0.358 0.912 0.194 0.20 
Magnesium 
b
(mg/d) 276.19 (99.36) 110.0-532.6 219.1(97.8) 73.5-478.2 289.1(132.2) 112.6-819.6 0.033 0.944 0.016 0.01 
Sodium 
b 
(mg/d) 2103.7(851.0) 660.30-4199.7 1505.3(853.6) 504.3-4423.0 2160.2(1037.3) 687.4-5867.1 0.004 0.999 0.004 0.001 
Potassium 
b
 (mg/d) 2564.0 (810.1) 1186.4-4124.1 1946.0(879.8) 809.7-4971.0 2585.9 (929.2) 984.7-5901.3 0.003 0.999 0.003 0.001 
a. P1, P2 and P3 demonstrate within- groups P- values between European and Indian, European and Iranian; and Indian and Iranian groups respectively 
b. P-values were determined after the variable was log transformed. All P-values were determined using a one-way ANOVA with Tukey’s HSD test; Sat. Fat, saturated fat; 
Mono. Fat, mono unsaturated fat; Poly. Fat, poly unsaturated fat.    
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Table 17: The main source of dietary intake along with the amount of dietary consumption by three ethnic groups 
Ethnicity/ 
Food intake 
Europeans Indians Iranians    
 








groups   
P-value 
Breads& Cereal 













0.783 0.156 0.044 0.04 














<0.001 <0.001 0.534 <0.001 





























0.916 <0.001 0.003 <0.001 
Vegetables& 













<0.001 <0.001 0.079 <0.001 














0.886 0.218 0.241 0.39 
 
  a. P1, P2 and P3 demonstrate P- values between European and Indian, European and Iranian; and Indian and Iranian groups respectively 
  b. P-values were determined after the variable was square-root transformed. 
  c. P-values were determined after the variable was log transformed. 
  d. P-values were determined using non-parametric test.  
  All P-values were determined using a one-way ANOVA with Tukey’s HSD test, except for edible fat which was determined using a nonparametric test (Kruskal Wallis). 
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4.4   Assessment of metabolic syndrome criteria 
 
4.4.1 Anthropometric measurements 
European, Indian and Iranian study participants had mean BMI (±SD) of 30.8 (±3.9), 
29.0 (±3.7) and 29.9 (±3.8) kg/m
2
, respectively. The higher BMI in European 
participants was accompanied with a higher body fat percentage (derived from 
DEXA analysis) when they were compared with Indians (39.6±8.2% vs. 37.2±7.6 %, 
P=0.45) and Iranians (39.6±8.2% vs. 35.1±7.3%, P<0.05) [Table 18& Figure 9]. 
 
Using multiple regression analysis, a model including ethnicity, sex, BMI, physical 
activity, and total energy intake could predict 79.5% and 78.7 % of variability in total 
body fat percentage and total fat-to-lean mass ratio in the participants, respectively. 
Interestingly, after adjustment for age and gender Indians had a significantly higher 
total body fat percentage when they were compared with Europeans (38.68±0.75% 
vs. 36.13±0.76%, P<0.05) and Iranians (38.68±0.75% vs. 36.67±0.70%, P<0.05) 
with the same BMI [Figure 10].     
 
The effect of ethnicity on the body fat distribution was assessed by evaluating the 
participants’ truncal body fat percentages. Participants in Indian group had a higher 
mean (±SD) truncal body fat percentage (56.4±5.3) relative to European (54.8±6.7) 
and Iranian (54.5±8.6) groups, although the differences were not statistically 
significant (P values >0.05) [Figure 9]. 
 
Using stepwise backward multiple regression, truncal body fat percentage was 
significantly related to ethnicity (P=0.002; for Europeans: β= - 0.007; for Indians: 
β=2.5; Iranians: β=0, as the reference group), age (β= 0.1, P=0.002), sex (P<0.001; 
for female: β= - 10.2; for male: β= 0, as the reference gender) and waist 
circumference (β= 0.2, P<0.001).  
 
Neither participants’ energy& nutrient intakes nor their physical activity levels had 
significant effect on the body fat distribution. There was no change in the trend, but 
the differences between the Indians’ truncal body fat percentages (estimated 
mean±SEM) and those determined in Europeans and Iranians increased after 
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adjustment for age, sex and WC (European: 54.4±1.0%, Indian: 57.8±0.9%, Iranians: 























Table 18: Body composition characteristics derived from DEXA  
Participants’ characteristics 















Mean (SD) Range Mean (SD) Range Mean (SD) Range 
Total body mass (kg) 85.80(14.26) 56.44-109.84 79.19(12.58) 55.06-96.48 86.16(13.34) 63.86-129.59 0.129 0.993 0.110 0.08 
Total fat mass (kg) 33.88(9.34) 19.95-62.31 29.21(6.78) 21.78-45.57 30.40(8.52) 12.74-53.21 0.072 0.204 0.842 0.07 
Total lean mass (kg) 49.16(11.50) 32.71-76.35 47.25(10.80) 29.58-64.20 52.76(9.18) 35.84-80.07 0.751 0.343 0.106 0.12 
Total bone mass (kg) 2.76(0.52) 1.96-4.03 2.74(0.56) 1.75-4.02 30.08(0.47) 2.07-3.91 0.984 0.122 0.104 0.07 
Total body fat  (%) c 39.60(8.21) 23.32-57.02 37.24(7.58) 24.29-53.08 35.07(7.31) 18.91-51.08 0.445 <0.05 0.516 0.06 
Total body lean mass (%) d 57.16(7.95) 40.58-73.49 59.30(7.27) 43.62-71.22 61.40(7.03) 45.86-76.68 0.489  0.054 0.511 0.07 
Total body Fat/Lean mass ratio 0.73(0.24) 0.32-1.41 0.65(0.22) 0.34-1.22 0.59(0.20) 0.24-0.77 0.413 0.042 0.53 0.05 
Truncal fat mass (kg) 18.48(5.38) 9.58-35.80 16.45(3.96) 11.41-24.61 16.68(5.59) 6.77-28.99 0.252 0.313 0.982 0.21 
Total trunk mass (kg) 43.50(8.85) 26.12-63.58 39.73(7.16) 26.20-51.72 42.49(1.55) 25.45-72.97 0.181 0.873 0.407 0.20 
Truncal body fat percentage (%)e 54.81(6.74) 43.72-70.24 56.37(5.31) 47.78-63.87 54.55(8.62) 32.72-67.47 0.657 0.987 0.571 0.56 
Truncal fat percentage  (%)f 42.40(7.14) 27.46-59.08 41.42(6.17) 27.98-57.43 38.57(7.65) 22.25-53.70 0.846 0.07 0.256 0.07 
Truncal fat/ lean ratio 0.79(0.23) 0.39-1.50 0.75(0.21) 0.41-1.42 0.68(0.22) 0.29-1.23 0.811 0.105 0.371 0.12 
Z-Score 1.26(0.95) -0.57-4.23 2.20(1.09) 0.00-4.21 2.04(1.30) -0.46-4.33 0.003 0.014 0.836 0.002 
a. P1, P2 and P3 demonstrate P- values between European and Indian, European and Iranian; and Indian and Iranian groups respectively; b. P-values were determined after the variable was log 
transformed; c. Total body fat percentage was calculated using following equation: Total fat mass (kg)/Total body mass (kg) ×100; d. Total body lean mass percentage was calculated using 
following equation: Total lean mass (kg)/Total body mass (kg) ×100; e. Truncal body fat percentage was calculated using following equation: Truncal fat mass (kg)/Total fat mass (kg) ×100; f. 






   
Figure 9: Comparison between BMI, total body fat percentage and fat distribution in three 
ethnic groups. Data are  presented as mean ± SEM. *, Significant difference (P<0.05) in comparison 
with European group; Truncal body fat percentage, Truncal fat mass /Total body fat ×100; Total 
body fat percentage, Total fat mass/Total body mass×100.  
 
 
Figure 10: Comparison between the estimated mean values of BMI, total body fat 
percentage and fat distribution in three ethnic groups, after adjustment for potential 
confounders (age, sex and BMI). Data are presented as mean ± SEM. *, Significant difference 
















































A pattern similar to that observed for BMI and total body fat percentage was also 
found when the three ethnic groups were compared for WC, truncal fat percentage 
and truncal fat/lean ratio, as indices of central obesity [Table 18]. Indian and 
European participants had the lowest and the highest mean (±SD) values of WC 
[Table 11], respectively. Higher WC in European group was accompanied with 
tendencies toward higher truncal fat percentage and truncal fat-to-lean mass ratio. 
However, Indians had higher percentages of fat and fat-to-lean mass ratio in the 
abdominal region in comparison with Iranians, although the difference was not 
statistically significant [Table 18 & Figure 11]. 
 
This trend changed after adjustment for age, sex and WC. Namely, for a given age 
(47.16 y) and WC (99.36 cm), the Indian group had the highest estimated mean 
percentage of truncal fat (mean±SEM) (European: 39.5±1.0 %, Indian: 42.7±1.0 %, 
Iranian: 39.5±0.9 %; P values between Europeans & Indians and Iranians & 
Indians<0.05) and truncal fat-to-lean mass ratio (European: 0.39±0.01, Indian: 
0.43±0.01, Iranian: 0.39±0.009; P values between Europeans & Indians and Iranians 
& Indians <0.05) among three ethnic groups [Figure 12]. In the other word, truncal 
mass in Indian participants contained higher amount of fat mass relative to 
Europeans and Iranians with the same WC. 
 
In correlation analysis, there was a strong relationship between BMI and WC 
measured in the three ethnic groups after controlling for age and sex (European: r = 
0.90, P <0.001; Indian: r = 0.88, P <0.001; Iranian r = 0.81, P<0.001). Also, BMI and 
WC were significantly correlated with different measures of total and truncal 
adiposity whether expressed in absolute or relative terms, except for truncal body fat 
percentage [Table 19]. There was a significant correlation between WC and the 
truncal body fat percentage in European (r=0.41, P=0.017) and Iranian (r=0.59, 




   
Figure 11: Comparison between WC, truncal fat mass, and percentages of truncal fat and 
fat/lean mass in three ethnic groups. Data are presented as mean ±SEM; Truncal fat percentage, 
Truncal fat/Total trunk mass%. 
    
  
Figure 12: Comparison between the estimated means of truncal fat and fat/lean percentages 
and truncal fat mass in three ethnic groups after adjustment for age, sex and WC. Data are 
presented as mean ±SEM; Truncal fat percentage, Truncal fat/Total trunk mass%.*, Significant 




































Table 19: Correlation between anthropometric measurements and different measures of total and truncal adiposity in three ethnic groups after 
controlling for age and sex 
BMI, body mass index; WC, waist circumference; HC, hip circumference
Ethnicity / variables WC HC 
Total body 








































































































































































































































































Figure 13: Comparison between BMI, total body fat and fat distribution in male and female 
participants. Data are presented as mean ± SEM. *, Significant difference (P<0.05) in comparison 
with males; Truncal body fat percentage, Truncal fat mass /Total body fat %; Body fat percentage, 
Total fat mass/Total body mass %. 
 
There was no significant difference between the mean BMI of men and women (M: 
29.8± 3.4 vs. W: 30.1±4.2 kg/m
2
, P=0.67) [Figure 13]. However, women had 
significantly higher total body fat (34.2± 9.5 vs. 28.4± 6.5 kg, P= 0.001), body fat 
percentage (43.4±5.3 vs. 31.4 ±4.8%, p<0.001) and total body fat/total lean mass 
ratio (0.83±0.2 vs. 0.49±0.1, p<0.001) as well as a lower truncal fat percentage 
(51.0±6.3 vs. 59.3±5.0, p<0.001) relative to men. This pattern was also observed for 
men and women in all three ethnic groups. For all ethnicities, men had a lower total 
body fat compared to women; however they were more likely to accumulate fat in 
the abdominal or visceral area (indicated by truncal body fat percentage)[Table 20].  
 
By bivariate correlation analysis, BMI was positively associated with different 
cardiovascular risk factors, including SBP (r = 0.26, P=0.01), HOMA (r = 0.49, 
P<0.001), hs- CRP (r = 0.40, P=0.001), TG (r = 0.29, P=0.004), insulin (r = 0.49, 
























Table 20: Comparison between different measures of total and truncal adiposity in males and females of each ethnic group, estimated after adjusting for age 
and related anthropometric variables (BMI/WC). 
Variables/
Ethnicity 
 Total fat mass (kg) Total body fat%  Truncal body fat%  Truncal fat mass (kg) Truncal fat/lean   




 31.2-34.6 38.92 (1.31) 
a†









 34.9-38.0 44.18 (0.68) 
b*
 42.8-45.5 52.07(0.91) 
b*
 50.2-53.9 19.63(0.51) 
f*






 26.0-30.5 29.62 (0.01) 
b
 27.5-31.7 60.80(1.35) 
b
 58.0-63.5 15.00(0.76) 
f







 28.6-32.2 38.02 (1.40) 
a
 35.2-40.7 58.23 (1.32) 
a
 55.6-60.9 17.29(0.57) 
e












 26.1-29.2 31.94(0.87) 
c
 30.2-33.7 59.48(1.05) 57.3-61.6 15.22(0.62) 
g






 28.7-31.9 35.11 (1.23) 
a
 32.7-37.6 55.13 (1.17) 
a
 52.8-57.5 16.58(0.50) 
e





 30.3-35.6 41.19(1.35) d* 38.4-44.0 47.04 (1.69)d* 43.6-50.5 17.43(0.93) 
h





 27.2-31.0 32.01(0.96) 
d
 30.1-33.9 58.29 (1.95) 55.9-60.7 16.30(0.65) 
h
 15.0-17.6 0.61(0.04) 
h
 0.54-0.68 
a. The mean values are estimated at the following values: Age= 46.16, BMI= 29.95, b. The mean values are estimated at the following values: Age= 55.56, BMI= 30.78;  
c. The mean values are estimated at the following values: Age= 38.21, BMI=29.02; d. The mean values are estimated at the following values: Age 43.19. BMI=29.88;  
e. The mean values are estimated at the following values: Age= 46.16, WC= 99.36, f. The mean values are estimated at the following values: Age= 55.56, WC= 102.27;  
g. The mean values are estimated at the following values: Age= 38.21, WC=96.07; h. The mean values are estimated at the following values: Age 43.19. WC=99.15,  
Estimated means were determined using a multiple linear regression analysis; *. Significant difference at the 0.05 levels compared with males in the same ethnic group, † and 




Table 21: Comparison between different adiposity measurements of European, Indian and Iranian participants in each gender group, estimated after adjusting 




 Total fat mass (kg) Total body fat%  Truncal body fat%  Truncal fat mass (kg)  Truncal fat/lean (%)  




 32.8-35.1 43.34 (0.56) 
a*
 42.2-44.4 50.63 (0.74) 
a*
 49.1-52.1 18.57(0.39) 
d*
 17.8-19.34 0.89(0.02) 
d*
 0.84-0.93 
Europeans  35.17 (0.80) 
b
 33.5-36.7 43.34 (0.83) 
b
  41.7-45.0 50.76 (1.31) 
b
 48.1-53.4 17.92 (0.69) 
e
 16.5-19.3 0.84(0.04) 
e
 0.77-0.93 
Indians  33.19 (1.08) 
b
 31.0-35.4 45.09 (1.12) 
b†
 42.8-47.3 53.10 (1.76) 
b†
 50.4-57.5 18.09 (0.93) 
e
 16.2-19.9 0.95 (0.05) 
e†
 0.84-1.06 
Iranians  33.35 (1.10) 
b
 31.1-35.6 41.63 (1.14) 
b
 39.3-43.9 47.86 (1.81) 
b
 44.2-51.5 16.38 (0.95) 
e






 27.6-29.7 31.50 (0.56) 
a
 30.4-32.6 59.65 (0.74) 
a
 58.2-61.1 15.97(0.38) 
d
 15.2-16.7 0.59 (0.02) 
d
 0.55-0.64 
Europeans  27.65 (1.28) 
c
 25.1-30.2 29.10 (1.30) 
c
 26.5-31.7 57.70 (1.28) 
c††
 55.1-60.3 16.50 (0.73) 
f
 15.0-18.0 0.56 (0.04) 
f
 0.48-0.63 
Indians  28.38 (0.99) 
c
 16.4-30.4 32.38 (1.00) 
c
 30.4-34.4 61.54 (0.99) 
c†
 59.5-63.5 16.89 (0.56) 
f
 15.7-18.0 0.65 (0.03) 
f
 0.59-0.71 
Iranians  28.88 (0.79) 
c
 27.3-30.5 31.86 (0.81) 
c
 30.2-33.5 58.50 (0.79)
 c
 56.9-60.1 17.14 (0.45) 
f




a. The mean values are estimated at the following values: Age= 46.16, BMI= 29.95, b. The mean values are estimated at the following values: Age= 48.05, BMI= 30.12;  
c. The mean values are estimated at the following values: Age= 44.31, BMI=29.78; d. The mean values are estimated at the following values: Age= 46.16, WC= 99.36,  
e. The mean values are estimated at the following values: Age= 48.05, WC= 97.43; f. The mean values are estimated at the following values: Age= 44.31, WC=101.24;  
Estimated means were determined using a multiple linear regression analysis *. Significant difference at the 0.05 levels compared with males in overall, † and ††. Significant 




Figure 14: Glucose, insulin and HOMA Score in three ethnic groups. Data are presented as 
mean ± SEM; a*, b* and ab*, Significant difference (P<0.05) in comparison with Europeans, Indians, 
and both European and Indian groups, respectively.  
 
4.4.2 Glucose, insulin and HOMA score  
As shown in Table 11, European participants had a significantly higher mean value of 
fasting glucose relative to Indians (5.6±1.1 vs. 5.2±1.0 mmol/L, P=.0.017) and 
Iranians (5.6±1.1 vs. 4.8±1.0 mmol/L, P<0.001) in non-parametric tests. There was 
no significant difference between mean fasting glucose measured in Indian group 
compared to those in Iranians. Also, a tendency toward an increased mean value was 
detected when European participants were compared with Iranian group (10.6 ±5.6 
vs. 8.35±5.98 µIU/mL, P=0.052) for insulin.  
 
This was accompanied with a significant difference between Europeans’ HOMA 
score and those determined in Iranians (P=0.019). Furthermore, in spite of having a 
lower BMI [Table 11], Indian participants had higher mean values of glucose 
(P=0.073); insulin (P=0.034) and HOMA score (P=0.037) in comparison with 
Iranians [Figure 14].  
 
Interestingly, the results of HOMA mentioned above changed after adjusting for age, 
gender and WC. Namely, in the same age (46.2 y) and WC (99.4 cm), Indians had 



















0.70 ± 0.1, P = 0.35) and Iranians (0.85 ± 0.1 vs. 0.37± 0.1, P = 0.001). There was a 
significant difference between the mean value estimated in Europeans and Iranians 
(P= 0.03), after adjustment for these variables. Also, this pattern remained with no 
change after additional adjustment for the level of physical activity and total 
carbohydrate intake; it just resulted in a slight change in the estimated mean (± SE) 
in Europeans (0.69 ± 0.1) and Iranians (0.38±0.1). 
 
Partial correlation analysis showed that, in overall, the measures of general and 
truncal adiposity were more closely correlated with insulin and HOMA score than 
glucose after controlling for age and gender [Table 22]. This was also true across 
ethnicities. No significant association was detected between glucose and body 
composition assessments in the three ethnic groups (all P values > 0.05), except for 
glucose levels in European participants which were correlated with WC (r=0.35, 
P=0.046) and BMI (r=0.46, P=0.007). 
 
The strongest correlations between insulin (HOMA score) and BMI, WC and 
different body fat measurements were found among Iranians. In the Indian group, 
insulin and HOMA score were more correlated with total body fat mass (insulin: 
r=0.43, P=0.025; HOMA: r=0.46, P=0.015) and total body fat percentage (insulin: 
r=0.38, P=0.051; HOMA:  r=0.39, P=0.043) than BMI (insulin: r=0.35, P=0.073; 
HOMA: r=0.36, P=0.069). 
 
Multiple regression analysis highlighted that HOMA (Ln) was related to ethnicity 
(P= 0.01) as well as WC (P= 0.01), truncal fat mass (P=0.04), truncal body fat 
percentage (P=0.006) and total fat mass (P=0.02), but BMI and total body fat 
percentage had no significant role (P>0.05).   
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 Table 22: Correlation between glucose, insulin and HOMA score determined in three ethnic groups and different body composition measurements after 
controlling for age and sex  
BMI, body mass index; WC, waist circumference; HOMA, homeostatic model of assessment    
 
Ethnicity / variables BMI WC 
Total body 




























































































































































































































































































Figure 15: Systolic and diastolic blood pressure measured in three ethnic groups. European 
participants had higher systolic and diastolic blood pressure relative to Indian and Iranian groups. 
Data are presented as mean ± SEM. *, Significant difference (P<0.05) in comparison with Indian 
group.  
 
4.4.3 Systolic and diastolic blood pressure 
Analysis of the raw data indicated that European participants had a trend to higher 
mean systolic and diastolic blood pressure relative to Indians and Iranians [Figure 15 
& Table 11]. However, this trend changed after adjusting data for age and gender 
[Figure 16 & Table 12]. Namely, Indian participants then had a higher mean (± 
SEM) resting systolic blood pressure (123.8 ± 2.6 mmHg) relative to European 
(120.5 ±2.6 mmHg, P=0.422) and Iranian (117.9 ± 2.4 mmHg, P=0.094) groups, 
although differences were not significant statistically. Similarly, the age & gender 
adjusted mean (±SEM) value of diastolic blood pressure measured in Indian group 
(82.0 ± 2.0 mmHg) was higher than those measured in Europeans (80.7 ± 2.1 mmHg, 
P = 0.692) and Iranians (75.2 ± 1.9 mmHg, P=0.014). Interestingly, the difference 
between SBP / DBP in Indians and Iranians became more significant after additional 




















Figure 16: Systolic and diastolic blood pressure measured in three ethnic groups, after 
adjusting for age and sex. Indian participants had higher systolic and diastolic blood pressure 
relative to European and Iranian groups. Data are presented as mean ± SEM. *, Significant 
difference (P<0.05) in comparison with Indian group. 
 
There were significant correlations (r) between systolic blood pressure and BMI 
(0.23, P= 0.023), WC (0.33, P=0.001) and body fat measurements including total 
body fat mass (0.24, P= 0.020, total body fat percentage (0.229, P=0.029), total 
fat/lean (0.24, P=0.019), truncal fat mass (0.300, P= 0.003), truncal body fat 
percentage (0.29, P=0.004 ) and truncal fat/lean (0.281, P= 0.006) after controlling 
for age and gender. However, among these variables, diastolic blood pressure was 
only significantly correlated with WC (0.263, P=0.010).  
 
There were also borderline associations between diastolic blood pressure and truncal 
fat assessments including truncal fat mass (0.20, P=0.054) and truncal body fat 
percentage (0.19, P=0.060) .No significant dietary effect was observed in any of the 
correlation analyses (all p values > 0.05). By multiple regression analysis, diastolic 
blood pressure was predicted by WC (β= 0.365, p<0.001), ethnicity (P= 0.007; for 
Europeans: β=6.604; for Indians: β=7.378; for Iranian: β=0, as the reference group), 
sodium intake (β=0.004, P=0.028), and thiamin intake (β= - 6.324, P= 0.04). While, 
WC (β= 0.003, p=0.023) and HOMA (β= 0.021, p<0.007) were found as significant 

































Figure 17: lipid profile assessed in three ethnic groups, after adjusting for age and gender. 
Iranian participants had lower total cholesterol, LDL, HDL and triglyceride relative to Indian and 
European groups. Data are presented as mean ± SEM .a, Significant difference (P<0.05) in 
comparison with European group. b, Significant difference (P<0.05) in comparison with Indian 
group.  
 
4.4.4 Lipid profile, hs-CRP and renal function test 
After adjusting for age and gender, participants in European group had higher mean 
(±SEM) total cholesterol (5.4±0.2 vs. 4.7±0.2 mmol/L, P=0.003), LDL (3.4±0.1 vs. 
3.0±0.1 mmol/L, P=0.05), triglyceride (1.6±0.1 vs. 1.2±0.1 mmol/L, P=0.037) and 
trend to lower HDL (1.3±0.05 vs. 1.7±0.04 mmol/L, P=0.102) and relative to 
Iranians [Table 12 & Figure 17]. This trend was similar to what observed when lipid 
profile data was analysed without adjustment [Table 11]. 
 
Similarly, the age & gender adjusted mean (±SEM) values of total cholesterol 
(5.4±0.2 vs. 5.2±0.2 mmol/L, P=0.14), LDL (3.4±0.1 vs. 3.4±0.1 mmol/L, P=0.98), 
HDL (1.3±0.05 vs. 1.2±0.05 mmol/L, P=0.125) and triglyceride (1.6±0.1 vs. 1.5±0.1 
mmol/L, P=0.98) estimated in the European group were higher than those in the 
Indian group. In comparison with the Indian group, Iranian participants had 
significantly lower mean values when they were compared for total cholesterol 























Partial correlation analysis showed positive and significant associations between the 
levels of triglyceride and, BMI (r=0.30, P= 0.003), WC (r=0.30, P= 0.004), total 
body fat mass (r=0.23, P= 0.024) and truncal adiposity measurements including 
truncal fat mass (r=0.28, P= 0.006) and truncal body fat percentage (r=0.28, 
P=0.006) after controlling for age and sex [Table 23]. 
 
These variables also tended to be significantly but negatively correlated with HDL-
cholesterol [BMI: r= - 0.28, P= 0.006), WC: r= - 0.30, P= 0.003, total body fat mass: 
r= - 0.21, P= 0.045, truncal fat mass: r= - 0.30, P= 0.003 and truncal body fat 
percentage: r= - 0.37, p<0.001]. There was no significant relationship between total 
cholesterol or LDL-cholesterol and the measures of general and truncal fatness.  
 
As presented in Table 24, the degree of associations between the lipid profile and 
different body fat measurements varied among three ethnic groups. In Europeans, 
HDL-cholesterol and triglyceride were significantly correlated with WC, BMI and 
truncal fat content. But, the levels of HDL and triglyceride measured in Iranians were 
significantly associated with truncal body fat percentage (HDL: r=0.47, P=0.008; 
triglyceride: r= -0.60, P=0.001). In Indians, HDL-cholesterol (but not triglyceride), 
was correlated with BMI (r= - 0.41, P= 0.031), WC (r= - 0.49, P= 0.010), total body 
fat mass (r= - 0.53, P= 0.005) total body fat% (r= - 0.42, P= 0.029) total fat/lean (r= - 
0.42, P= 0.030) truncal fat mass (r= - 0.42, P= 0.031, truncal fat /truncal mass  (r= - 
0.39, P= 0.044). 
 
In regression analysis, ethnicity was found to be a significant predictor of total 
cholesterol (P<0.001), HDL (P=0.002) and LDL (P=0.017), TG (Ln, P=0.019), after 



















BMI, body mass index; WC, waist circumference; LDL-chol, low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol 
 










































































































Table 24: Correlations between lipid profile and different body fat measurements in three ethnic groups after controlling for age and sex. 
BMI, body mass index; WC, waist circumference; LDL-chol, low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol 
 
Ethnicity / variables BMI WC 
Total body 























































































































































































































































































After adjusting for age and gender, European participants revealed trends to a higher 
mean (±SD) value of hs-CRP relative to Indians (4.6±0.8 vs. 3.5±0.8 mg/L, P=0.85) 
and Iranians (4.6±0.8 vs. 2.8±0.8 mg/L, P=0.65), although they were not statistically 
significant [Table 12]. Females participating in the present study had a significantly 
higher mean value of hs-CRP than that measured in males (4.6±4.6 vs. 2.6±3.5, P 
(Ln) =0.001).    
 
There was evidence of weak but significant correlations (r) between hs-CRP and, 
BMI (0.35, P=0.001), WC (0.28, P=0.006), HC (0.27, P=0.007), total body fat mass 
(0.33, P=0.001), total body fat percentage (0.24, P=0.019), total body fat /lean (0.27, 
P=0.009), truncal fat mass (0.30, P=0.003), truncal fat/lean (0.24, P=0.021) and 
truncal fat/truncal mass (0.21, P=0.045) after controlling for age and sex. However, 
these associations were not constant in three ethnic groups [Table 25].  
 
In partial correlation analysis, hs-CRP was also correlated with glucose (r=0.22, 
P=0.03), insulin (r= 0.28, P= 0.007) and HOMA (r=0.28, P=0.006), after controlling 
for age and sex. However, these associations remained significant only in Indians 
(HOMA: r=0.42, P=0.03) and Iranians (HOMA: r=0.47, P=0.008; insulin: r=0.45, 
P=0.01) when data was analysed for three ethnic groups, separately. There was no 
correlation between hs-CRP and systolic or diastolic blood pressure (P values >0.05). 
The bivariate correlation analysis showed that hs-CRP was significantly associated 
with triglyceride (r=0.21, P= 0.04) and total cholesterol (r=0.22, P=0.03). However, 
there was no significant association between hs-CRP and these serum lipids, after 
controlling for age and gender. Furthermore, hs-CRP measured in Indians was 
significantly correlated with LDL-chol. (r=0.40, P=0.04) and HDL-chol (r= - 0.47, 
P=0.01), after analysing data based on ethnicities.   
 
Microalbuminuria (an albumin /creatinine ratio ≥ 30 and <299 µg/mg) was detected 
in 11.4 % of participants in European group (4 of 35 subjects), compared to 12.1% of 
those in Indian group (4 of 33 subjects). Additionally, clinical albuminuria (albumin 
/creatinine ratio ≥ 300 µg/mg) was present in 1 European subject (0.03%), but no 
participant in Indian group. All participants in Iranian group had an albumin 






Table 25: Correlations between hs-CRP and different body fat measurements in three ethnic groups after controlling for age and sex. 
BMI, body mass index; WC, waist circumference; HC, hip circumference; hs-CRP, high sensitive C-reactive protein   
 
 











































































































4.5 The effects of ethnicity on endothelial dysfunction 
 
In this study, European, Indian and Iranian participants were also compared for 
soluble forms of VCAM-1 and E-selectin, as biomarkers of endothelial dysfunction. 
 
The age & gender adjusted mean value (±SE) of VCAM-1 measured in Iranians was 
higher than Indians (223.3± 12.8 vs. 191.0±13.0 ng/mL, P (Ln) = 0.01) and 
Europeans (223.3± 12.8 vs. 198.4±13.4 ng/mL, P (Ln) = 0.20). There were no 
significant difference between VCAM-1 measured in males and females participating 
in this study (F: 203.5±73.6, M: 195.2±67.0, P=0.56) in overall. The only significant 
difference detected was between the mean VCAM-1 measured in Iranian’s men and 
women [Figure 18].  
 
In Europeans and Iranians, there was no significant correlation between VCAM-1 
and different anthropometric or metabolic measurements after controlling for age and 
sex. However, the levels of VCAM-1 measured in Indians was positively associated 
with BMI (r = 0.56, p = 0.002), WC (r = 0.58, p = 0.002), HC (r = 0.48, p = 0.011), 
total body fat mass (r=0.46, P= 0.015) and truncal fat mass (r=0.39, P=0.041). There 
was no significant correlation between VCAM-1 and intake of different nutrients.  
 
After adjusting for age and gender, European participants had a significantly higher 
mean (±SE) value of E-selectin relative to Indians (23.7±1.4 vs. 16.4±1.4 ng/mL, P 
(Ln) =0.002) and Iranians (23.7±1.4 vs. 16.9±1.30 ng/mL, P (Ln) =0.004). Also, E-
selectin concentrations were significantly higher in men than in women (20.8±7.87 
vs. 17.2±7.69 ng/mL, P=0.026). This trend was consistent across ethnicities [Figure 
19]. In regression analysis, ethnicity remained a significant predictor of circulating 
levels of E-selectin (Ln, P=0.003) (for Europeans: β=0.450, p<0.01; for Indians: β=-
0.166, P=0.254; Iranian as the reference group), after controlling for age, sex and 
BMI. The elevated level of E-selectin in European group were significantly 
correlated with insulin (r = 42, P = 0.016) and HOMA score (r = 0.39, P = 0.026). No 
significant association was observed between E-selectin and different components of 
metabolic syndrome in Indians and Iranians. Also, there were significant associations 
between E-selectin and dietary intakes of protein (ρ=0.24, P=0.02), cholesterol 






Figure 18: Comparison between the mean VCAM-1 measured in men and women in three 
ethnic groups. Data are presented as mean ± SEM. *, Significant difference (P<0.05) in comparison 





Figure 19: Comparison between the mean of E-Selectin measured in men and women in 
three ethnic groups. Data are presented as mean ± SEM. a*, Significant difference in comparison 
with European males (p<0.05); b*, Significant differences in comparison with Indian males 
(P=0.002) and European females (P=0.001). c*, Significant difference in comparison with European 



















































4.6 Assessment of adiponectin in three ethnic groups 
 
The mean value (±SD) of adiponectin was the highest in the European group 
compared to Indians (22.2±16.8 vs. 8.2±2.8, p<0.001) and Iranians (22.2±16.8 vs. 
8.9±3.4, p<0.001). There was no significant difference between adiponectin 
measured in Indians and those in Iranians using a non-parametric test (8.2±2.8 vs. 
8.9±3.4, p=0.306). There was also a significantly lower adiponectin level in men and 
in women participating in this study (M: 9.3±6.0 vs. W: 17.8±15.2, p<0.001). For all 
ethnicities, women had a higher mean value of adiponectin than men [Figure 20].  
 
In overall, circulating levels of adiponectin was found to be negatively correlated 
with TG (r= - 0.24, p<0.020), insulin (r= - 0.23, p<0.023), truncal body fat 
percentage (r= - 0.43, p<0.001) and total carbohydrate intake (r= - 0.25, p<0.015), 
and positively with HDL-chol (r= 0.56, p<0.015) and vegetable and legume (r= 0.31, 
p<0.002).  
 
   
 
Figure 20: Comparison between the mean of Adiponectin measured in men and women in 
three ethnic groups. Data are presented as mean ± SEM. a*, Significant difference (P=0.001) in 




























There was no significant association between adiponectin and, different 
anthropometric and metabolic measurements in European and Indian groups, after 
controlling for age and sex. However, the adiponectin measured in Iranians was 
negatively correlated with glucose (r = - 0.39, P=0.03), insulin (r = - 0.37, P=0.039), 
HOMA score(r = - 0.43, P=0.015) and truncal body fat percentage (r= - 0.36, 
P=0.044).   
 
The results of the regression models showed that the levels of adiponectin (Ln) were 
predicted (55.5%) by ethnicity (for Europeans: β=0.758, p<0.001; for Indians: β=-
0.004, P=0.967; Iranian as the reference group), W/H ratio (β= 1.98, P=0.013), SBP 
(β=0.013, P=0.002), DBP (β= - 0.014, P=0.008), insulin (β= - 0.024, P=0.009), 






Discussion of Results 
  
As mentioned in the first chapter, the main objective of this research was to study the 
effects of ethnicity on metabolic syndrome risk factors. It was hypothesed that 
ethnicity plays a significant role in developing metabolic syndrome components 
including general and central obesity, hypertension, dyslipidaemia, hyperglycemia 
and insulin resistance.  
 
Specifically, this study: 
 compared metabolic syndrome criteria among a cross-section of immigrants from 
three ethnic groups in Western Australia using four common international 
definitions of metabolic syndrome,  
 described the effects of ethnicity on the endothelial dysfunction in the ethnic 
groups under study,  
 investigated the impact of diet on metabolic syndrome among the three ethnic 
groups, and finally  
 explored the correlation between adiponectin and different components of 
metabolic syndrome amongst ethnic groups. 
 
Accordingly, these objectives are addressed and discussed in this chapter. 
  
5.1 Comparison of different definition of metabolic syndrome 
 
In this study, the highest overall prevalence was shown by IDF definition and 
followed by ATP III, WHO and EGIR. These findings were consistent with other 
studies, like the AusDiab in Australia (Cameron et al. 2007), Esteghamati et al. 
(2010) in Iran and Zainuddin et al. (2011) in Malaysia.  However, the results derived 
from a research in India showed that the highest prevalence of metabolic syndrome 




There was also the excellent alignment between the definitions of IDF and ATPIII in 
all ethnic groups. This may be due to the fact that unlike the WHO and EGIR 
definitions, IDF and ATPIII considers central obesity as the main criterion. Also, 
hyperinsulinemia and insulin resistance are not prerequisite criteria in IDF or ATP 
III.  
 
The overall prevalence of metabolic syndrome was significantly higher in females 
than males using all definitions. This finding was consistent with studies carried out 
in India (Ramachandran et al. 2003; Gupta et al. 2004) and Iran (Ayatollahi and 
Ghoreshizadeh 2010), but  not with the results of the AusDiab study conducted on a 
national sample population of 11247 Australian adults. Studies carried out in 
European countries showed a variety of dominancy between males and females. The 
studies carried out in France (Dallongeville et al. 2005), Germany (Assmann et al. 
2007), Greece (Skoumas et al. 2007) and Italy (Bo et al. 2005) showed a higher 
prevalence of metabolic syndrome among males, however the prevalence in 
Netherlands (Dekker et al. 2005), Portugal (Santos and Barros 2003) and Spain 
(Lorenzo et al. 2006) were greater in females than males. Accordingly, the 
discrepancy in the prevalence of metabolic syndrome amongst males and females 
observed in the AusDiab and the current study may be due to the differences in the 
ethnic composition of individuals participating in these studies and the samples sizes. 
Also, AusDiab was a population-based survey including a range of normal, 
overweight and obese participants; while individuals participating in the study were 
only overweight and obese volunteers. 
 
In the current study, WHO- and EGIR-defined participants were more insulin 
resistant than participants categorised as having metabolic syndrome based on IDF 
and ATPIII definitions. These results were not surprising, because as mentioned 
before insulin resistance is an essential component for metabolic syndrome according 
to WHO and EGIR, but not IDF and ATPIII definitions. It was also found that the 
highest percentages of participants with insulin resistance were revealed using WHO 
definition. Given the key role of insulin resistance as a main underlying contributor 
for developing of cardiovascular diseases, the findings support the results of 
AusDiab (Cameron et al. 2007), indicating the highest association between WHO 
definition and cardiovascular risk among four definitions. 
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Although the overall criteria for metabolic syndrome offered by different 
organisations are similar, they differ in some important respects. For example, in 
contrast to IDF and ATPIII, the WHO criteria includes impaired glucose tolerance 
(IGT), on account of some potential advantages (Grundy et al. 2004). Firstly, IGT 
detected by an oral glucose tolerance test (OGTT) could be considered a metabolic 
risk factor in individuals with normal fasting glucose. Secondly, it is known that IGT 
is directly associated with an accelerated risk for developing type 2 diabetes. Thirdly, 
performing OGTT is strongly recommended in individuals with impaired fasting 
glucose (IFG) for recognition of diabetes, which is in turn a known risk factor for 
cardiovascular diseases. Therefore, by including OGTT, the value for cardiovascular 
disease risk prediction significantly increased.   
 
In this study, the percentage of participants with insulin resistance revealed by IDF 
definition was slightly lower than WHO. In line with the findings, the AusDiab 
survey indicated that after WHO, the greatest odd ratio for having a 10 year 
cardiovascular disease risk > or = 15% was observed for those defined as having 
metabolic syndrome based on IDF. Also, according to AusDiab results, the IDF 
definition showed the highest population attributable risk (PAR) of high 
cardiovascular risk due to metabolic syndrome. As discussed above, the lower power 
of IDF definition in predicting the risk of CVD can be in part due to omitting the IGT 
among the risk factors of metabolic syndrome; however this omission was to avoid 
the additional inconvenience and the cost of OGTT. Therefore, although the IDF 
definition seems to be slightly less accurate than the WHO definition in identifying 
individuals with higher risk of CVD, it can be more practical from clinical aspect.  
 
Previous studies showed that the percentage of fat mass, particularly truncal fat is 
one of the most important predictor of metabolic syndrome (Nguyen-Duy et al. 
2003). In this study, truncal fat mass was significantly related to waist circumference 
in all ethnic groups (see Section 4.4.1). The result also supports the prior findings 
suggesting ethnicity as a major determinant of truncal fat accumulation (Wu et al. 
2007). Despite these findings, among different definitions of metabolic syndrome, 
only the cut-off points of waist circumference offered by IDF is defined according to 
ethnic diversity. Therefore, the IDF definition seems to be also more reliable than 
others in estimating the prevalence of metabolic syndrome in different ethnic groups. 
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This point is particularly important for establishing appropriate prevention strategies 
in countries like Australia; receive emigrants from different countries and ethnic 
groups.  
  
5.2 Comparison of metabolic syndrome criteria  
 
5.2.1 Anthropometric variables 
A. Body mass index  
The results of comparative studies comparing the BMI of Indians and Caucasians in 
European and non-European countries were controversial. While, in some studies 
Indians had higher BMI than Caucasians, it was different in others (Raji et al. 2001). 
The findings were in line with the results reported by Raji et al. (2001), probably 
because both studies were conducted on participants with similar age ranges.  
 
From another point, many studies have consistently shown that Indians have a higher 
body fat percentage and accordingly higher metabolic risks in comparison to 
Caucasians for a given BMI, age and gender (Forouhi et al. 1999; Chandalia et al. 
2007; Rush et al. 2007; Nair et al. 2008; Rush, Freitas, and Plank 2009).  
  
Although, there are several existing studies on Indians and Caucasians, there are few 
studies comparing metabolic syndrome between Iranians and Caucasians in a 
common environment. The higher BMI in Europeans found in the study is not 
consistent with a study comparing Caucasians and Iranian migrants in Sweden, 
which found a higher BMI in Iranians than Europeans (Koochek et al. 2008). The 
possible explanation for this discrepancy is that this study has focused on elderly 
Iranians and accordingly is not representative of all age groups. Moreover, this study 
is influenced by the natural facts of decreasing metabolism and increasing body fat 
during the aging process. 
 
Body mass index has been used characteristically as an index evaluating total body 
fat mass. According to the presented classifications by WHO, the BMI cut-off points 
of 25 and 30 kg/m
2
 have been recommended for overweight and obesity categories 
respectively. However, further studies revealed that the unique BMI cut-off point is 
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not appropriate for all population and genders. Therefore, an accurate cut-of point 
needs to be defined for each ethnic group separately.  
 
Since, the study did not include a very large population; it was limited to recommend 
the certain BMI cut-off point for each ethnic group. However, the results suggest an 
appropriate ranking for the cut-off points in different ethnic groups evaluated in this 
study, since it is carried out in unique environment.  
 
After adjustment for BMI, females participating in this study had significantly higher 
total body fat percentages than males overall and in all ethnic groups separately. 
Given the significant differences between male and females, it could be inferred that 
the BMI cut-off point should be gender specific.  
 
Moreover, according to the results, Indian and Iranian females had the highest and 
the lowest body fat percentage among three ethnic groups. Given that BMI is 
accepted as an index for general fatness, the findings suggest that the BMI cut-off 
points for the Indian and Iranian females would be defined lower and higher than 
European females respectively. In addition, the Indian and European males had the 
highest and the lowest body fat percentage amongst the participants. So, the BMI 
cut-off point for Iranians should be defined higher and lower than Indians and 
Europeans respectively. 
 
B. Waist and hip circumferences  
Unlike BMI, waist circumference is an index evaluating central obesity and truncal 
body fat mass. Subsequent to the official recommended cut-off points for WC by 
International Diabetes Federation (IDF), many studies tried to find much more 
accurate cut-off points in specific populations (Misra et al. 2006; Nilsson et al. 2008; 
Dhanaraj et al. 2009; Shabnam et al. 2012). However, there is still no general 
consensus on the WC cut-off points in ethnic groups and genders. The International 
Diabetes Federation (IDF) recommended the WC cut-off points of ≥94cm and ≥80 
cm for both European and Iranian males and females respectively; and ≥90cm and 
≥80cm for Indian males and females respectively. However, several studies 
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suggested lower WC cut-off points in Indians than those recommended by ATP III 
and IDF (Raji et al. 2001; Misra et al. 2006; Dhanaraj et al. 2009).  
 
In addition, in separate comparison of males and females in three ethnic groups, 
Indian and Iranian females had the highest and the lowest truncal fat among of the 
female participants. This suggests that the cut-off points for Indian and Iranian 
women should be defined lower and higher than European women respectively. This 
was consistent with the lower cut-off point for Indian females already recommended 
by IDF and some studies. However, it challenged the conception that the WC cut-off 
points are the same in European and Iranian females.  
 
Analysing the truncal body fat in males in the same WC showed that Iranian males 
had higher and lower truncal fat percentage in comparison to European and Indian 
males. Accordingly, the WC cut-off point for Iranian males is suggested to be higher 
than that in Indian males, but lower than European males.  
 
So, overall conclusions from these findings are: 
 
The suggested cut-off points for BMI and WC in different ethnic groups are:  
 Indian females < European females < Iranian females 
 Indian males < Iranian males < European males 
 
5.2.2 Glucose, insulin and HOMA score 
In this study, the mean values of glucose, insulin and HOMA in Caucasians were 
higher than two other groups. But, Indian participants had the highest mean of 
HOMA score, after adjustment for age, gender and WC, a trend similar to what was 
found for truncal fat measurements. These results were consistent with other studies 
(McKeigue, Miller, and Marmot 1989; Raji et al. 2001) reporting higher prevalence 
of insulin resistance in Indians compare to Caucasians.  
 
The results of both regression and correlation analyses showed significant 
associations between HOMA and different measurements of adiposity. However, 
HOMA tended to be more correlated with the measurements of truncal fat than total 
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fatness. The inverse correlation between truncal adiposity and insulin sensitivity has 
been also reported in other studies (Evans et al. 1984; Kelley et al. 2000a).  
Although, the mechanism behind this association is not fully understood, the excess 
release of non-esterified fatty acids (NEFA) by truncal adipose tissue and subsequent 
decreases in glucose utilisation and insulin sensitivity has been suggested as a 
possible reason (Randle et al. 1963; Jensen et al. 1989). Indians had been shown to 
have higher truncal fat relative to Europeans and Iranians at the same age, gender and 
WC (Section 4.4.1). These findings support previous studies suggesting that the 
higher rates of insulin resistance in Indians compared to Caucasians may be in part 
due to their higher truncal adiposity (Misra et al. 2004).  
 
However, in the current study, ethnicity was found as a significant predictor of 
insulin resistance after controlling for different measurements of fatness.  In line with 
the findings, it has been proposed that Asian Indians are also susceptible to insulin 
resistance independent of fat tissue volume or distribution (Chandalia et al. 1999). In 
this study, it was shown that the degree of association between HOMA and different 
body fat measurements varied significantly across three ethnic groups. Since, it is 
known that there are significant differences in functional characteristics of adipose 
tissue in different sites of the body (Arner, Engfeldt, and Lithell 1981; Jansson, 
Smith, and Lonnroth 1990), the findings suggest that there may be also functional 
heterogeneity in regional adipose tissue of individuals with different ethnicities. 
Accordingly, tendency for insulin resistance in some ethnic groups, including 
Indians, may be due to a hereditary adipose tissue dysfunction resulting in excessive 
response of adipocytes to factors contributing in the development of insulin 
resistance. Further studies are required to investigate the effects of ethnicity on the 
function of adipocytes in different regions, and also compare the impact of 
increase/decrease in truncal adipose tissue on the insulin resistance state in 
individuals with different ethnicity. 
 
5.2.3 Systolic and diastolic blood pressure 
Previous studies comparing the blood pressure levels of Indians with Caucasians 
were mainly conducted on South Asians, reporting different results. While, in some 
studies South Asian men had a higher systolic and diastolic blood pressure than 
Caucasians (Miller et al. 1988; McKeigue, Shah, and Marmot 1991), others reported 
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higher blood pressure in Caucasians (McKeigue et al. 1988; Bhopal et al. 1999; 
Perumal et al. 2012). The discrepancy between these results could be partly due to 
the fact that the term ‘South Asian’ is not essentially equal to Indian but includes 
people from the Indian subcontinent including India, Pakistan, Bangladesh and Sri 
Lanka, and there is obvious heterogeneity between South Asian subgroups 
(Agyemang and Bhopal 2002). The results of the Newcastle Heart Project study 
conducted in UK (Bhopal et al. 1999) showed that among three South Asian groups, 
Indians had higher blood pressure than Pakistanis, and the lowest blood pressure was 
observed in Bangladeshis. Other than the difference in the composition of South 
Asian groups, the inconsistent findings may be also because of sample population 
variations and differences in study methods. For example, in a study conducted by 
Chaturvedi et al. (2007) in UK 84 Asian Indian and 83 European men aged 45 years 
and older were recruited, however in another study in New Zealand (Perumal et al. 
2012), the CVD risk profile of 47091 Europeans and 8830 Indian people aged 35-74, 
who completed PREDIC (a web-based computerised decision support system) risk 
assessments were reported.  
 
The findings showed diastolic blood pressure was significantly lower in Iranians 
compare to Indians. This was supported by the regression analysis result showing 
ethnicity as a significant predictor of diastolic blood pressure after controlling for 
other variables. Also, Indian and Iranian ethnicities had the highest and the lowest 
regression coefficients among three ethnic groups, respectively. Since, current study 
is the first clinical assessment comparing Indians and Iranians in unique society; it 
was impossible to compare the findings to other similar studies in this regard.  
 
There was also significant association between diastolic blood pressure and the 
dietary intake of sodium in regression analysis. The relation of nutritional factors 
with hypertension has been assessed in several clinical and epidemiological studies 
(Ascherio et al. 1996; Swaminathan 2003). It is known that there is a positive 
relationship between arterial blood pressure and sodium intake (Cheung et al. 2000; 
Hu and Tian 2001; Dumler 2009). However, higher systolic and diastolic blood 
pressure observed in the Indian group was accompanied with a significantly lower 




On the other hand, Iranian participants with the highest average of sodium intake had 
the lowest mean systolic and diastolic blood pressure among three ethnic groups. It 
seems that these inconsistencies could be explained by higher intake of other 
minerals. It has been shown that the increased levels of blood pressure resulted from 
high sodium intake can be modified by the intakes of other dietary factors having 
inverse effects (Ono, Ando, and Fujita 1994; Akita et al. 2003). Blood pressure is 
inversely associated with intakes of magnesium, calcium and potassium (Ascherio et 
al. 1996; Swaminathan 2003; Karppanen and Mervaala 2006), and Iranian and 
European participants in the study had higher intakes of these minerals than Indians. 
 
In line with the findings, in a survey conducted in Iran, there was a significant 
inverse association between calcium intake and both systolic and diastolic blood 
pressure in Iranian boys and girls (Azizi, Mirmiran, and Azadbakht 2004). These 
results are compatible with the possibilities that in addition to ethnicity, imbalanced 
dietary intake of minerals may contribute to higher levels of blood pressure reported 
in some ethnic groups. 
 
According to the results, SBP was positively correlated with BMI, WC, total body fat 
percentage, truncal body fat percentage and truncal fat/lean ratio, after controlling for 
age and gender. As discussed before (Section 4.4.1) for the same BMI, WC, HC and 
age, Indian individuals participating in the current study had higher percentages of 
total body fat, total body fat/lean and truncal body fat relative to Europeans and 
Iranians. Given the significant associations between SBP and different total and 
truncal adiposity measurements discussed previously, these findings could probably 
explain the higher SBP observed in the Indian participants. 
 
5.2.4 Lipid profile, hs-CRP and renal function 
 
A. Lipid profile 
In the current study, ethnicity was found to be a significant predictor of serum lipids, 
after controlling for age, sex and BMI. It is known that ethnic difference in lipid 
profile may be due to ethnic-specific lifestyle factors as well as genetic variation 




The results indicated that the age & sex-adjusted mean values of total cholesterol, 
LDL-chol and triglycerides in Iranian participants were lower than those in other 
ethnic groups. These findings were inconsistent with other studies conducted in Iran, 
showing relatively high levels of these lipid measurements in Iranian adults and 
adolescents (Azizi et al. 2002; Azizi et al. 2003; Kelishadi et al. 2004). For example, 
in a survey conducted by Azizi et al (2003), mean values of 210 mg/dl (5.43 mmol/l), 
133 mg/dl (3.44 mmol/l) and 173 mg/dl (1.95 mmol/l) were reported for total 
cholesterol, LDL- cholesterol and triglycerides concentrations of 6246 participants 
aged 20-64years living in Tehran, respectively. These results are much higher than 
those found in this study (total cholesterol: 4.75 mmol/l; LDL-chol: 3.00 mmol/l; 
triglycerides: 1.30 mmol/l) which was conducted in Australia. However, mean HDL- 
chol observed in Azizi et al.’s study was almost equal to that in our study (1.11 vs 
1.12 mmol/l). These findings suggest that the levels of total cholesterol, LDL-chol 
and triglycerides in Iranian population may be affected mainly by lifestyle factors 
rather than genetics. 
 
It is known that lifestyle factors, including unhealthy diet and physical inactivity play 
key roles in developing dyslipidaemia in some populations (Kelishadi et al. 2004; 
Ghosh 2007; Kelishadi et al. 2012; Huffman et al. 2012). There are several studies 
reporting high levels of serum lipids and lipoproteins (except HDL-chol) in people 
consuming foods rich in saturated and trans fatty acids, and cholesterol (Ghosh 2007; 
de Roos, Schouten, and Katan 2001). However, the health hazards of trans-fatty 
acids are more than do saturated fats (de Roos, Schouten, and Katan 2001). Because, 
in addition to increasing total cholesterol and LDL- cholesterol (like saturated fatty 
acids), they decrease serum HDL- cholesterol concentrations. Trans-fatty acids are 
present mainly in margarines and partially hydrogenated vegetable oils produced 
commercially in food manufactures.  
 
Mandatory labelling of trans-fatty acid on packaged food products as well as 
increasing awareness of customers of the unfavourable effects of saturated fat on 
lipid profile have led to significant decrease in consuming saturated fat and trans- 
fatty acids in western countries. However, hydrogenated and partially hydrogenated 
vegetable oils are still widely used in Asian countries such as Iran, resulted in 
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consuming trans-fatty acids as about twice as those in developed countries 
(Mozaffarian et al. 2007). 
 
In this study, the levels of total and LDL cholesterol measured in Indian participants 
were significantly higher than Iranians, while they had significantly lower dietary fat 
and cholesterol intake. This could be due to the fact that serum lipids may be also 
affected by consumption of dietary factors such as fibre (Brown et al. 1999), 
magnesium (Olatunji and Soladoye 2007) and calcium (Ditscheid, Keller, and Jahreis 
2005), which were consumed in lesser amounts by Indian than Iranian participants. 
Moreover, despite of significantly lower cholesterol in Iranian participants compared 
to Europeans, there was no significant difference between them in the intakes of 
different dietary components. This discrepancy could be also explained by a 
tendency for higher physical activity in Iranians than those determined in European 
participants.   
 
In the current study, there was no significant relationship between total cholesterol or 
LDL-cholesterol and the measures of general and truncal fatness. Consistent with 
these results, in an intervention study conducted on 578 (222 cases and 356 controls) 
Iranian adults, despite a significant increase in BMI of both intervention and control 
groups, significant decrease in dietary intake of cholesterol in intervention group was 
accompanied with concomitant decrease in their serum total cholesterol 
concentrations compared to control group (Mirmiran et al. 2008). These findings 
confirm that the levels of total cholesterol and LDL-chol are influenced more by 
dietary fat and cholesterol intake than by the body fat.  
 
In contrast to total and LDL cholesterol, the levels of triglyceride and HDL-chol 
were significantly correlated with the measures of general and truncal fatness. 
However, the degree of associations between these lipid profile and different body 
fat measurements varied among three ethnic groups. These findings were consistent 
with another study conducted by Valsamaki et al. (2004) showing significant 
relationships between TG (positively) and HDL – chol (negatively), and visceral 




In this study, HDL–chol measured in Indian participants was negatively correlated 
with total and truncal adiposity. Additionally, the results showed that (Section 4.4), 
Indians are susceptible to have a higher percentage of total and truncal body fat for 
the same BMI compared to Caucasians. These results are in line with other studies 
comparing anthropometric features of South Asians, Europeans and Afro-Caribbean 
people in West London (McKeigue, Shah, and Marmot 1991). These findings 
support this hypothesis that the lower HDL-chol in Indians than that in Europeans 
reported in previous research (Raji et al. 2001; Valsamakis et al. 2004) and the 
current study may be due to their relatively high percentages of total body and 
abdominal fat.  
 
The lower HDL-chol relative to Europeans was also found in the Iranian participants, 
although the difference was not significant statistically. It is known that genetic 
variation may also cause a different response of the body to acquired factors. An 
elevation of 1unit in BMI has been shown to be associated with an overall decrease 
in HDL- chol of 0.08 mmol/l (Anderson et al. 1987). However, the amount of 
increase/decrease in HDL-chol resulted from the changes in BMI is not the same 
among different ethnic groups, and they may present different degree of sensitivity. 
In an epidemiological study evaluating changes in anthropometric measurements and 
lipid profile during a period of 3.6 years in Iranian adults, an increase in BMI of 1 
unit leaded to a decrease in HDL-chol of 0.10-0.13 mmol/l (Bozorgmanesh et al. 
2008), which was higher than value observed in Caucasians (Anderson et al. 1987). 
These findings may explain the higher prevalence of low HDL-chol phenotype found 
in some ethnic groups including Iranians (Azizi et al. 2002; Sharifi et al. 2008; 
Schwandt, Kelishadi, and Haas 2010). 
 
B. hs-CRP 
Acute phase reactants including CRP have been shown to play an important role in 
the atherosclerotic inflammatory process (Zwaka, Hombach, and Torzewski 2001). 
According to the guideline issued by American Heart Association, hs-CRP levels of 
0 to <1mg/L, 1-3mg/L, >3-10 mg/L are associated with low risk, intermediate risk 
and high risk for cardiovascular diseases, respectively (Pearson et al. 2003). In the 
current study, European and Indian participants had higher mean concentrations of 
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hs-CRP relative to Iranians. Although, the differences between groups were not 
significant statistically, the mean values >3 mg/L found in Europeans (4.64±0.83 
mg/l) and Indians (3.50±0.81 mg/L) indicated that they are at higher risk of 
cardiovascular events relative to Iranians who had mean hs-CRP<3 mg/L. 
 
Regardless of ethnicity, hs-CRP determined in our participants was correlated with 
different measures of obesity. In agreement with the results, excess fat tissue has 
been indicated to induce the production of inflammatory markers such as CRP 
(Yudkin et al. 1999). However, according to our results hs-CRP tended to be 
significantly more correlated with total body fat than with truncal adiposity. As 
mentioned before (Section 4.4.1), the European and Iranian participants had the 
highest and the lowest total body fat percentages, the same pattern as that observed 
for hs-CRP. 
 
In the current study, female participants had a significantly higher mean value of hs-
CRP compared to males. This was in line with some previous studies assessing 
gender difference in CRP levels (Khera et al. 2005; Lakoski et al. 2006). 
Furthermore, CRP has been also suggested as a better predicting marker for the risk 
of cardiovascular diseases in women than men (Qasim et al. 2011). For all 
ethnicities, females participating in the study had a higher total body fat compared to 
males; however they were less likely to accumulate fat in the abdominal area 
(indicated by truncal body fat percentage) (see Section 4.4.1). Also, as mentioned 
above hs-CRP measured in the participants was significantly more correlated with 
total body fat than with truncal fat. These findings would also help explain the 
significantly higher hs-CRP reported in females participating in the present study 
than that measured in males.   
  
Given the findings mentioned above, among different biomarkers of metabolic 
syndrome, hs-CRP was significantly associated with those being more correlated 
with total body fat including glucose, insulin and HOMA. This was consistent with 
the results of several studies conducted in different countries, age and ethnic groups 
(Chambers et al. 2001; McLaughlin et al. 2002; Zuliani et al. 2009). In the current 
study, there were overall associations between hs- CRP and some serum lipids (TG, 
total chol.); however they did not remain significant after controlling for age and 
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gender. The results also showed no significant correlation between hs- CRP and 
systolic and diastolic blood pressure. It is suggested that inflammation may 
contribute to initiation of hypertension via secretion of some mediators, such as CRP 
(Bautista 2003). However, the results of human studies investigating the link 
between CRP and blood pressure have been controversial. While, analysis of the 
Third National Health and Nutrition Examination Survey (NHANES III) data 
collected from 1988 to 1994 showed a positive relationship between CRP and blood 
pressure across a wide range of blood pressure categories (King et al. 2004), no 
significant association was found in some other studies (Bautista et al. 2005).   
 
Interestingly, it was observed that the degree of associations between CRP and 
biomarkers associated with the metabolic syndrome were not constant across 
ethnicities. It has been shown that the serum CRP levels in populations can be 
affected by genetic variation (Crawford et al. 2006). According to the results, there 
was significant associations between hs-CRP and HOMA, as a marker of insulin 
resistance, in Iranian and Indian groups, but not in Europeans. Similarly, the 
associations between hs-CRP and various body fat measurements tended to be 
stronger and more significant in Iranians and Indians than in Europeans. 
Additionally, there was no overall association between hs-CRP and serum lipids, 
after controlling for age and gender. However, hs-CRP measured in Indians was 
significantly correlated with LDL-chol (positively) and HDL-chol (negatively), when 
data was analysed for three ethnic groups, separately. On the other hand, as discussed 
above, hs-CRP has been found to be more correlated with total body fat rather than 
truncal fatness. As a result, there is a possibility that it would not reflect the risk of 
cardiovascular disease accurately. 
 
Given the strong link between metabolic syndrome components and the occurrence 
of cardiovascular diseases, these findings suggest that hs-CRP may be more accurate 
to predict cardiovascular events in Iranians than in Indians and Europeans.  
 
Microalbuminuria was detected in a greater number of European participants than 
Indian participants. Although, the difference was not statistically significant, the 
higher rate of microalbuminuria with a lower mean age (38.2 versus 55.6 year) in 
Indian is considerable. This finding agrees with the findings of the United Kingdom 
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Asian Diabetes Study (UKADS) which compared microalbuminuria and proteinuria 
in south Asian and white European ethnicity. Similar to the present study, younger 
south Asian participants had statistically significant higher proteinuria in comparison 
to white European (Raymond et al. 2011). Accordingly, the difference between 
Indian and other ethnic groups suggest Indians present microalbuminuria and related 
disorders more commonly than other ethnic groups. Further studies needed to focus 
more from this view in metabolic syndrome amongst Indian compare to other ethnic 
groups. 
 
5.3 The effects of ethnicity on endothelial markers 
 
Cellular adhesion molecules including E-selectin and VCAM-1 have been postulated 
to participate in the pathogenesis of atherosclerosis (Cybulsky and Gimbrone 1991; 
Li et al. 1993; Kawakami et al. 2006). These adhesion molecules are detectable in the 
serum in their soluble forms. Increased concentrations of soluble adhesion molecules 
have been shown in patients with coronary artery atherosclerosis (Blann, Amiral, and 
McCollum 1996; Damnjanovic et al. 2009) and peripheral artery diseases (De 
Caterina et al. 1997).          
In the current study, the serum level of E-selectin in Europeans was significantly 
correlated with insulin and HOMA. This was in line with the results of previous 
studies reporting the elevated levels of E-selectin in patients with different 
cardiovascular diseases risk factors, including insulin resistance, hypertension, 
dyslipidemia and diabetes mellitus (Hackman et al. 1996; Abe et al. 1998; 
Matsumoto et al. 2000; Palomo et al. 2003; Glowinska et al. 2005; Boulbou et al. 
2005; Song et al. 2007; Maggio et al. 2012). European volunteers participating in the 
study had significantly higher insulin, HOMA and serum lipids levels as well as total 
body fat percentage relative to Iranians (see Section 4.4). Moreover, it has been 
found that there is a close correlation between the increased level of E-selectin and 
general obesity (Matsumoto et al. 2002).  An elevation of 1 unit in BMI has been 
shown to be associated with an approximate 2% increase in E-selectin level (Miller 
and Cappuccio 2006). Therefore, the higher E-selectin levels detected in Europeans 




However, the differences between European and Indian participants were statistically 
significant only when they were compared for glucose, but not for other 
measurements mentioned above (see section 4.4). In this study, ethnicity was found 
as a significant predictor for circulating level of E-selectin after controlling for age, 
gender and BMI. To the best of our knowledge, this is the first report showing the 
association between ethnicity and E-selectin in these ethnic groups.  
 
VCAM-1 was another endothelial marker assessed in this study. In the present study, 
the trends found for VCAM-1 were contrary to what was observed for E-selectin. 
The ethnic-related differences in the circulating VCAM-1 concentrations have been 
found among some ethnic groups. In a study conducted on 261 white, 188 African 
origin and 215 South Asian individuals living in England, participants with African 
ancestry had significantly lower VCAM-1 concentration relative to two other groups.  
There was no significant difference between the VCAM-1 concentrations measured 
in white and South Asian participants (Miller et al. 2003). However, there has been 
no study to compare the levels of circulating VCAM-1 in Iranians with any other 
ethnic groups. Also, we are unable to explain these findings based on the differences 
in metabolic syndrome components observed among three ethnic groups. Because, as 
mentioned above, the relationship between VCAM-1 and cardiovascular risk factors 
is still a matter of controversy. Therefore, further studies are required to confirm 
these results and provide the most possible justifications in this regard.   
 
According to the data, there was no significant association between VCAM-1 and 
different metabolic measurements of FBG, insulin, HOMA, lipid profile and blood 
pressure after controlling for age and gender. As mentioned above, the correlations 
between E-selectin and the risk factors of cardiovascular diseases have been 
confirmed by several studies. However, the results of research examining the 
relationship between VCAM-1 and the metabolic measurements mentioned above 
have been controversial.  
 
For example, the elevated levels of VCAM-1 have been reported in older men with 
uncomplicated essential hypertension by DeSouza et al. (1997), but in a study 
conducted by Ferri et al. (1999) there was no significant difference between VCAM-
1 levels evaluated in hypertensive and normotensive men, in either obese or non-
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obese groups. Or, in another study examining the association between blood pressure 
and cellular adhesion molecules levels of P-selectin, E-selectin, ICAM-1 and 
VCAM-1 in a multi- ethnic population, only the correlation between circulating 
levels of E- selectin and blood pressure remained significant after adjustment for age 
(Miller et al. 2004).  
 
Similarly, the results of a study evaluating the relationship between insulin resistance 
and different soluble adhesion molecules including E-selectin, ICAM-1 and VCAM-
1, has shown that the degree of insulin resistance was significantly associated with 
all of these markers. However, the correlation between VCAM-1 and insulin 
resistance was abolished after adjustment for age and gender as possible confounders 
(Chen, Holmes, and Reaven 1999). Moreover, it was shown that the relationship 
between cellular adhesion molecules and cardiovascular risk factors is adhesion 
molecule specific and may differ with age and gender (Miller et al. 2004). Given 
these findings, it seems that among different cellular adhesion molecules mentioned 
above, E-selectin has a strong association with metabolic syndrome markers; and 
may possibly be a better marker for predicting of cardiovascular diseases.   
 
5.4 The assessment of ethnicity on Adiponectin 
 
Adiponectin is an adipocytokinase secreted specifically and plentifully by 
adipocytes, and plays an important role in preventing obesity-linked disorders, 
particularly insulin resistance. The findings of the current study highlight that the 
European group had significantly higher adiponectin levels than Indians and Iranians. 
The lower adiponectin level found in Indians than Europeans was consistent with 
other multiethnic studies undertaken on Indian and Caucasian subjects (Smith et al. 
2006; Mente et al. 2010; Vuksan et al. 2012). It has been shown that Indians have 
higher rates of cardiovascular events compared to Caucasians (Anand et al. 2000; 
Vuksan et al. 2012); however the underlying causes are not fully understood.  It is 
known that adiponectin has an anti-diabetic, anti-atherogenic and anti-inflammatory 
effects, and a decrease in the circulatory adiponectin level may have a role in 
developing type 2 diabetes and metabolic syndrome (Lindsay et al. 2002; Matsuzawa 
et al. 2004; Mente et al. 2010).  
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There was no study comparing the adiponectin level and metabolic syndrome risk 
factors between Europeans and Iranians in one environment. The level of adiponectin 
determined in normal Iranians living in Iran (Shojaie, Sotoodah, and Shafaie 2009) 
was obviously lower than those reported in Caucasians participating in different 
studies (Mente et al. 2010; Pischon et al. 2005). Namely, the level of adiponectin in 
relatively healthy Iranians was almost equal to those in Caucasians with 
cardiovascular events, indicating that in the basis of adiponectin, Iranians are more 
prone to the cardiovascular diseases and metabolic syndrome compared to 
Europeans. Existing evidence confirmed a higher risk of cardiovascular events and 
type 2 diabetes mellitus among Iranians having a lower level of adiponectin (Shojaie, 
Sotoodah, and Shafaie 2009; Mohammadzadeh and Zarghami 2009).    
 
It has also been shown that the level of adiponectin can be affected by genetic, 
environmental factors resulting in obesity, and dietary habits. In the current study, 
serum adiponectin concentration was inversely correlated with truncal body fat 
percentage. Furthermore, truncal body fat percentage remained a significant predictor 
of circulatory adiponectin after controlling for other factors. In agreement with these 
results, Staiger et al. showed that serum concentration of adiponectin is associated 
with proportion of fat accumulated in the abdominal area (Staiger et al. 2003). Given 
the anti-atherogenic effects of adiponectin, the findings also confirm other studies 
demonstrating that the susceptibility for atherosclerosis is mainly determined by the 
localisation of fat mass rather than general obesity (Tanko et al. 2003; Ferreira et al. 
2004). As mentioned before (see Section 4.4.1), Indian subjects participating in this 
study had a higher truncal body fat percentage relative to Europeans. This can be a 
probable explanation for the lower level of adiponectin detected in Indians when 
compared to European participants.     
 
In all ethnicities, women participating in this study had a higher mean value of 
adiponectin than men. This finding was consistent with another study in this regard 
(Staiger et al. 2003). Given the relationship of fat distribution and adiponectin 
discussed above, the significant difference in circulatory level of adiponectin 
between men and women participating in this study can be explained partly by the 
significant difference between their truncal body fat percentages. As indicated before 
(see Section 4.4.1), for all ethnicities, men had a lower total body fat compared to 
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women; however they were more likely to accumulate fat in the abdominal or 
visceral area. Furthermore, the higher adiponectin level found in female humans and 
rodents suggest that adiponectin regulation may be affected by sexual hormones, 
such as oestrogen and testosterone (Combs et al. 2003; Xu et al. 2005).  
 
In the current study, the adiponectin showed inverse correlation with glucose, insulin 
and HOMA score in Iranians, but not in Indians and Europeans. These findings were 
partially in line with the results of Giahi et al.’s  study (2008) showing a positive 
correlation between adiponectin and insulin sensitivity in diabetic and non-diabetic 
Iranian men, although the association was statistically significant only in non-
diabetics. Similarly, in other studies conducted on native Canadians and Alaskan 
Eskimo, the level of adiponectin was negatively correlated with insulin and HOMA-
IR (Hanley et al. 2003; Goropashnaya et al. 2009). It was shown that the effect of 
adiponectin on insulin sensitivity can be modified by ethnicity. Namely, each given 
decrease in adiponectin may result in different amount of increase in HOMA score 
across ethnic groups (Mente et al. 2010). This may explain the different association 
between adiponectin and insulin resistance among ethnic groups in the current study.      
 
In this study, adiponectin showed a negative association with the total carbohydrate 
intake. Additionally, the intake of carbohydrate was found to be a significant 
predictor of serum adiponectin after controlling for other factors. These results were 
consistent with previous studies investigating the relationship between high 
carbohydrate diet and adiponectin level (Nakamura et al. 2004; Pischon et al. 2005; 
Laughlin et al. 2007). Legumes and vegetables are other dietary factors which were 
suggested to have a role in relation to adiponectin. It was shown that there is a 
positive correlation between consumption of legumes and the level of adiponectin 
(Detopoulou et al. 2010). Iranian subjects participating in this study had a tendency 
toward an increased intake of carbohydrate relative to Europeans. In addition, the 
amount of vegetables and legumes consumed by Iranians and Indians were 
significantly lower than those in Europeans. These findings indicate that apart from 
race differences, the significantly lower adiponectin observed in Iranians compared 




To sum up, the European participants had generally higher mean values of total and 
truncal body fat percentages, glucose, insulin, HOMA, serum lipids and blood 
pressure (SBP & DBP) relative to Indians and Iranians. The tendency for a higher 
risk of cardiovascular diseases found in European participants were confirmed with 
their higher levels of hs-CRP and E-selectin relative to those of Indians and Iranians. 
Also, in overall, Iranian participants seem to be healthier than two other groups.  
 
In this study, the mean values of BMI/WC measured in Indian participants were just 
slightly lower than those in Europeans and Iranians. However, the patterns observed 
for some measurements changed when data were adjusted for these non-significant 
differences. Namely, after adjustment, Indian participants had the highest total and 
truncal body fat, HOMA and blood pressure among three ethnic groups. These 
results suggest that a better health situation found in the Indian group relative to 
Europeans may be in part due to these slight differences. Accordingly, Indians may 
be at a higher risk for metabolic syndrome than others in populations with exactly 
similar BMI and WC measurements. The next chapter is the concluding chapter of 






Recommendations, Significance and Conclusions 
 
 
6.1  Brief overview 
 
This final chapter presents the recommendations, significance and conclusions drawn 
from the research and supported by the literature. Metabolic syndrome is a cluster of 
risk factors leading individuals to diabetes and cardiovascular diseases. Given the 
personal and socio-economic impacts of these widespread chronic diseases, 
gathering sufficient and accurate knowledge and evidence concerning the metabolic 
syndrome plays a key role in defining effective prevention programs. 
 
Despite many studies having been undertaken globally and offering various 
definitions for the metabolic syndrome, there is still no general consensus on how to 
apply the accurate definitions and their diagnostic criteria, among different ethnic 
groups. Given this gap, research in a region such as Australia comprising people with 
different ethnicity living in a unique environment provides an opportunity to clear up 
some controversies around this issue. 
 
Therefore, in order to achieve the first objective, metabolic syndrome criteria among 
a cross-section of immigrants from three ethnic groups in Western Australia using 
four common international definitions of metabolic syndrome was compared. 
Subsequently, the effects of ethnicity on different components of metabolic 
syndrome were investigated. 
 
The findings of this study showed that using various definitions for metabolic 
syndrome lead to a wide range of prevalence estimates. This in turn can influence the 
prevention strategies for chronic diseases in the populations. Accordingly, there is 
still a need for clear consensus on a uniform definition of metabolic syndrome. In 
this study, the percentage of participants defined as having metabolic syndrome by 
WHO was lower than those with metabolic syndrome based on ATP III and IDF; 
however, the highest percentage of participants with insulin resistance was 
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discovered by WHO definition. Given the association between insulin resistance and 
other cardiovascular risk factors, these findings suggest that the WHO definition may 
have more accuracy to recognise individuals with higher risk of CVD compared to 
other three definitions of metabolic syndrome. Moreover, although the IDF definition 
seems to have slightly lower power in predicting the risk of CVD than WHO, it may 
be more practical from a clinical diagnostic perspective. 
 
It is known that among different components of metabolic syndrome, obesity 
(general & central) has a central role. Therefore, establishing optimal cut-off points 
for BMI and waist circumference, as anthropometric indices of total and truncal body 
fat, is necessary. While, several studies have shown that recommended cut-off points 
for BMI and waist circumference vary according to ethnicity and gender, there has 
been no general agreement so far about the specific values being applied for men and 
women in different ethnic groups.  
 
The results showed that European participants had higher total body fat percentage 
relative to Indians and Iranians; however this trend changed after adjusting for age 
and BMI. For a given age and BMI, the Indian group had higher mean value of total 
body fat percentage and total body fat/lean ratio, relative to Europeans and Iranians. 
In addition, there was no significant difference between the mean BMI of men and 
women participating in this study, but in all three ethnic groups, women had 
significantly higher total body fat, body fat percentage and total fat/lean mass ratio 
compared to men. This pattern was also observed for men and women in all ethnic 
groups, when they were evaluated for the age & WC adjusted mean values of truncal 
fat mass and truncal fat/lean ratio.  
 
In this study, despite the higher mean values of glucose, insulin and HOMA in 
Caucasians relative to two the other groups, Indian participants had the highest mean 
of HOMA score, after adjustment for age, gender and WC. Regression and 
correlation analyses showed that insulin resistance (indicated by HOMA) was related 
to different measurements of adiposity. However, HOMA tended to be more 
correlated with the measurements of truncal fat than generalised fatness. In the 
current study, ethnicity was found as a significant predictor of insulin resistance after 
controlling for different measurements of fatness. This suggests that the higher rates 
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of insulin resistance reported in Indians may be in part due to their higher truncal 
adiposity resulted from ethnic differences.  
 
Similarly, the European participants had higher means of systolic and diastolic blood 
pressure compared to Indians and Iranians, but after adjusting for age and gender, the 
mean values of systolic and diastolic blood pressure in Indians were higher than two 
other groups. The regression analysis showed ethnicity as a significant predictor of 
diastolic blood pressure after controlling for other variables.  
 
According to the results, SBP was positively correlated with different measurements 
of total and truncal adiposity, after controlling for age and gender. Additionally, the 
difference in SBP/DBP between Indians and Iranians became more significant after 
adjustment for WC. It was shown that for the given WC and age, Indian individuals 
participating in this study had higher percentages truncal body fat relative to 
Europeans and Iranians. These findings could partly explain the higher SBP observed 
in Indian participants.     
     
The results indicated that European and Iranian participants had the highest and the 
lowest age & sex-adjusted mean values of total cholesterol, LDL-cholesterol and 
triglycerides among three ethnic groups, respectively. In the current study, ethnicity 
was also shown as a strong predictor of total cholesterol, HDL-cholesterol, LDL-
cholesterol and TG, after controlling for other variables. It is known that the ethnic 
difference in lipid profile may be due to genetic variation as well as ethnic–specific 
lifestyle factors, such as dietary pattern and physical activity. We found no 
significant correlation between total or LDL-cholesterol and the measures of general 
and truncal fatness. Accordingly, the serum levels of these lipids are thought to be 
more influenced by dietary factors and physical activity. However, HDL-cholesterol 
and TG were significantly correlated with visceral adiposity, which can be affected 
by both acquired and genetic factors.   
 
These findings support the hypothesis (see Section 1.2) that ethnicity plays a 
significant role in developing metabolic syndrome risk factors affecting components 
such as, body mass index (BMI), central obesity, hypertension, dyslipidaemia, 
fasting blood glucose and Insulin resistance.  Based on the guidelines issued by 
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American Heart Association, the hs-CRP mean values >3 mg/L found in the 
European and Indian groups indicated that based on hs-CRP levels, they are at higher 
risk of cardiovascular events relative to Iranians who had mean hs-CRP<3 mg/L.  
 
Regardless of ethnicity, not only, hs-CRP determined in the participants was 
correlated with several different measures of obesity, but also it tended to be 
significantly more correlated with total body fat than with truncal adiposity. This 
finding would help explain the significantly higher hs-CRP reported in Europeans 
relative to Indians and Iranians, and in the females participating in the present study 
than those measured in males. 
 
Additionally, the degree of associations between CRP and different metabolic 
syndrome components assessed in this study varied across ethnic groups. Since, the 
associations between hs-CRP and different components of metabolic syndrome 
assessed in Iranians were stronger than those observed in Indians and Europeans, 
these findings suggest that the prognostic value of hs-CRP for predicting 
cardiovascular diseases may be more accurate in Iranians than two other groups.  
 
The second specific objective, evaluated the effects of ethnicity on the endothelial 
function in the ethnic groups. In this study, European, Indian and Iranian participants 
were compared for soluble forms of E-selectin and VCAM-1, as biomarkers of 
endothelial dysfunction. The mean values of E-selectin measured in Europeans were 
significantly higher than those in Iranians and Indians. This was in line with the 
results of hs-CRP suggesting that Europeans may be at a higher risk for 
cardiovascular diseases compared to two other groups. However, comparison 
between VCAM-1 measured in three ethnic groups showed a pattern contrary to 
what was observed for E-selectin. In this study, ethnicity was found as a significant 
predictor for circulating level of E-selectin after adjusting for age, gender and BMI. 
Since, E-selectin has a strong association with metabolic syndrome components and 
markers; it seems that among different cellular adhesion molecules, it would be a 
more reliable marker for prediction of cardiovascular diseases risk.  
 
It is known that the increased risks of metabolic syndrome in different populations 
can be because of the factors related to health behaviours. Accordingly, individuals 
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participating in this study were also evaluated for their dietary habits and nutrients 
intakes, as the third specific objective.  
  
In the current study, there was no significant difference between the amounts of 
carbohydrate taken by three ethnic groups; however they showed differences in 
regard to the intake of other nutrients. Namely, participants in Indian group had 
significantly lower intakes of protein, magnesium and sodium compared to 
Europeans and Iranians. Indian participants also had the lowest intakes, when three 
ethnic groups were compared for total daily energy intake, dietary fat, and calcium. 
 
The highest consumption of vegetables & legumes per day was consumed by 
Europeans, while participants in Iranian group consumed the highest amounts of 
fruits and breads & cereal foods in comparison with Europeans and Indians. 
 
Additionally, the relationship between these differences in nutrient intakes and 
different metabolic syndrome components were evaluated. The results highlighted a 
significant positive association between diastolic blood pressure and the dietary 
intake of sodium in regression analysis. However, the higher systolic and diastolic 
blood pressure observed in the Indian group was accompanied with a significantly 
lower intake of sodium in comparison to European and Iranian descents [Table 13 
&Table 16]. On the other hand, Iranian participants with the highest average of 
sodium intake had the lowest mean systolic and diastolic blood pressure among three 
ethnic groups. We suggest that these inconsistencies may be explained by higher 
intake of other minerals (magnesium, calcium and potassium) modifying the effects 
of sodium. Iranian and European participants in this study had higher intakes of these 
minerals than Indians. These findings suggest that in addition to ethnic susceptibility, 
and total & truncal adiposity, imbalanced dietary intake of minerals may contribute 
to higher levels of blood pressure reported in some ethnic groups. 
 
The levels of total and LDL cholesterol measured in Indians participating in this 
study were significantly higher than Iranians, while they had significantly lower 
dietary fat and cholesterol intake. This could be due to the fact that serum lipids may 
be also affected by consumption of dietary factors such as fibre (Brown et al. 1999), 
magnesium (Olatunji and Soladoye 2007) and calcium (Ditscheid, Keller, and Jahreis 
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2005), which were consumed in lesser amounts by Indian than by Iranian 
participants. Also, there was no significant relationship between total cholesterol or 
LDL-cholesterol and the measures of general and truncal fatness. These findings 
were consistent with other intervention studies indicating that the levels of total 
cholesterol and LDL-chol are influenced considerably more by dietary factors than 
by the body fat (Mirmiran et al. 2008).  
 
Among different metabolic biomarkers evaluated in this study, there was a negative 
association between adiponectin and the total carbohydrate intake. Additionally, the 
intake of carbohydrate was found to be a significant predictor of serum adiponectin 
after controlling for other factors. These results were consistent with previous studies 
investigating the relationship between high carbohydrate diet and adiponectin level 
(Nakamura et al. 2004; Pischon et al. 2005; Laughlin et al. 2007). Legumes and 
vegetables are other dietary factors which were suggested to have a role in relation to 
adiponectin.  It was shown that there is a positive correlation between consumption 
of legumes and the level of adiponectin (Detopoulou et al. 2010). As presented in 
Table 16, Iranian subjects participating in this study had a tendency toward an 
increased intake of carbohydrate relative to Europeans. In addition, the amount of 
vegetables and legumes consumed by Iranians and Indians were significantly lower 
than those in Europeans. These findings indicate that apart from race differences, the 
significantly lower adiponectin observed in Iranians compared to Europeans may be 
due to their different dietary habits. 
 
As the final specific aim, the relationship between adiponectin and different 
components of metabolic syndrome amongst ethnic groups was explored. According 
to the results, Iranian and Indian individuals participating in the current study had a 
significantly lower adiponectin compared to Europeans. It was also found that other 
than the race differences, the significantly lower adiponectin observed in Indians and 
Iranians relative to Europeans can be in part due to their different truncal body fat 
percentages and dietary habits respectively. Also, ethnicity was demonstrated as a 






6.2 Significance of the study 
 
It is well known that the metabolic syndrome and its related outcomes present a 
significant burden of disease all over the world. Despite many studies trying to 
define accurate diagnostic criteria and cut-offs for metabolic syndrome particularly 
among different ethnic groups, there is still no general consensus about the definition 
and criteria. The controversies were mostly due to the differences in methods applied 
for these researches such as using different samples from dissimilar ethnic groups as 
well as doing their studies in different countries and regions.  
 
This study was undertaken in the same region compromising immigrants from 
different ethnicities. This condition along with including the criteria of living in 
Australia for at least 5 years were to minimise the potential biases resulting from the 
factors related to the environment and lifestyle, which may have roles in developing 
of metabolic syndrome. 
 
This is the first experimental study in Australia comparing a wide range of elements 
such as routine biomedical factors, some specific endothelial markers, 
anthropometric measurements, dietary and body fat measurements using dual energy 
X-ray absorptiometry in three different ethnic groups. Accordingly, the effects of 
ethnicity on different cardiovascular risk factors have been investigated much more 
comprehensive than other similar studies.  
 
Three ethnic groups including immigrants with a background from European 
countries, India and Iran were chosen for this study since they either were major 
ethnic group in Australia and can thus have a significant impact on health nationally 
or there are existing similar studies about migrants from these ethnic groups in the 
origin or other countries.  
 
It is significant that unlike most of the other studies this research follows a multi-
approach to metabolic syndrome. Therefore, the results of the current study can be 
considered for both decision makers and health professionals in the societies to 





The current study should be interpreted within the context of its limitations. First of 
all, this study was conducted with a pilot-scale sample size. Although different 
methods of recruitment were undertaken for this purpose, only a limited number of 
eligible participants could be recruited. The small sample size precludes generalising 
the results to a wider population. Although the selection of 14 suburbs with the most 
population of targeted ethnic groups could decrease biases to minimum, this method 
could not omit the whole biases in this regard. There were also financial limitations 
in conducting this study with a larger sample size. Without these limitations, there 
was a good opportunity to enhance the power of study. 
 
The ability to examine oral glucose tolerance tests (OGTT) was also limited because 
of volunteers’ time limitation. The prevalence of impaired glucose tolerance was 
reported as 10.6% in Australia according to the AusDiab study. Due to limitation in 
performing oral glucose tolerance test, the prevalence of metabolic syndrome for the 
WHO definition reported in the current study may be underestimated by up to 10.6%. 
However, some of the participants with impaired glucose tolerance may have been 
characterized as metabolic syndrome cases in the analyses, because they may have 
met other components of the WHO definition.  
 
Another limitation of the current study is that the insulin sensitivity is determined by 
HOMA-IR formula rather than the insulin sensitivity index derived from 
hyperinsulinemic euglycemic clamp as the gold standard method. Other studies show 
that the correlations between the insulin sensitivity index and HOMA-IR range from 
0.69 to 0.79 (Bonora et al. 1998; Matsuda and DeFronzo 1999). However, HOMA-




The results of the current study as well as a review of different studies in the 
literature show the importance of ethnicity on metabolic syndrome criteria and 
components using four common definitions. This part suggests a range of particular 




6.4.1 Recommendation for the World Health Organisation  
Since, ethnicity plays a key role in metabolic syndrome demonstrations, it is 
recommended to the WHO to improve the definition of metabolic syndrome through 
consider the ethnicity as principal criteria in further definition/s. Namely, not only 
the cut-off points of BMI and WC, but also other components such as fat profile cut-
offs would be considered according to the ethnical specifies and differences. As it 
mentioned in section 2.2.1, only the definition recommended by the International 
Diabetes Federation (IDF) has considered the criterion of WC according to the 
population specifics.  
 
Moreover, because of the role of body fat in metabolic syndrome, it seems that the 
amount of fat would be considered as a criterion in new definitions of metabolic 
syndrome. However, it should be defined on gender and ethnic based. 
 
It is also recommended that in the management of metabolic syndrome at global 
scale needs to follow the policy of “think globally and act locally”. 
 
6.4.2 Recommendation for health economic and insurance organisations 
Due to the importance of the health economy and the heavy impact of burden of 
diseases related to metabolic syndrome, it is recommended that the economic 
policies in health sector would be based on the more accurate criteria and definitions. 
These policies help them to decrease the costs in health sector from both 
commonwealth and out of pocket proportions via well-timed screening as well as 
prevention programs which are much inexpensive than further treatments. 
 
6.4.3 Recommendation for the scientific organisations and researchers 
It is recommended that to improve and complete their current strategic and action 
plans through considering the effects of ethnicity on different preventable diseases 
for further research. This approach may cause a convergence between different 





6.4.4 Recommendation for the department of health in Australia and other 
health policy makers in multi-cultural countries 
 
The recommendation to the department of health in multi-cultural countries 
particular Australia is that they should plan screening programs according to the 
ethnic basis for different diseases particular those related to the metabolic syndrome. 
This plan can decrease the health sector costs where the diagnosis and subsequently 
related preventive intervention programs are done at the beginning stages. It also 
may improve the quality of life leading to an increase of life expectancy index.  
 
It is also recommended that the reference range of BMI and WC for detecting 
metabolic syndrome in both Indian men and women would be lower than those in the 
same gender of two other groups.  Furthermore, the recommended cut-off points of 
BMI and WC in European women should be lower than that in Iranians women; 
however higher cut-off points need to be applied for European men compared to 
Iranian men.  
 
6.5 Conclusion 
This study highlights that, different components of metabolic syndrome including 
general and central obesity, insulin resistance, dyslipidaemia and hypertension may 
be affected by ethnicity. These findings support the hypothesis that ethnicity plays a 
significant role in developing metabolic syndrome risk factors. 
 Based on the adjusted measurements of comparing the total and truncal fatness in 
men and women of three ethnic groups, it is recommended that the reference range of 
BMI and WC for detecting metabolic syndrome in both Indian men and women 
would be lower than those in the same gender of two other groups. Also, the 
recommended cut-off points of BMI and WC in European women should be lower 
than that in Iranians women; however higher cut-off points need to be applied for 
European men compared to Iranian men.     
 
The initial analysis showed that European and Iranian individuals participating in this 
study had the highest and the lowest mean values of total and truncal fat, serum 
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glucose, insulin and lipids, HOMA and blood pressure, respectively. These results 
were compatible with hs-CRP and E-selectin data analyses, indicating that Europeans 
may be at a higher risk of cardiovascular events. The initial patterns observed for 
most risk factors reformed then when data were adjusted for potential confounders 
(age and sex). Namely, Indian participants had the highest degree of total and truncal 
fatness and insulin resistance (indicated by HOMA), and systolic and diastolic blood 
pressure in new analysis, and the changes were more significant after additional 
adjustment for WC.  However, there was no difference between the patterns 
observed for hs-CRP and E-selectin before or after adjustment for these variables.  
 
The results of the regression analysis showed ethnicity as a main predictor of hs-
CRP, E-selectin and adiponectin. The results found that the degree of associations 
between different components of metabolic syndrome and these biomarkers vary 
between ethnic groups. This may cause bias in predicting the risk of cardiovascular 
events in populations having a specific risk factor dominantly. These results along 
with the findings mentioned above suggest that biomarkers of cardiovascular 
diseases may have different levels of accuracy across ethnic groups. This important 
point should be considered when these biomarkers are used to compare the risk of 
cardiovascular diseases among ethnic groups.  
 
It is hoped that the results of the study will provide a new path to further 
investigations with a larger sample size to extend these encouraging outcomes 










Abe, Y., B. El-Masri, K. T. Kimball, H. Pownall, C. F. Reilly, K. Osmundsen, C. W. 
Smith, and C. M. Ballantyne. 1998. "Soluble cell adhesion molecules in 
hypertriglyceridemia and potential significance on monocyte adhesion."  
Arteriosclerosis, thrombosis, and vascular biology 18 (5):723-31. 
ABS. 2006. "National Health Survey: Summary of Results, Australia, 2004-05." In. 
Canberra: Australian Bureau of Statistics  
Agyemang, C., and R. S. Bhopal. 2002. "Is the blood pressure of South Asian adults 
in the UK higher or lower than that in European white adults? A review of 
cross-sectional data."  Journal of human hypertension 16 (11):739-51. doi: 
10.1038/sj.jhh.1001488. 
Akita, S., F. M. Sacks, L. P. Svetkey, P. R. Conlin, and G. Kimura. 2003. "Effects of 
the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-
natriuresis relationship."  Hypertension 42 (1):8-13. doi: 
10.1161/01.HYP.0000074668.08704.6E. 
Albert, C. M., J. Ma, N. Rifai, M. J. Stampfer, and P. M. Ridker. 2002. "Prospective 
study of C-reactive protein, homocysteine, and plasma lipid levels as 
predictors of sudden cardiac death."  Circulation 105 (22):2595-9. 
Alberti, K. G., P. Zimmet, and J. Shaw. 2006. "Metabolic syndrome--a new world-
wide definition. A Consensus Statement from the International Diabetes 
Federation."  Diabetic medicine 23 (5):469-80. 
Alberti, K. G., and P. Z. Zimmet. 1998a. "Definition, diagnosis and classification of 
diabetes mellitus and its complications. Part 1: diagnosis and classification of 
diabetes mellitus provisional report of a WHO consultation."  Diabetic 
medicine 15 (7):539-53. doi: 10.1002/(SICI)1096-
9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. 
Alberti, K., and PZ Zimmet. 1998b. "New diagnostic criteria and classification of 
diabetes—again?"  Diabetic medicine 15 (7):535-6. 
Amati, F., M. Pennant, K. Azuma, J. J. Dube, F. G. Toledo, A. P. Rossi, D. E. 
Kelley, and B. H. Goodpaster. 2012. "Lower thigh subcutaneous and higher 
visceral abdominal adipose tissue content both contribute to insulin 
resistance."  Obesity 20 (5):1115-7. doi: 10.1038/oby.2011.401. 
American Diabetes Association. 2006. "Diagnosis and classification of diabetes 
mellitus."  Diabetes Care 29 Suppl 1:S43-8. doi: 29/suppl_1/s43 [pii]. 
Anand, S. S., F. Razak, Q. Yi, B. Davis, R. Jacobs, V. Vuksan, E. Lonn, K. Teo, M. 
McQueen, and S. Yusuf. 2004. "C-reactive protein as a screening test for 
cardiovascular risk in a multiethnic population."  Arterioscler Thromb Vasc 
Biol 24 (8):1509-15. doi: 10.1161/01.ATV.0000135845.95890.4e 
 
Anand, S. S., S. Yusuf, V. Vuksan, S. Devanesen, K. K. Teo, P. A. Montague, L. 
Kelemen, et al. 2000. "Differences in risk factors, atherosclerosis, and 
cardiovascular disease between ethnic groups in Canada: the Study of Health 
Assessment and Risk in Ethnic groups (SHARE)."  Lancet 356 (9226):279-
84. 
Anderson, K. M., P. W. Wilson, R. J. Garrison, and W. P. Castelli. 1987. 
"Longitudinal and secular trends in lipoprotein cholesterol measurements in a 
general population sample. The Framingham Offspring Study."  
Atherosclerosis 68 (1-2):59-66. 
151 
 
Arner, P., P. Engfeldt, and H. Lithell. 1981. "Site differences in the basal metabolism 
of subcutaneous fat in obese women."  The Journal of Clinical Endocrinology 
& Metabolism 53 (5):948-52. 
Ascherio, A., C. Hennekens, W. C. Willett, F. Sacks, B. Rosner, J. Manson, J. 
Witteman, and M. J. Stampfer. 1996. "Prospective study of nutritional 
factors, blood pressure, and hypertension among US women."  Hypertension 
27 (5):1065-72. 
Assan, R., C. Perronne, D. Assan, L. Chotard, C. Mayaud, S. Matheron, and D. 
Zucman. 1995. "Pentamidine-induced derangements of glucose homeostasis. 
Determinant roles of renal failure and drug accumulation. A study of 128 
patients."  Diabetes Care 18 (1):47-55. 
Assmann, G., R. Guerra, G. Fox, P. Cullen, H. Schulte, D. Willett, and S. M. 
Grundy. 2007. "Harmonizing the definition of the metabolic syndrome: 
comparison of the criteria of the Adult Treatment Panel III and the 
International Diabetes Federation in United States American and European 
populations."  Am J Cardiol 99 (4):541-8. doi: 
10.1016/j.amjcard.2006.08.045. 
Austin, M.A., J.L. Breslow, C.H. Hennekens, J.E. Buring, W.C. Willett, and R.M. 
Krauss. 1988. "Low-density lipoprotein subclass patterns and risk of 
myocardial infarction."  The Journal of the American Medical Association 
260 (13):1917. 
Australian Bureau of Statistics. 2010. "Year Book Australia 2009-10." In. Canberra: 
ABS. 
———. 2014. "AUSTRALIA'S POPULATION BY COUNTRY OF BIRTH." 
Australian Bureau of Statistics,. 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/3412.0Chapter12011-
12%20and%202012-13. 
Australian Institute of Health and Welfare. "Diabetes prevalence in Australia: 
detailed estimates for 2007–08. Diabetes series no. 17." AIHW, Accessed 
2011 Sep 29. http://www.aihw.gov.au/publication-
detail/?id=10737419311&tab=2. 
———. 2014. Australia's Health 2014, The 14th biennial health report of the 
Australian Institute of Health and Welfare: AIHW,. 
Ayatollahi, S. M., and Z. Ghoreshizadeh. 2010. "Prevalence of obesity and 
overweight among adults in Iran."  Obesity reviews : an official journal of the 
International Association for the Study of Obesity 11 (5):335-7. doi: 
10.1111/j.1467-789X.2010.00725.x. 
Azadbakht, L., M. Kimiagar, Y. Mehrabi, A. Esmaillzadeh, M. Padyab, F. B. Hu, 
and W. C. Willett. 2007. "Soy inclusion in the diet improves features of the 
metabolic syndrome: a randomized crossover study in postmenopausal 
women."  Am J Clin Nutr 85 (3):735-41. doi: 85/3/735 [pii]. 
Azadbakht, L., P. Mirmiran, A. Esmaillzadeh, and F. Azizi. 2005. "Dairy 
consumption is inversely associated with the prevalence of the metabolic 
syndrome in Tehranian adults."  Am J Clin Nutr 82 (3):523-30. 
Azadbakht, L., P. Mirmiran, A. Esmaillzadeh, T. Azizi, and F. Azizi. 2005. 
"Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan 
on features of the metabolic syndrome."  Diabetes Care 28 (12):2823-31. 
Azizi, F., P. Mirmiran, and L. Azadbakht. 2004. "Predictors of cardiovascular risk 
factors in Tehranian adolescents: Tehran Lipid and Glucose Study."  
International journal for vitamin and nutrition research 74 (5):307-12. 
152 
 
Azizi, F., M. Rahmani, H. Emami, P. Mirmiran, R. Hajipour, M. Madjid, J. Ghanbili, 
et al. 2002. "Cardiovascular risk factors in an Iranian urban population: 
Tehran lipid and glucose study (phase 1)."  Sozial- und Praventivmedizin 47 
(6):408-26. 
Azizi, F., M. Rahmani, A. Ghanbarian, H. Emami, P. Salehi, P. Mirmiran, and N. 
Sarbazi. 2003. "Serum lipid levels in an Iranian adults population: Tehran 
Lipid and Glucose Study."  European journal of epidemiology 18 (4):311-9. 
Babio, N., M. Bullo, J. Basora, M. A. Martinez-Gonzalez, J. Fernandez-Ballart, F. 
Marquez-Sandoval, C. Molina, and J. Salas-Salvado. 2009. "Adherence to the 
Mediterranean diet and risk of metabolic syndrome and its components."  
Nutrition, Metabolism & Cardiovascular Diseases 19 (8):563-70. 
Balasubramanyam, A., S. Rao, R. Misra, R. V. Sekhar, and C. M. Ballantyne. 2008. 
"Prevalence of metabolic syndrome and associated risk factors in Asian 
Indians."  Journal of Immigrant and Minority Health 10 (4):313-23. doi: 
10.1007/s10903-007-9092-4. 
Balkau, B., M. A. Charles, T. Drivsholm, K. Borch-Johnsen, N. Wareham, J. S. 
Yudkin, R. Morris, et al. 2002. "Frequency of the WHO metabolic syndrome 
in European cohorts, and an alternative definition of an insulin resistance 
syndrome."  Diabetes & Metabolism 28 (5):364-76. doi: MDOI-DM-11-
2002-28-5-1262-3636-101019-ART3 [pii]. 
Ball, K., D. Crawford, P. Ireland, and A. Hodge. 2003. "Patterns and demographic 
predictors of 5-year weight change in a multi-ethnic cohort of men and 
women in Australia."  Public Health Nutrition 6 (3):269-81. doi: 
10.1079/PHN2002431. 
Banerji, M. A., R. L. Chaiken, H. Huey, T. Tuomi, A. J. Norin, I. R. Mackay, M. J. 
Rowley, P. Z. Zimmet, and H. E. Lebovitz. 1994. "GAD antibody negative 
NIDDM in adult black subjects with diabetic ketoacidosis and increased 
frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes."  
Diabetes 43 (6):741-5. 
Barclay, A. W., P. Petocz, J. McMillan-Price, V. M. Flood, T. Prvan, P. Mitchell, 
and J. C. Brand-Miller. 2008. "Glycemic index, glycemic load, and chronic 
disease risk--a meta-analysis of observational studies."  Am J Clin Nutr 87 
(3):627-37. doi: 87/3/627 [pii]. 
Bautista, L. E. 2003. "Inflammation, endothelial dysfunction, and the risk of high 
blood pressure: epidemiologic and biological evidence."  Journal of human 
hypertension 17 (4):223-30. 
Bautista, L. E., L. M. Vera, I. A. Arenas, and G. Gamarra. 2005. "Independent 
association between inflammatory markers (C-reactive protein, interleukin-6, 
and TNF-alpha) and essential hypertension."  Journal of human hypertension 
19 (2):149-54. 
Bazzano, L. A., J. He, L. G. Ogden, C. Loria, S. Vupputuri, L. Myers, and P. K. 
Whelton. 2001. "Legume consumption and risk of coronary heart disease in 
US men and women: NHANES I Epidemiologic Follow-up Study."  Archives 
of Internal Medicine 161 (21):2573-8. 
Belfrage, P., G. Fredrikson, H. Olsson, and P. Stralfors. 1985. "Molecular 
mechanisms for hormonal control of adipose tissue lipolysis."  International 
journal of obesity 9 Suppl 1:129-35. 
Beltran-Sanchez, H., M. O. Harhay, M. M. Harhay, and S. McElligott. 2013. 
"Prevalence and trends of metabolic syndrome in the adult U.S. population, 
153 
 
1999-2010."  J Am Coll Cardiol 62 (8):697-703. doi: 
10.1016/j.jacc.2013.05.064. 
Bentley, A. R., G. Chen, D. Shriner, A. P. Doumatey, J. Zhou, H. Huang, J. C. 
Mullikin, et al. 2014. "Gene-based sequencing identifies lipid-influencing 
variants with ethnicity-specific effects in African Americans."  PLoS Genet 
10 (3):e1004190. doi: 10.1371/journal.pgen.1004190. 
Berghofer, A., T. Pischon, T. Reinhold, C. M. Apovian, A. M. Sharma, and S. N. 
Willich. 2008. "Obesity prevalence from a European perspective: a 
systematic review."  BMC Public Health 8:200. doi: 10.1186/1471-2458-8-
200. 
Bhardwaj, S., A. Misra, R. Misra, K. Goel, S.P. Bhatt, K. Rastogi, N.K. Vikram, and 
S. Gulati. 2011. "High Prevalence of Abdominal, Intra-Abdominal and 
Subcutaneous Adiposity and Clustering of Risk Factors among Urban Asian 
Indians in North India."  PloS one 6 (9):e24362. 
Bhopal, R., N. Unwin, M. White, J. Yallop, L. Walker, K. G. Alberti, J. Harland, et 
al. 1999. "Heterogeneity of coronary heart disease risk factors in Indian, 
Pakistani, Bangladeshi, and European origin populations: cross sectional 
study."  British Medical Journal 319 (7204):215-20. 
Blake, G. J., J. D. Otvos, N. Rifai, and P. M. Ridker. 2002. "Low-density lipoprotein 
particle concentration and size as determined by nuclear magnetic resonance 
spectroscopy as predictors of cardiovascular disease in women."  Circulation 
106 (15):1930-7. 
Blann, A. D., J. Amiral, and C. N. McCollum. 1996. "Circulating endothelial 
cell/leucocyte adhesion molecules in ischaemic heart disease."  British 
Journal of Haematology 95 (2):263-5. 
Bo, S., L. Gentile, G. Ciccone, C. Baldi, L. Benini, F. Dusio, C. Lucia, et al. 2005. 
"The metabolic syndrome and high C-reactive protein: prevalence and 
differences by sex in a southern-European population-based cohort."  
Diabetes/metabolism research and reviews 21 (6):515-24. doi: 
10.1002/dmrr.561. 
Bogardus, C., S. Lillioja, D. M. Mott, C. Hollenbeck, and G. Reaven. 1985. 
"Relationship between degree of obesity and in vivo insulin action in man."  
American Journal of Physiology 248 (3 Pt 1):E286-91. 
Bonora, E., S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. 
Bonadonna, and M. Muggeo. 2004. "Population-based incidence rates and 
risk factors for type 2 diabetes in white individuals: the Bruneck study."  
Diabetes 53 (7):1782-9. doi: 53/7/1782 [pii]. 
Bonora, E., S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, G. Targher, M. 
Alberiche, R. C. Bonadonna, and M. Muggeo. 1998. "Prevalence of insulin 
resistance in metabolic disorders: the Bruneck Study."  Diabetes 47 
(10):1643-9. 
Bonora, E., G. Targher, M. Alberiche, R.C. Bonadonna, F. Saggiani, M.B. Zenere, T. 
Monauni, and M. Muggeo. 2000. "Homeostasis model assessment closely 
mirrors the glucose clamp technique in the assessment of insulin sensitivity: 
studies in subjects with various degrees of glucose tolerance and insulin 
sensitivity."  Diabetes Care 23 (1):57. 
Bonow, R. O., and M. Gheorghiade. 2004. "The diabetes epidemic: a national and 




Boon NA, Fox KAA, Bloomfield P, Bradbuny A. 2002. Cardiovascular Disease in 
Davidson’s Principles and Practice of Medicine. 19 ed. New York: Churchill. 
Boos, C. J., and G. Y. Lip. 2005. "Elevated high-sensitive C-reactive protein, large 
arterial stiffness and atherosclerosis: a relationship between inflammation and 
hypertension?"  Journal of human hypertension 19 (7):511-3. doi: 
10.1038/sj.jhh.1001858. 
Boparai, J., H. Davila, and M. Chandalia. 2011. "Cardiovascular Disease in Asian 
Indians Living in the United States."  Current Cardiovascular Risk 
Reports:1-6. 
Bouchard, C., and L. Perusse. 1988. "Heredity and body fat."  Annual Review of 
Nutrition 8:259-77. doi: 10.1146/annurev.nu.08.070188.001355. 
Boulbou, M. S., G. N. Koukoulis, E. D. Makri, E. A. Petinaki, K. I. Gourgoulianis, 
and A. E. Germenis. 2005. "Circulating adhesion molecules levels in type 2 
diabetes mellitus and hypertension."  International Journal of Cardiology 98 
(1):39-44. doi: 10.1016/j.ijcard.2003.07.037. 
Bozorgmanesh, M. R., F. Hadaegh, M. Padyab, Y. Mehrabi, and F. Azizi. 2008. 
"Temporal changes in anthropometric parameters and lipid profile according 
to body mass index among an adult Iranian urban population."  Annals of 
nutrition & metabolism 53 (1):13-22. doi: 10.1159/000152869. 
Brasier, A. R., A. Recinos, 3rd, and M. S. Eledrisi. 2002. "Vascular inflammation 
and the renin-angiotensin system."  Arteriosclerosis, thrombosis, and 
vascular biology 22 (8):1257-66. 
Bray, G. A., and T. Bellanger. 2006. "Epidemiology, trends, and morbidities of 
obesity and the metabolic syndrome."  Endocrine 29 (1):109-17. doi: 
10.1385/ENDO:29:1:109. 
Brian, G., J. Ramke, L. Maher, A. Page, K. Fischer-Harder, and B. Sikivou. 2011. 
"Body mass index among Melanesian and Indian Fijians aged >/= 40 years 
living in Fiji."  Asia-Pacific Journal of Public Health 23 (1):34-43. doi: 
23/1/34 [pii] 
10.1177/1010539510390665. 
Brown, L., B. Rosner, W. W. Willett, and F. M. Sacks. 1999. "Cholesterol-lowering 
effects of dietary fiber: a meta-analysis."  Am J Clin Nutr 69 (1):30-42. 
Brown, N. J., M. A. Agirbasli, G. H. Williams, W. R. Litchfield, and D. E. Vaughan. 
1998. "Effect of activation and inhibition of the renin-angiotensin system on 
plasma PAI-1."  Hypertension 32 (6):965-71. 
Brunner, EJ, MG Marmot, K. Nanchahal, MJ Shipley, SA Stansfeld, M. Juneja, and 
K.G.M.M. Alberti. 1997. "Social inequality in coronary risk: central obesity 
and the metabolic syndrome. Evidence from the Whitehall II study."  
Diabetologia 40 (11):1341-9. 
Bull, FC., AE. Bauman, B. Bellew, and W. Brown. "Getting Australia Active II: An 
update of evidence on physical activity." National Public Health Partnership 
(NPHP). 
Byrne, M. M., J. Sturis, S. Menzel, K. Yamagata, S. S. Fajans, M. J. Dronsfield, S. 
C. Bain, et al. 1996. "Altered insulin secretory responses to glucose in 
diabetic and nondiabetic subjects with mutations in the diabetes susceptibility 
gene MODY3 on chromosome 12."  Diabetes 45 (11):1503-10. 
Calabro, P., D.W. Chang, J.T. Willerson, and E.T.H. Yeh. 2005. "Release of C-
reactive protein in response to inflammatory cytokines by human adipocytes: 
linking obesity to vascular inflammation."  Journal of the American College 
of Cardiology 46 (6):1112. 
155 
 
Calabró, P., J.T. Willerson, and E.T.H. Yeh. 2003. "Inflammatory cytokines 
stimulated C-reactive protein production by human coronary artery smooth 
muscle cells."  Circulation 108 (16):1930-2. 
Cameron, A. J., D. J. Magliano, P. Z. Zimmet, T. Welborn, and J. E. Shaw. 2007. 
"The metabolic syndrome in Australia: prevalence using four definitions."  
Diabetes Res Clin Pract 77 (3):471-8. 
Cameron, A., and J. Shaw. 2011. "Epidemiology of the Metabolic Syndrome and 
Risk for Cardiovascular Disease and Diabetes."  Atlas of Atherosclerosis and 
Metabolic Syndrome:27-44. 
Cameron, A.J., T.A. Welborn, P.Z. Zimmet, D.W. Dunstan, N. Owen, J. Salmon, M. 
Dalton, D. Jolley, and J.E. Shaw. 2003. "Overweight and obesity in Australia: 
the 1999-2000 Australian diabetes, obesity and lifestyle study (AusDiab)."  
Medical Journal of Australia 178 (9):427-32. 
Campbell, P. J., and M. G. Carlson. 1993. "Impact of obesity on insulin action in 
NIDDM."  Diabetes 42 (3):405-10. 
Cancer Council Victoria. "Dietary Questionnaire for Epidemiological Studies (DQES 
v2), User Information Guide." 
http://www.cancervic.org.au/downloads/cec/FFQs/CEC-DQESv2-User-
Guide-09.pdf. 
Cappuccio, F. P. 1997. "Ethnicity and cardiovascular risk: variations in people of 
African ancestry and South Asian origin."  Journal of human hypertension 11 
(9):571-6. 
Cavigiolio, G., B. Shao, E. G. Geier, G. Ren, J. W. Heinecke, and M. N. Oda. 2008. 
"The interplay between size, morphology, stability, and functionality of high-
density lipoprotein subclasses."  Biochemistry 47 (16):4770-9. doi: 
10.1021/bi7023354. 
Chagnon, Y. C., T. Rankinen, E. E. Snyder, S. J. Weisnagel, L. Perusse, and C. 
Bouchard. 2003. "The human obesity gene map: the 2002 update."  Obes Res 
11 (3):313-67. doi: 10.1038/oby.2003.47. 
Chahil, T. J., and H. N. Ginsberg. 2006. "Diabetic dyslipidemia."  Endocrinol Metab 
Clin North Am 35 (3):491-510, vii-viii. 
Chambers, J. C., S. Eda, P. Bassett, Y. Karim, S. G. Thompson, J. R. Gallimore, M. 
B. Pepys, and J. S. Kooner. 2001. "C-reactive protein, insulin resistance, 
central obesity, and coronary heart disease risk in Indian Asians from the 
United Kingdom compared with European whites."  Circulation 104 (2):145-
50. 
Chandalia, M., N. Abate, A. Garg, J. Stray-Gundersen, and S. M. Grundy. 1999. 
"Relationship between generalized and upper body obesity to insulin 
resistance in Asian Indian men."  J Clin Endocrinol Metab 84 (7):2329-35. 
Chandalia, M., P. Lin, T. Seenivasan, E. H. Livingston, P. G. Snell, S. M. Grundy, 
and N. Abate. 2007. "Insulin resistance and body fat distribution in South 
Asian men compared to Caucasian men."  PloS one 2 (8):e812. doi: 
10.1371/journal.pone.0000812. 
Chang, M. H., R. M. Ned, Y. Hong, A. Yesupriya, Q. Yang, T. Liu, A. C. Janssens, 
and N. F. Dowling. 2011. "Racial/ethnic variation in the association of lipid-
related genetic variants with blood lipids in the US adult population."  Circ 
Cardiovasc Genet 4 (5):523-33. doi: 10.1161/CIRCGENETICS.111.959577. 
Chaturvedi, N., E. Coady, J. Mayet, A. R. Wright, A. C. Shore, S. Byrd, G. Thom S. 
A. Mc, J. S. Kooner, C. G. Schalkwijk, and A. D. Hughes. 2007. "Indian 
Asian men have less peripheral arterial disease than European men for 
156 
 
equivalent levels of coronary disease."  Atherosclerosis 193 (1):204-12. doi: 
10.1016/j.atherosclerosis.2006.06.017. 
Chen, N. G., M. Holmes, and G. M. Reaven. 1999. "Relationship between insulin 
resistance, soluble adhesion molecules, and mononuclear cell binding in 
healthy volunteers."  J Clin Endocrinol Metab 84 (10):3485-9. 
Chen, Y. D., A. Golay, A. L. Swislocki, and G. M. Reaven. 1987. "Resistance to 
insulin suppression of plasma free fatty acid concentrations and insulin 
stimulation of glucose uptake in noninsulin-dependent diabetes mellitus."  J 
Clin Endocrinol Metab 64 (1):17-21. doi: 10.1210/jcem-64-1-17. 
Cheung, B. M., S. P. Ho, A. H. Cheung, and C. P. Lau. 2000. "Diastolic blood 
pressure is related to urinary sodium excretion in hypertensive Chinese 
patients."  QJM : monthly journal of the Association of Physicians 93 
(3):163-8. 
Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, 
D.W. Jones, B.J. Materson, S. Oparil, and J.T. Wright Jr. 2003. "The national 
high blood pressure education program coordinating committee."  The 
seventh report of the joint national committee on prevention, detection, 
evaluation, and treatment of high blood pressure: the JNC 7:1206-52. 
Church, S., P. Gilbert, and S. Khokhar. 2006. "Ethnic groups and foods in Europe."  
European Food Information Resource Network.[Links]. 
Cleland, S. J., and N. Sattar. 2005. "Impact of ethnicity on metabolic disturbance, 
vascular dysfunction and atherothrombotic cardiovascular disease."  Diabetes 
Obes Metab 7 (5):463-70. doi: DOM401 [pii] 
10.1111/j.1463-1326.2004.00401.x. 
Clement, K., M. E. Pueyo, M. Vaxillaire, B. Rakotoambinina, F. Thuillier, P. Passa, 
P. Froguel, J. J. Robert, and G. Velho. 1996. "Assessment of insulin 
sensitivity in glucokinase-deficient subjects."  Diabetologia 39 (1):82-90. 
Clement, K., C. Vaisse, N. Lahlou, S. Cabrol, V. Pelloux, D. Cassuto, M. 
Gourmelen, et al. 1998. "A mutation in the human leptin receptor gene causes 
obesity and pituitary dysfunction."  Nature 392 (6674):398-401. doi: 
10.1038/32911. 
ClevelandHeartLab. 2010. "Inflammatory Biomarkers and the Progression of 
Atherosclerosis." In. 
Combs, T. P., A. H. Berg, M. W. Rajala, S. Klebanov, P. Iyengar, J. C. Jimenez-
Chillaron, M. E. Patti, S. L. Klein, R. S. Weinstein, and P. E. Scherer. 2003. 
"Sexual differentiation, pregnancy, calorie restriction, and aging affect the 
adipocyte-specific secretory protein adiponectin."  Diabetes 52 (2):268-76. 
Craig, CL, AL Marshall, M Sjöström, AE Bauman, ML Booth, BE Ainsworth, M 
Pratt, U Ekelund, A Yngve, and JF Sallis. 2003. "and the IPAQ Consensus 
Group and the IPAQ Reliability and Validity Study Group. International 
Physical Activity Questionnaire (IPAQ): 12-country reliability and validity."  
Medicine & Science in Sports & Exercise 35:1381-95. 
Crawford, D. C., C. L. Sanders, X. Qin, J. D. Smith, C. Shephard, M. Wong, L. 
Witrak, M. J. Rieder, and D. A. Nickerson. 2006. "Genetic variation is 
associated with C-reactive protein levels in the Third National Health and 
Nutrition Examination Survey."  Circulation 114 (23):2458-65. doi: 
10.1161/CIRCULATIONAHA.106.615740. 
Cushman, M., L. A. McClure, V. J. Howard, N. S. Jenny, S. G. Lakoski, and G. 
Howard. 2009. "Implications of increased C-reactive protein for 
157 
 
cardiovascular risk stratification in black and white men and women in the 
US."  Clinical Chemistry 55 (9):1627-36. 
Cybulsky, M. I., and M. A. Gimbrone, Jr. 1991. "Endothelial expression of a 
mononuclear leukocyte adhesion molecule during atherogenesis."  Science 
251 (4995):788-91. 
Dallongeville, J., D. Cottel, J. Ferrieres, D. Arveiler, A. Bingham, J. B. Ruidavets, B. 
Haas, P. Ducimetiere, and P. Amouyel. 2005. "Household income is 
associated with the risk of metabolic syndrome in a sex-specific manner."  
Diabetes Care 28 (2):409-15. 
Damnjanovic, G., M. Jelic, B. Dindic, and S. Ilic. 2009. "[Serum concentration of 
soluble adhesive molecules in patients with different forms of coronary artery 
disease]."  Vojnosanit Pregl 66 (4):265-70. 
Danaei, G., M. M. Finucane, Y. Lu, G. M. Singh, M. J. Cowan, C. J. Paciorek, J. K. 
Lin, et al. 2011. "National, regional, and global trends in fasting plasma 
glucose and diabetes prevalence since 1980: systematic analysis of health 
examination surveys and epidemiological studies with 370 country-years and 
2.7 million participants."  Lancet 378 (9785):31-40. doi: 10.1016/S0140-
6736(11)60679-X. 
Daniels, S. R., D. K. Arnett, R. H. Eckel, S. S. Gidding, L. L. Hayman, S. 
Kumanyika, T. N. Robinson, B. J. Scott, S. St Jeor, and C. L. Williams. 2005. 
"Overweight in children and adolescents: pathophysiology, consequences, 
prevention, and treatment."  Circulation 111 (15):1999-2012. 
Davignon, J., and P. Ganz. 2004. "Role of endothelial dysfunction in 
atherosclerosis."  Circulation 109 (23 Suppl 1):III27-32. doi:  
. 
De Caterina, R., G. Basta, G. Lazzerini, G. Dell'Omo, R. Petrucci, M. Morale, F. 
Carmassi, and R. Pedrinelli. 1997. "Soluble vascular cell adhesion molecule-
1 as a biohumoral correlate of atherosclerosis."  Arteriosclerosis, thrombosis, 
and vascular biology 17 (11):2646-54. 
de Roos, N., E. Schouten, and M. Katan. 2001. "Consumption of a solid fat rich in 
lauric acid results in a more favorable serum lipid profile in healthy men and 
women than consumption of a solid fat rich in trans-fatty acids."  J Nutr 131 
(2):242-5. 
DECODE Study Group, European Diabetes Epidemiology Group. 1999. "Glucose 
tolerance and mortality: comparison of WHO and American Diabetes 
Association diagnostic criteria. The DECODE study group. European 
Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative 
analysis Of Diagnostic criteria in Europe."  Lancet 354 (9179):617-21. doi: 
S0140673698121311 [pii]. 
Deepa, M., S. Farooq, M. Datta, R. Deepa, and V. Mohan. 2007. "Prevalence of 
metabolic syndrome using WHO, ATPIII and IDF definitions in Asian 
Indians: the Chennai Urban Rural Epidemiology Study (CURES-34)."  
Diabetes/metabolism research and reviews 23 (2):127-34. doi: 
10.1002/dmrr.658. 
DeFronzo, R. A. 1988. "The triumvirate: beta-cell, muscle, liver. A collusion 
responsible for NIDDM."  Diabetes 37 (6):667-87. 
———. 2004. "Pathogenesis of type 2 diabetes mellitus."  Med Clin North Am 88 
(4):787-835, ix. doi: 10.1016/j.mcna.2004.04.013. 
158 
 
DeFronzo, R. A., and D. Tripathy. 2009. "Skeletal muscle insulin resistance is the 
primary defect in type 2 diabetes."  Diabetes Care 32 Suppl 2:S157-63. doi: 
10.2337/dc09-S302. 
Dekker, J. M., C. Girman, T. Rhodes, G. Nijpels, C. D. Stehouwer, L. M. Bouter, and 
R. J. Heine. 2005. "Metabolic syndrome and 10-year cardiovascular disease 
risk in the Hoorn Study."  Circulation 112 (5):666-73. doi: 
10.1161/CIRCULATIONAHA.104.516948. 
Denova-Gutierrez, E., S. Castanon, J. O. Talavera, K. Gallegos-Carrillo, M. Flores, 
D. Dosamantes-Carrasco, W. C. Willett, and J. Salmeron. 2010. "Dietary 
patterns are associated with metabolic syndrome in an urban Mexican 
population."  Journal of Nutrition 140 (10):1855-63. 
DeSouza, C. A., D. R. Dengel, R. F. Macko, K. Cox, and D. R. Seals. 1997. 
"Elevated levels of circulating cell adhesion molecules in uncomplicated 
essential hypertension."  American Journal of Hypertension 10 (12 Pt 
1):1335-41. doi: S0895706197002689 [pii]. 
Detopoulou, P., D. B. Panagiotakos, C. Chrysohoou, E. Fragopoulou, T. Nomikos, S. 
Antonopoulou, C. Pitsavos, and C. Stefanadis. 2010. "Dietary antioxidant 
capacity and concentration of adiponectin in apparently healthy adults: the 
ATTICA study."  Eur J Clin Nutr 64 (2):161-8. doi: 10.1038/ejcn.2009.130. 
Deurenberg-Yap, M., S. K. Chew, V. F. Lin, B. Y. Tan, W. A. van Staveren, and P. 
Deurenberg. 2001. "Relationships between indices of obesity and its co-
morbidities in multi-ethnic Singapore."  International journal of obesity and 
related metabolic disorders 25 (10):1554-62. doi: 10.1038/sj.ijo.0801739. 
Deurenberg-Yap, M., G. Schmidt, W. A. van Staveren, and P. Deurenberg. 2000. 
"The paradox of low body mass index and high body fat percentage among 
Chinese, Malays and Indians in Singapore."  International journal of obesity 
and related metabolic disorders 24 (8):1011-7. 
Deurenberg, P., M. Deurenberg-Yap, and S. Guricci. 2002. "Asians are different 
from Caucasians and from each other in their body mass index/body fat per 
cent relationship."  Obesity reviews : an official journal of the International 
Association for the Study of Obesity 3 (3):141-6. 
Dhanaraj, E., A. Bhansali, S. Jaggi, P. Dutta, S. Jain, P. Tiwari, and P. Ramarao. 
2009. "Predictors of metabolic syndrome in Asian north Indians with newly 
detected type 2 diabetes."  The Indian journal of medical research 129 
(5):506-14. 
Dhawan, J., C. L. Bray, R. Warburton, D. S. Ghambhir, and J. Morris. 1994. "Insulin 
resistance, high prevalence of diabetes, and cardiovascular risk in immigrant 
Asians. Genetic or environmental effect?"  British Heart Journal 72 (5):413-
21. 
Diabetes Australia Western Australia. "Western Australian impaired fasting 




Ditscheid, B., S. Keller, and G. Jahreis. 2005. "Cholesterol metabolism is affected by 
calcium phosphate supplementation in humans."  Journal of Nutrition 135 
(7):1678-82. 
Dumler, F. 2009. "Dietary sodium intake and arterial blood pressure."  Journal of 
renal nutrition : the official journal of the Council on Renal Nutrition of the 
National Kidney Foundation 19 (1):57-60. doi: 10.1053/j.jrn.2008.10.006. 
159 
 
Dunstan, D. W., J. Salmon, N. Owen, T. Armstrong, P. Z. Zimmet, T. A. Welborn, 
A. J. Cameron, T. Dwyer, D. Jolley, and J. E. Shaw. 2005. "Associations of 
TV viewing and physical activity with the metabolic syndrome in Australian 
adults."  Diabetologia 48 (11):2254-61. doi: 10.1007/s00125-005-1963-4. 
Dunstan, D., P. Zimmet, T. Welborn, R. Sicree, T. Armstrong, R. Atkins, A. 
Cameron, J. Shaw, and S. Chadban. "Diabesity and associated disorders in 
Australia: The accelerating epidemic.The Australian Diabetes, Obesity & 
Lifestyle Study (AusDiab)." International Diabetes Institute. 
http://www.diabetes.com.au/pdf/AusDiab_Report.pdf. 
Eckel, Robert H, Scott M Grundy, and Paul Z Zimmet. 2005. "The metabolic 
syndrome."  The Lancet 365 (9468):1415-28. 
Einhorn, D., G. M. Reaven, R. H. Cobin, E. Ford, O. P. Ganda, Y. Handelsman, R. 
Hellman, et al. 2003. "American College of Endocrinology position statement 
on the insulin resistance syndrome."  Endocrine Practice 9 (3):237-52. 
Engeli, S., R. Negrel, and A.M. Sharma. 2000. "Physiology and pathophysiology of 
the adipose tissue renin-angiotensin system."  Hypertension 35 (6):1270-7. 
Enkhmaa, B., K. Shiwaku, E. Anuurad, A. Nogi, K. Kitajima, M. Yamasaki, T. 
Oyunsuren, and Y. Yamane. 2005. "Prevalence of the metabolic syndrome 
using the Third Report of the National Cholesterol Educational Program 
Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (ATP III) and the modified ATP III definitions for 
Japanese and Mongolians."  Clinica Chimica Acta 352 (1-2):105-13. doi: 
10.1016/j.cccn.2004.08.012. 
Esmaillzadeh, A., and L. Azadbakht. 2012. "Legume consumption is inversely 
associated with serum concentrations of adhesion molecules and 
inflammatory biomarkers among Iranian women."  Journal of Nutrition 142 
(2):334-9. doi: jn.111.146167 [pii]10.3945/jn.111.146167. 
Esmaillzadeh, A., M. Kimiagar, Y. Mehrabi, L. Azadbakht, F. B. Hu, and W. C. 
Willett. 2007. "Dietary patterns, insulin resistance, and prevalence of the 
metabolic syndrome in women."  Am J Clin Nutr 85 (3):910-8. 
Esmaillzadeh, A., P. Mirmiran, and F. Azizi. 2005a. "Whole-grain consumption and 
the metabolic syndrome: a favorable association in Tehranian adults."  Eur J 
Clin Nutr 59 (3):353-62. doi: 10.1038/sj.ejcn.1602080. 
———. 2005b. "Whole-grain intake and the prevalence of hypertriglyceridemic 
waist phenotype in Tehranian adults."  Am J Clin Nutr 81 (1):55-63. 
Esposito, K., R. Marfella, M. Ciotola, C. Di Palo, F. Giugliano, G. Giugliano, M. 
D'Armiento, F. D'Andrea, and D. Giugliano. 2004. "Effect of a 
mediterranean-style diet on endothelial dysfunction and markers of vascular 
inflammation in the metabolic syndrome: a randomized trial."  The Journal of 
the American Medical Association 292 (12):1440-6. doi: 
10.1001/jama.292.12.1440. 
Esposti, M. D., A. Ngo, and M. A. Myers. 1996. "Inhibition of mitochondrial 
complex I may account for IDDM induced by intoxication with the 
rodenticide Vacor."  Diabetes 45 (11):1531-4. 
Esteghamati, A., H. Ashraf, O. Khalilzadeh, A. Zandieh, M. Nakhjavani, A. Rashidi, 
M. Haghazali, and F. Asgari. 2010. "Optimal cut-off of homeostasis model 
assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic 
syndrome: third national surveillance of risk factors of non-communicable 




Esteghamati, A., O. Khalilzadeh, A. Rashidi, A. Meysamie, M. Haghazali, F. Asgari, 
M. Abbasi, S. Rastad, and M. M. Gouya. 2009. "Association between 
physical activity and insulin resistance in Iranian adults: National 
Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-
2007)."  Preventive Medicine 49 (5):402-6. 
Evans, D. J., R. G. Hoffmann, R. K. Kalkhoff, and A. H. Kissebah. 1984. 
"Relationship of body fat topography to insulin sensitivity and metabolic 
profiles in premenopausal women."  Metabolism 33 (1):68-75. 
Expert Panel on Detection, Evaluation, and Adults Treatment of High Blood 
Cholesterol in. 2001. "Executive Summary of The Third Report of The 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III)."  The Journal of the American Medical Association 285 
(19):2486-97. 
Expert panel on the identification evaluation and treatment of overweight in adults. 
1998. "Clinical guidelines on the identification, evaluation, and treatment of 
overweight and obesity in adults." 
Fabris, P., C. Betterle, A. Floreani, N. A. Greggio, F. de Lazzari, R. Naccarato, and 
M. Chiaramonte. 1992. "Development of type 1 diabetes mellitus during 
interferon alfa therapy for chronic HCV hepatitis."  Lancet 340 (8818):548. 
Fabsitz, R. R., D. Carmelli, and J. K. Hewitt. 1992. "Evidence for independent 
genetic influences on obesity in middle age."  International journal of obesity 
and related metabolic disorders 16 (9):657-66. 
Fauci, A.S., E. Braunwald, and K.J. Isselbacher. 2003. Harrison’s Principles of 
Internal Medicine. 15 ed. Vol. 1. New York: McGraw-Hill. 
Ferrannini, E., G. Buzzigoli, R. Bonadonna, M. A. Giorico, M. Oleggini, L. 
Graziadei, R. Pedrinelli, L. Brandi, and S. Bevilacqua. 1987. "Insulin 
resistance in essential hypertension."  N Engl J Med 317 (6):350-7. 
Ferreira, I., M. B. Snijder, J. W. Twisk, W. van Mechelen, H. C. Kemper, J. C. 
Seidell, and C. D. Stehouwer. 2004. "Central fat mass versus peripheral fat 
and lean mass: opposite (adverse versus favorable) associations with arterial 
stiffness? The Amsterdam Growth and Health Longitudinal Study."  J Clin 
Endocrinol Metab 89 (6):2632-9. doi: 10.1210/jc.2003-031619. 
Ferri, C., G. Desideri, M. Valenti, C. Bellini, M. Pasin, A. Santucci, and G. De 
Mattia. 1999. "Early upregulation of endothelial adhesion molecules in obese 
hypertensive men."  Hypertension 34 (4 Pt 1):568-73. 
Fisher, M., M. Cushman, V. Knappertz, and G. Howard. 2008. "An assessment of the 
joint associations of aspirin and statin use with C-reactive protein 
concentration."  American Heart Journal 156 (1):106-11. 
Fleiss, Joseph L. 1981. Statistical methods for rates and proportion. 2nd Edition ed. 
New York: Wiley & Sons. 
Fleming, RM. 1999. The Pathogenesis of Vascular Disease. Textbook of Angiology. 
New York: Springer-Verlag. 
Fogli-Cawley, J. J., J. T. Dwyer, E. Saltzman, M. L. McCullough, L. M. Troy, J. B. 
Meigs, and P. F. Jacques. 2007. "The 2005 Dietary Guidelines for Americans 
and risk of the metabolic syndrome."  Am J Clin Nutr 86 (4):1193-201. doi: 
86/4/1193 [pii]. 
Ford, E. S., W. H. Giles, and W. H. Dietz. 2002. "Prevalence of the metabolic 
syndrome among US adults: findings from the third National Health and 
161 
 
Nutrition Examination Survey."  The Journal of the American Medical 
Association 287 (3):356-9. doi: jbr10281 [pii]. 
Ford, E. S., W. H. Giles, and A. H. Mokdad. 2004. "Increasing prevalence of the 
metabolic syndrome among u.s. Adults."  Diabetes Care 27 (10):2444-9. doi: 
27/10/2444 [pii]. 
Ford, E. S., H. W. Kohl, 3rd, A. H. Mokdad, and U. A. Ajani. 2005. "Sedentary 
behavior, physical activity, and the metabolic syndrome among U.S. adults."  
Obes Res 13 (3):608-14. doi: 13/3/608 [pii] 
10.1038/oby.2005.65. 
Forouhi, N. G., G. Jenkinson, E. L. Thomas, S. Mullick, S. Mierisova, U. Bhonsle, P. 
M. McKeigue, and J. D. Bell. 1999. "Relation of triglyceride stores in skeletal 
muscle cells to central obesity and insulin sensitivity in European and South 
Asian men."  Diabetologia 42 (8):932-5. doi: 10.1007/s001250051250. 
Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. "Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, without use of 
the preparative ultracentrifuge."  Clinical Chemistry 18 (6):499-502. 
Funk, S. D., A. Yurdagul, Jr., and A. W. Orr. 2012. "Hyperglycemia and endothelial 
dysfunction in atherosclerosis: lessons from type 1 diabetes."  International 
Journal of Vascular Medicine 2012:569654. doi: 10.1155/2012/569654. 
Garrett, RH, and CM Grisham. 1995. "Biochemistry." In, 1154. Orlando, FL: 
Saunders College Publishing. 
Gautier, A, B Balkau, C Lange, J Tichet, and F Bonnet. 2010. "Risk factors for 
incident type 2 diabetes in individuals with a BMI of 2: the role of -
glutamyltransferase. Data from an Epidemiological Study on the Insulin 
Resistance Syndrome (DESIR)."  Diabetologia 53 (2):247-53. 
Gennest, J., and P. Libby. 2011. "Lipoprotein disorders and cardiovascular disease."  
Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. 
Philadelphia, Pa: Saunders Elsevier. 
Ghosh, A. 2007. "Comparison of anthropometric, metabolic and dietary fatty acids 
profiles in lean and obese dyslipidaemic Asian Indian male subjects."  Eur J 
Clin Nutr 61 (3):412-9. doi: 10.1038/sj.ejcn.1602534. 
Giahi, L, A Djazayery, A Rahimy, M Rahmany, and B Larijani. 2008. "Serum level 
of adiponectin and its association with insulin sensitivity in overweight 
diabetic and non-diabetic Iranian men."  Iranian Journal of Public Health 37 
(2). 
Gibson, R.S. 2005. Principles of nutritional assessment. 2nd ed. New York: Oxford 
University Press. 
Giles, G.G., and P. Ireland. 1996. Dietary questionnaire for epidemiological studies 
(version 2). Melbourne: The Cancer Council Victoria. 
Glenday, K., B. N. Kumar, A. Tverdal, and H. E. Meyer. 2006. "Cardiovascular 
disease risk factors among five major ethnic groups in Oslo, Norway: the 
Oslo Immigrant Health Study."  The European Journal of Cardiovascular 
Prevention & Rehabilitation 13 (3):348-55. doi: 00149831-200606000-00009 
[pii]. 
Glowinska, B., M. Urban, J. Peczynska, and B. Florys. 2005. "Soluble adhesion 
molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL 
selectin) levels in children and adolescents with obesity, hypertension, and 
diabetes."  Metabolism 54 (8):1020-6. doi: 10.1016/j.metabol.2005.03.004. 
Glueck, C. J., P. Gartside, P. M. Laskarzewski, P. Khoury, and H. A. Tyroler. 1984. 
"High-density lipoprotein cholesterol in blacks and whites: potential 
162 
 
ramifications for coronary heart disease."  American Heart Journal 108 (3 Pt 
2):815-26. 
Goh, V. H., C. F. Tain, T. Y. Tong, H. P. Mok, and M. T. Wong. 2004. "Are BMI 
and other anthropometric measures appropriate as indices for obesity? A 
study in an Asian population."  The Journal of Lipid Research 45 (10):1892-
8. doi: 10.1194/jlr.M400159-JLR200. 
Gornik, H. L., and J. A. Beckman. 2005. "Cardiology patient page. Peripheral arterial 
disease."  Circulation 111 (13):e169-72. doi: 
10.1161/01.CIR.0000160581.58633.8B. 
Goropashnaya, A. V., J. Herron, M. Sexton, P. J. Havel, K. L. Stanhope, R. Plaetke, 
G. V. Mohatt, and B. B. Boyer. 2009. "Relationships between plasma 
adiponectin and body fat distribution, insulin sensitivity, and plasma 
lipoproteins in Alaskan Yup'ik Eskimos: the Center for Alaska Native Health 
Research study."  Metabolism 58 (1):22-9. doi: 
10.1016/j.metabol.2008.09.002. 
Gould, J.M., and J.N. Weiser. 2001. "Expression of C-reactive protein in the human 
respiratory tract."  Infection and immunity 69 (3):1747-54. 
Govindarajan, G, A Whaley-Connell, M Mugo, C Stump, and JR Sowers. 2005. "The 
cardiometabolic syndrome as a cardiovascular risk factor."  The American 
journal of the medical sciences 330 (6):311. 
Grundy, S. M. 2004a. "Metabolic syndrome: part I."  Endocrinol Metab Clin North 
Am 33 (2):ix-xi. 
———. 2008. "Metabolic syndrome pandemic."  Arteriosclerosis, thrombosis, and 
vascular biology 28 (4):629-36. doi: 10.1161/ATVBAHA.107.151092. 
Grundy, S. M., H. B. Brewer, Jr., J. I. Cleeman, S. C. Smith, Jr., and C. Lenfant. 
2004. "Definition of metabolic syndrome: Report of the National Heart, 
Lung, and Blood Institute/American Heart Association conference on 
scientific issues related to definition."  Circulation 109 (3):433-8. 
Grundy, S. M., J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. 
Franklin, D. J. Gordon, et al. 2005. "Diagnosis and management of the 
metabolic syndrome: an American Heart Association/National Heart, Lung, 
and Blood Institute Scientific Statement."  Circulation 112 (17):2735-52. doi: 
10.1161/CIRCULATIONAHA.105.169404. 
Grundy, S.M. 2004b. "Obesity, metabolic syndrome, and cardiovascular disease."  
Journal of Clinical Endocrinology & Metabolism 89 (6):2595-600. 
———. 2006. "Metabolic Syndrome: Therapeutic Considerations." In HANDBOOK 
OF EXPERIMANTAL PHARMACOLOGY, 107-33. 
Gu, D., K. Reynolds, X. Wu, J. Chen, X. Duan, R. F. Reynolds, P. K. Whelton, J. 
He, and Asia Collaborative Group Inter. 2005. "Prevalence of the metabolic 
syndrome and overweight among adults in China."  Lancet 365 (9468):1398-
405. doi: 10.1016/S0140-6736(05)66375-1. 
Guillaume, M., L. Lapidus, F. Beckers, A. Lambert, and P. Bjorntorp. 1995. 
"Familial trends of obesity through three generations: the Belgian-
Luxembourg child study."  International journal of obesity and related 
metabolic disorders 19 Suppl 3:S5-9. 
Gupta, R., P. C. Deedwania, A. Gupta, S. Rastogi, R. B. Panwar, and K. Kothari. 
2004. "Prevalence of metabolic syndrome in an Indian urban population."  
International Journal of Cardiology 97 (2):257-61. 
163 
 
Hackman, A., Y. Abe, W. Insull, Jr., H. Pownall, L. Smith, K. Dunn, A. M. Gotto, 
Jr., and C. M. Ballantyne. 1996. "Levels of soluble cell adhesion molecules in 
patients with dyslipidemia."  Circulation 93 (7):1334-8. 
Haffner, S. M., M. P. Stern, J. Dunn, M. Mobley, J. Blackwell, and R. N. Bergman. 
1990. "Diminished insulin sensitivity and increased insulin response in 
nonobese, nondiabetic Mexican Americans."  Metabolism 39 (8):842-7. 
Hanley, A. J., P. W. Connelly, S. B. Harris, and B. Zinman. 2003. "Adiponectin in a 
native Canadian population experiencing rapid epidemiological transition."  
Diabetes Care 26 (12):3219-25. 
Harris, M. I. 1993. "Undiagnosed NIDDM: clinical and public health issues."  
Diabetes Care 16 (4):642-52. 
Hayashi, Y., K. Okumura, H. Matsui, A. Imamura, M. Miura, R. Takahashi, R. 
Murakami, Y. Ogawa, Y. Numaguchi, and T. Murohara. 2007. "Impact of 
low-density lipoprotein particle size on carotid intima-media thickness in 
patients with type 2 diabetes mellitus."  Metabolism 56 (5):608-13. doi: 
10.1016/j.metabol.2007.01.001. 
He, M., R. M. van Dam, E. Rimm, F. B. Hu, and L. Qi. 2010. "Whole-grain, cereal 
fiber, bran, and germ intake and the risks of all-cause and cardiovascular 
disease-specific mortality among women with type 2 diabetes mellitus."  
Circulation 121 (20):2162-8. doi: 
10.1161/CIRCULATIONAHA.109.907360. 
Helmrich, S. P., D. R. Ragland, R. W. Leung, and R. S. Paffenbarger, Jr. 1991. 
"Physical activity and reduced occurrence of non-insulin-dependent diabetes 
mellitus."  N Engl J Med 325 (3):147-52. doi: 
10.1056/NEJM199107183250302. 
Herd, S. L., B. A. Gower, N. Dashti, and M. I. Goran. 2001. "Body fat, fat 
distribution and serum lipids, lipoproteins and apolipoproteins in African-
American and Caucasian-American prepubertal children."  International 
journal of obesity and related metabolic disorders 25 (2):198-204. doi: 
10.1038/sj.ijo.0801524. 
Hermsdorff, H. H., M. A. Zulet, I. Abete, and J. A. Martinez. 2011. "A legume-based 
hypocaloric diet reduces proinflammatory status and improves metabolic 
features in overweight/obese subjects."  European journal of nutrition 50 
(1):61-9. doi: 10.1007/s00394-010-0115-x. 
Hernandez-Presa, M., C. Bustos, M. Ortego, J. Tunon, G. Renedo, M. Ruiz-Ortega, 
and J. Egido. 1997. "Angiotensin-converting enzyme inhibition prevents 
arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-
1 expression, and macrophage infiltration in a rabbit model of early 
accelerated atherosclerosis."  Circulation 95 (6):1532-41. 
Hodge, A, AJ Patterson, WJ Brown, P Ireland, and G Giles. 2000. "The Anti Cancer 
Council of Victoria FFQ: relative validity of nutrient intakes compared with 
weighed food records in young to middle-aged women in a study of iron 
supplementation."  Australian and New Zealand Journal of Public Health 24 
(6):576-83. 
Hossain, P., B. Kawar, and M. El Nahas. 2007. "Obesity and diabetes in the 
developing world--a growing challenge."  New England Journal of Medicine 
356 (3):213-5. doi: 10.1056/NEJMp068177. 
Hu, G., Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnsen, and K. Pyorala. 2004. 
"Prevalence of the metabolic syndrome and its relation to all-cause and 
cardiovascular mortality in nondiabetic European men and women."  
164 
 
Archives of Internal Medicine 164 (10):1066-76. doi: 
10.1001/archinte.164.10.1066. 
Hu, G., and H. Tian. 2001. "A comparison of dietary and non-dietary factors of 
hypertension and normal blood pressure in a Chinese population."  Journal of 
human hypertension 15 (7):487-93. doi: 10.1038/sj.jhh.1001218. 
Huffman, K. M., V. H. Hawk, S. T. Henes, C. I. Ocampo, M. C. Orenduff, C. A. 
Slentz, J. L. Johnson, et al. 2012. "Exercise effects on lipids in persons with 
varying dietary patterns-does diet matter if they exercise? Responses in 
Studies of a Targeted Risk Reduction Intervention through Defined Exercise 
I."  American Heart Journal 164 (1):117-24. doi: 10.1016/j.ahj.2012.04.014. 
Hughes, K., T.C. Aw, P. Kuperan, and M. Choo. 1997. "Central obesity, insulin 
resistance, syndrome X, lipoprotein (a), and cardiovascular risk in Indians, 
Malays, and Chinese in Singapore."  Journal of epidemiology and community 
health 51 (4):394-9. 
Hulthe, J., and B. Fagerberg. 2002. "Circulating oxidized LDL is associated with 
subclinical atherosclerosis development and inflammatory cytokines (AIR 
Study)."  Arterioscler Thromb Vasc Biol 22 (7):1162-7. 
International Diabetes Federation. "A desktop guide to type 2 diabetes mellitus." 
http://www.staff.ncl.ac.uk/philip.home/t2dg1999.pdf. 
———. "The IDF worldwide definition of the metabolic syndrome." Accessed 2008 
Jun 10. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. 
———. "The Global Burden " IDF. http://www.idf.org/diabetesatlas/5e/the-global-
burden. 
Isomaa, BO, P. Almgren, T. Tuomi, B. Forsén, K. Lahti, M. Nissén, M.R. Taskinen, 
and L. Groop. 2001. "Cardiovascular morbidity and mortality associated with 
the metabolic syndrome."  Diabetes Care 24 (4):683-9. 
Jabs, W. J., B. A. Logering, P. Gerke, B. Kreft, E. M. Wolber, M. H. Klinger, L. 
Fricke, and J. Steinhoff. 2003. "The kidney as a second site of human C-
reactive protein formation in vivo."  European Journal of Immunology 33 
(1):152-61. doi: 10.1002/immu.200390018. 
Jakes, R. W., N. E. Day, K. T. Khaw, R. Luben, S. Oakes, A. Welch, S. Bingham, 
and N. J. Wareham. 2003. "Television viewing and low participation in 
vigorous recreation are independently associated with obesity and markers of 
cardiovascular disease risk: EPIC-Norfolk population-based study."  Eur J 
Clin Nutr 57 (9):1089-96. doi: 10.1038/sj.ejcn.1601648. 
James, P. T., N. Rigby, R. Leach, and Force International Obesity Task. 2004. "The 
obesity epidemic, metabolic syndrome and future prevention strategies."  Eur 
J Cardiovasc Prev Rehabil 11 (1):3-8. 
Jansson, P. A., U. Smith, and P. Lonnroth. 1990. "Interstitial glycerol concentration 
measured by microdialysis in two subcutaneous regions in humans."  The 
American journal of physiology 258 (6 Pt 1):E918-22. 
Jensen, M. D., M. W. Haymond, R. A. Rizza, P. E. Cryer, and J. M. Miles. 1989. 
"Influence of body fat distribution on free fatty acid metabolism in obesity."  
Journal of Clinical Investigation 83 (4):1168-73. doi: 10.1172/JCI113997. 
Jernigan, V. B., B. Duran, D. Ahn, and M. Winkleby. 2010. "Changing patterns in 
health behaviors and risk factors related to cardiovascular disease among 
American Indians and Alaska Natives."  American journal of public health 
100 (4):677-83. doi: 10.2105/AJPH.2009.164285. 
Jeyaseelan, L., and P. S. Rao. 1989. "Methods of determining sample sizes in clinical 
trials."  Indian Pediatr 26 (2):115-21. 
165 
 
Jialal, I., S. Devaraj, and S.K. Venugopal. 2004. "C-reactive protein: risk marker or 
mediator in atherothrombosis?"  Hypertension 44 (1):6-11. 
Jovanovic, L., and D. J. Pettitt. 2001. "Gestational diabetes mellitus."  The Journal of 
the American Medical Association 286 (20):2516-8. doi: jct10015 [pii]. 
Kahn, S. E., R. L. Hull, and K. M. Utzschneider. 2006. "Mechanisms linking obesity 
to insulin resistance and type 2 diabetes."  Nature 444 (7121):840-6. doi: 
10.1038/nature05482. 
Karelis, A. D., M. Faraj, J. P. Bastard, D. H. St-Pierre, M. Brochu, D. Prud'homme, 
and R. Rabasa-Lhoret. 2005. "The metabolically healthy but obese individual 
presents a favorable inflammation profile."  J Clin Endocrinol Metab 90 
(7):4145-50. doi: 10.1210/jc.2005-0482. 
Karppanen, H., and E. Mervaala. 2006. "Sodium intake and hypertension."  Progress 
in cardiovascular diseases 49 (2):59-75. doi: 10.1016/j.pcad.2006.07.001. 
Karve, A., and R.A. Hayward. 2010. "Prevalence, diagnosis, and treatment of 
impaired fasting glucose and impaired glucose tolerance in nondiabetic US 
adults."  Diabetes Care 33 (11):2355-9. 
Kawakami, A., M. Aikawa, P. Alcaide, F. W. Luscinskas, P. Libby, and F. M. Sacks. 
2006. "Apolipoprotein CIII induces expression of vascular cell adhesion 
molecule-1 in vascular endothelial cells and increases adhesion of monocytic 
cells."  Circulation 114 (7):681-7. doi: 
10.1161/CIRCULATIONAHA.106.622514. 
Kearney, P. M., M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He. 
2005. "Global burden of hypertension: analysis of worldwide data."  Lancet 
365 (9455):217-23. doi: 10.1016/S0140-6736(05)17741-1. 
Kelishadi, R., M. Hashemipour, A. Sheikh-Heidar, and S. Ghatreh-Samani. 2012. 
"Changes in serum lipid profile of obese or overweight children and 
adolescents following a lifestyle modification course."  ARYA atherosclerosis 
8 (3):143-8. 
Kelishadi, R., M. H. Pour, N. S. Zadegan, M. Kahbazi, G. Sadry, A. Amani, R. 
Ansari, H. Alikhassy, and N. Bashardoust. 2004. "Dietary fat intake and lipid 
profiles of Iranian adolescents: Isfahan Healthy Heart Program--Heart Health 
Promotion from Childhood."  Preventive Medicine 39 (4):760-6. doi: 
10.1016/j.ypmed.2004.02.047. 
Kelley-Hedgepeth, A., D. M. Lloyd-Jones, A. Colvin, K. A. Matthews, J. Johnston, 
M. R. Sowers, B. Sternfeld, R. C. Pasternak, and C. U. Chae. 2008. "Ethnic 
differences in C-reactive protein concentrations."  Clinical Chemistry 54 
(6):1027-37. doi: 10.1373/clinchem.2007.098996. 
Kelley, D. E., F. L. Thaete, F. Troost, T. Huwe, and B. H. Goodpaster. 2000a. 
"Subdivisions of subcutaneous abdominal adipose tissue and insulin 
resistance."  American journal of physiology. Endocrinology and metabolism 
278 (5):E941-8. 
———. 2000b. "Subdivisions of subcutaneous abdominal adipose tissue and insulin 
resistance."  American journal of physiology. Endocrinology and metabolism 
278 (5):E941-8. 
Kelly, T, W Yang, CS Chen, K Reynolds, and J He. 2008. "Global burden of obesity 
in 2005 and projections to 2030."  International journal of obesity 32 
(9):1431-7. 
Keskin, M., S. Kurtoglu, M. Kendirci, M.E. Atabek, and C. Yazici. 2005. 
"Homeostasis model assessment is more reliable than the fasting 
glucose/insulin ratio and quantitative insulin sensitivity check index for 
166 
 
assessing insulin resistance among obese children and adolescents."  
Pediatrics 115 (4):e500. 
Keys, A., A. Menotti, M. J. Karvonen, C. Aravanis, H. Blackburn, R. Buzina, B. S. 
Djordjevic, et al. 1986. "The diet and 15-year death rate in the seven 
countries study."  American journal of epidemiology 124 (6):903-15. 
Khera, A., D. K. McGuire, S. A. Murphy, H. G. Stanek, S. R. Das, W. 
Vongpatanasin, F. H. Wians, Jr., S. M. Grundy, and J. A. de Lemos. 2005. 
"Race and gender differences in C-reactive protein levels."  Journal of the 
American College of Cardiology 46 (3):464-9. doi: 
10.1016/j.jacc.2005.04.051. 
Kim, J., and I. Jo. 2011. "Grains, vegetables, and fish dietary pattern is inversely 
associated with the risk of metabolic syndrome in South korean adults."  
Journal of the American Dietetic Association 111 (8):1141-9. doi: 
10.1016/j.jada.2011.05.001. 
Kimokoti, R.W., and B.E. Millen. 2011. "Diet, the global obesity epidemic, and 
prevention."  Journal of the American Dietetic Association 111 (8):1137-40. 
King, D. E., B. M. Egan, A. G. Mainous, 3rd, and M. E. Geesey. 2004. "Elevation of 
C-reactive protein in people with prehypertension."  The Journal of Clinical 
Hypertension 6 (10):562-8. 
King, H., R.E. Aubert, and W.H. Herman. 1998. "Global burden of diabetes, 1995–
2025: prevalence, numerical estimates, and projections."  Diabetes Care 21 
(9):1414-31. 
King, H., and M. Rewers. 1993. "Global estimates for prevalence of diabetes mellitus 
and impaired glucose tolerance in adults."  Diabetes Care 16 (1):157-77. 
Kintscher, U., M. Hartge, K. Hess, A. Foryst-Ludwig, M. Clemenz, M. Wabitsch, P. 
Fischer-Posovszky, et al. 2008. "T-lymphocyte infiltration in visceral adipose 
tissue: a primary event in adipose tissue inflammation and the development of 
obesity-mediated insulin resistance."  Arteriosclerosis, thrombosis, and 
vascular biology 28 (7):1304-10. doi: 10.1161/ATVBAHA.108.165100. 
Kip, K. E., O. C. Marroquin, D. E. Kelley, B. D. Johnson, S. F. Kelsey, L. J. Shaw, 
W. J. Rogers, and S. E. Reis. 2004. "Clinical importance of obesity versus the 
metabolic syndrome in cardiovascular risk in women: a report from the 
Women's Ischemia Syndrome Evaluation (WISE) study."  Circulation 109 
(6):706-13. doi: 10.1161/01.CIR.0000115514.44135.A8. 
Kissebah, A. H., N. Vydelingum, R. Murray, D. J. Evans, A. J. Hartz, R. K. 
Kalkhoff, and P. W. Adams. 1982. "Relation of body fat distribution to 
metabolic complications of obesity."  J Clin Endocrinol Metab 54 (2):254-60. 
Knox, SA, CM Harrison, HC Britt, and JV Henderson. 2008. "Estimating prevalence 
of common chronic morbidities in Australia."  Medical Journal of Australia 
189 (2):66-70. 
Kolonel, L. N., J. H. Hankin, A. S. Whittemore, A. H. Wu, R. P. Gallagher, L. R. 
Wilkens, E. M. John, et al. 2000. "Vegetables, fruits, legumes and prostate 
cancer: a multiethnic case-control study."  Cancer Epidemiol Biomarkers 
Prev 9 (8):795-804. 
Koochek, A., P. Mirmiran, T. Azizi, M. Padyab, S. E. Johansson, B. Karlstrom, F. 
Azizi, and J. Sundquist. 2008. "Is migration to Sweden associated with 
increased prevalence of risk factors for cardiovascular disease?"  The 




Korkeila, M., J. Kaprio, A. Rissanen, and M. Koskenvuo. 1991. "Effects of gender 
and age on the heritability of body mass index."  International journal of 
obesity 15 (10):647-54. 
Koster, A., S. Stenholm, D. E. Alley, L. J. Kim, E. M. Simonsick, A. M. Kanaya, M. 
Visser, et al. 2010. "Body fat distribution and inflammation among obese 
older adults with and without metabolic syndrome."  Obesity 18 (12):2354-
61. doi: 10.1038/oby.2010.86. 
Kotsis, V., S. Stabouli, S. Papakatsika, Z. Rizos, and G. Parati. 2010. "Mechanisms 
of obesity-induced hypertension."  Hypertension research : official journal of 
the Japanese Society of Hypertension 33 (5):386-93. doi: 10.1038/hr.2010.9. 
Kovacs, P., and M. Stumvoll. 2005. "Fatty acids and insulin resistance in muscle and 
liver."  Best Practice & Research Clinical Endocrinology & Metabolism 19 
(4):625-35. doi: 10.1016/j.beem.2005.07.003. 
Kranzhofer, R., J. Schmidt, C. A. Pfeiffer, S. Hagl, P. Libby, and W. Kubler. 1999. 
"Angiotensin induces inflammatory activation of human vascular smooth 
muscle cells."  Arteriosclerosis, thrombosis, and vascular biology 19 
(7):1623-9. 
Kristiansson, K., M. Perola, E. Tikkanen, J. Kettunen, I. Surakka, A. S. Havulinna, 
A. Stancakova, et al. 2012. "Genome-wide screen for metabolic syndrome 
susceptibility Loci reveals strong lipid gene contribution but no evidence for 
common genetic basis for clustering of metabolic syndrome traits."  
Circulation Cardiovascular Genetics 5 (2):242-9. doi: 
10.1161/CIRCGENETICS.111.961482. 
Kuller, L. H. 2004. "Ethnic differences in atherosclerosis, cardiovascular disease and 
lipid metabolism."  Current Opinion in Lipidology 15 (2):109-13. doi: 
00041433-200404000-00003 [pii]. 
Kumar, B. N., H. E. Meyer, M. Wandel, I. Dalen, and G. Holmboe-Ottesen. 2006. 
"Ethnic differences in obesity among immigrants from developing countries, 
in Oslo, Norway."  International journal of obesity 30 (4):684-90. doi: 
0803051 [pii] 
10.1038/sj.ijo.0803051. 
Kumashiro, N., D. M. Erion, D. Zhang, M. Kahn, S. A. Beddow, X. Chu, C. D. Still, 
et al. 2011. "Cellular mechanism of insulin resistance in nonalcoholic fatty 
liver disease."  Proceedings of the National Academy of Sciences of the 
United States of America 108 (39):16381-5. doi: 10.1073/pnas.1113359108. 
Lakoski, S. G., M. Cushman, M. Criqui, T. Rundek, R. S. Blumenthal, R. B. 
D'Agostino, Jr., and D. M. Herrington. 2006. "Gender and C-reactive protein: 
data from the Multiethnic Study of Atherosclerosis (MESA) cohort."  
American Heart Journal 152 (3):593-8. doi: 10.1016/j.ahj.2006.02.015. 
Lakoski, SG, M. Cushman, DS Siscovick, RS Blumenthal, W. Palmas, G. Burke, and 
DM Herrington. 2010. "The relationship between inflammation, obesity and 
risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA)."  
Journal of human hypertension 25 (2):73-9. 
Lamarche, B., A. C. St-Pierre, I. L. Ruel, B. Cantin, G. R. Dagenais, and J. P. 
Despres. 2001. "A prospective, population-based study of low density 
lipoprotein particle size as a risk factor for ischemic heart disease in men."  
Canadian Journal of Cardiology 17 (8):859-65. 
Lamb, E. J., and A. P. Day. 2000. "New diagnostic criteria for diabetes mellitus: are 
we any further forward?"  Annals of Clinical Biochemistry 37 ( Pt 5):588-92. 
168 
 
Landis, J. R., and G. G. Koch. 1977. "The measurement of observer agreement for 
categorical data."  Biometrics 33 (1):159-74. 
Landmesser, U., B. Hornig, and H. Drexler. 2004. "Endothelial function: a critical 
determinant in atherosclerosis?"  Circulation 109 (21 Suppl 1):II27-33. doi: 
10.1161/01.CIR.0000129501.88485.1f. 
Laughlin, G. A., E. Barrett-Connor, S. May, and C. Langenberg. 2007. "Association 
of adiponectin with coronary heart disease and mortality: the Rancho 
Bernardo study."  American journal of epidemiology 165 (2):164-74. doi: 
10.1093/aje/kwk001. 
Li, H., M. I. Cybulsky, M. A. Gimbrone, Jr., and P. Libby. 1993. "An atherogenic 
diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte 
adhesion molecule, in rabbit aortic endothelium."  Arteriosclerosis, 
thrombosis, and vascular biology 13 (2):197-204. 
Lillioja, S., D. M. Mott, B. V. Howard, P. H. Bennett, H. Yki-Jarvinen, D. 
Freymond, B. L. Nyomba, F. Zurlo, B. Swinburn, and C. Bogardus. 1988. 
"Impaired glucose tolerance as a disorder of insulin action. Longitudinal and 
cross-sectional studies in Pima Indians."  N Engl J Med 318 (19):1217-25. 
doi: 10.1056/NEJM198805123181901. 
Lim, S. C., E. S. Tai, B. Y. Tan, S. K. Chew, and C. E. Tan. 2000. "Cardiovascular 
risk profile in individuals with borderline glycemia: the effect of the 1997 
American Diabetes Association diagnostic criteria and the 1998 World Health 
Organization Provisional Report."  Diabetes Care 23 (3):278-82. 
Lin, GM, YH Li, LES Jaiteh, and CL Han. 2012. "C-Reactive Protein, Metabolic 
Syndrome and Cardiovascular Disease."  Journal of Metabolic Syndrome 
1:e106. 
Lin, S. X., and E. X. Pi-Sunyer. 2007. "Prevalence of the metabolic syndrome among 
US middle-aged and older adults with and without diabetes--a preliminary 
analysis of the NHANES 1999-2002 data."  Ethnicity & Disease 17 (1):35-9. 
Lindsay, R. S., T. Funahashi, R. L. Hanson, Y. Matsuzawa, S. Tanaka, P. A. 
Tataranni, W. C. Knowler, and J. Krakoff. 2002. "Adiponectin and 
development of type 2 diabetes in the Pima Indian population."  Lancet 360 
(9326):57-8. doi: 10.1016/S0140-6736(02)09335-2. 
Linnemann, B., W. Voigt, W. Nobel, and H. U. Janka. 2006. "C-reactive protein is a 
strong independent predictor of death in type 2 diabetes: association with 
multiple facets of the metabolic syndrome."  Experimental and Clinical 
Endocrinology & Diabetes 114 (3):127-34. doi: 10.1055/s-2006-924012. 
Lorenzo, C., M. Serrano-Rios, M. T. Martinez-Larrad, J. L. Gonzalez-Sanchez, S. 
Seclen, A. Villena, C. Gonzalez-Villalpando, K. Williams, and S. M. Haffner. 
2006. "Geographic variations of the International Diabetes Federation and the 
National Cholesterol Education Program-Adult Treatment Panel III 
definitions of the metabolic syndrome in nondiabetic subjects."  Diabetes 
Care 29 (3):685-91. 
Lutsey, P. L., L. M. Steffen, and J. Stevens. 2008. "Dietary intake and the 
development of the metabolic syndrome: the Atherosclerosis Risk in 
Communities study."  Circulation 117 (6):754-61. doi: 
10.1161/CIRCULATIONAHA.107.716159. 
Madarász, E., G. Tamás, Á.G. Tabák, and Z. Kerényi. 2009. "Carbohydrate 
metabolism and cardiovascular risk factors 4 years after a pregnancy 




Maggio, A. B., N. J. Farpour-Lambert, F. Montecucco, G. Pelli, L. M. Marchand, V. 
Schwitzgebel, F. Mach, Y. Aggoun, and M. Beghetti. 2012. "Elevated E-
selectin and diastolic blood pressure in diabetic children."  European journal 
of clinical investigation 42 (3):303-9. doi: 10.1111/j.1365-
2362.2011.02583.x. 
Malis, C., E. L. Rasmussen, P. Poulsen, I. Petersen, K. Christensen, H. Beck-Nielsen, 
A. Astrup, and A. A. Vaag. 2005. "Total and regional fat distribution is 
strongly influenced by genetic factors in young and elderly twins."  Obes Res 
13 (12):2139-45. doi: 10.1038/oby.2005.265. 
Mallika, V., B. Goswami, and M. Rajappa. 2007. "Atherosclerosis pathophysiology 
and the role of novel risk factors: a clinicobiochemical perspective."  
Angiology 58 (5):513-22. doi: 10.1177/0003319707303443. 
Martins, A. R., R. T. Nachbar, R. Gorjao, M. A. Vinolo, W. T. Festuccia, R. H. 
Lambertucci, M. F. Cury-Boaventura, L. R. Silveira, R. Curi, and S. M. 
Hirabara. 2012. "Mechanisms underlying skeletal muscle insulin resistance 
induced by fatty acids: importance of the mitochondrial function."  Lipids in 
Health and Disease 11:30. doi: 10.1186/1476-511X-11-30. 
Matsuda, M., and R. A. DeFronzo. 1999. "Insulin sensitivity indices obtained from 
oral glucose tolerance testing: comparison with the euglycemic insulin 
clamp."  Diabetes Care 22 (9):1462-70. 
Matsumoto, K., S. Miyake, M. Yano, Y. Ueki, and Y. Tominaga. 2000. "High serum 
concentrations of soluble E-selectin in patients with impaired glucose 
tolerance with hyperinsulinemia."  Atherosclerosis 152 (2):415-20. 
Matsumoto, K., Y. Sera, Y. Abe, T. Tominaga, K. Horikami, K. Hirao, Y. Ueki, and 
S. Miyake. 2002. "High serum concentrations of soluble E-selectin correlate 
with obesity but not fat distribution in patients with type 2 diabetes mellitus."  
Metabolism 51 (7):932-4. 
Matsuzawa, Y., T. Funahashi, S. Kihara, and I. Shimomura. 2004. "Adiponectin and 
metabolic syndrome."  Arteriosclerosis, thrombosis, and vascular biology 24 
(1):29-33. doi: 10.1161/01.ATV.0000099786.99623.EF. 
Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. 
C. Turner. 1985. "Homeostasis model assessment: insulin resistance and beta-
cell function from fasting plasma glucose and insulin concentrations in man."  
Diabetologia 28 (7):412-9. 
Maziere, C., and J. C. Maziere. 2009. "Activation of transcription factors and gene 
expression by oxidized low-density lipoprotein."  Free Radical Biology & 
Medicine 46 (2):127-37. doi: S0891-5849(08)00586-8 [pii] 
10.1016/j.freeradbiomed.2008.10.024. 
McKeigue, P. M., J. E. Ferrie, T. Pierpoint, and M. G. Marmot. 1993. "Association 
of early-onset coronary heart disease in South Asian men with glucose 
intolerance and hyperinsulinemia."  Circulation 87 (1):152-61. 
McKeigue, P. M., M. G. Marmot, Y. D. Syndercombe Court, D. E. Cottier, S. 
Rahman, and R. A. Riemersma. 1988. "Diabetes, hyperinsulinaemia, and 
coronary risk factors in Bangladeshis in east London."  British Heart Journal 
60 (5):390-6. 
McKeigue, P. M., G. J. Miller, and M. G. Marmot. 1989. "Coronary heart disease in 
south Asians overseas: a review."  Journal of clinical epidemiology 42 
(7):597-609. 
McKeigue, P. M., B. Shah, and M. G. Marmot. 1991. "Relation of central obesity 
and insulin resistance with high diabetes prevalence and cardiovascular risk 
170 
 
in South Asians."  Lancet 337 (8738):382-6. doi: 0140-6736(91)91164-P 
[pii]. 
McKeown, N. M., J. B. Meigs, S. Liu, E. Saltzman, P. W. Wilson, and P. F. Jacques. 
2004. "Carbohydrate nutrition, insulin resistance, and the prevalence of the 
metabolic syndrome in the Framingham Offspring Cohort."  Diabetes Care 
27 (2):538-46. 
McLaughlin, T., F. Abbasi, C. Lamendola, L. Liang, G. Reaven, P. Schaaf, and P. 
Reaven. 2002. "Differentiation between obesity and insulin resistance in the 
association with C-reactive protein."  Circulation 106 (23):2908-12. 
Mehdad, S., A. Hamrani, K. El Kari, A. El Hamdouchi, A. Barakat, M. El Mzibri, N. 
Mokhtar, and H. Aguenaou. 2012. "Body mass index, waist circumference, 
body fat, fasting blood glucose in a sample of moroccan adolescents aged 11-
17 years."  J Nutr Metab 2012:510458. doi: 10.1155/2012/510458. 
Meis, S. B., D. Schuster, T. Gaillard, and K. Osei. 2006. "Metabolic syndrome in 
nondiabetic, obese, first-degree relatives of African American patients with 
type 2 diabetes: African American triglycerides-HDL-C and insulin 
resistance paradox."  Ethnicity & Disease 16 (4):830-6. 
Mente, A., F. Razak, S. Blankenberg, V. Vuksan, A. D. Davis, R. Miller, K. Teo, et 
al. 2010. "Ethnic variation in adiponectin and leptin levels and their 
association with adiposity and insulin resistance."  Diabetes Care 33 
(7):1629-34. doi: 10.2337/dc09-1392. 
Miller, G. J., S. Kotecha, W. H. Wilkinson, H. Wilkes, Y. Stirling, T. A. Sanders, A. 
Broadhurst, J. Allison, and T. W. Meade. 1988. "Dietary and other 
characteristics relevant for coronary heart disease in men of Indian, West 
Indian and European descent in London."  Atherosclerosis 70 (1-2):63-72. 
Miller, M. A., and F. P. Cappuccio. 2006. "Cellular adhesion molecules and their 
relationship with measures of obesity and metabolic syndrome in a 
multiethnic population."  International journal of obesity 30 (8):1176-82. doi: 
10.1038/sj.ijo.0803264. 
Miller, M. A., S. M. Kerry, D. G. Cook, and F. P. Cappuccio. 2004. "Cellular 
adhesion molecules and blood pressure: interaction with sex in a multi-ethnic 
population."  Journal of hypertension 22 (4):705-11. 
Miller, M. A., G. A. Sagnella, S. M. Kerry, P. Strazzullo, D. G. Cook, and F. P. 
Cappuccio. 2003. "Ethnic differences in circulating soluble adhesion 
molecules: the Wandsworth Heart and Stroke Study."  Clinical science 104 
(6):591-8. doi: 10.1042/CS20020333. 
Mirmiran, P., A. Ramezankhani, A. Hekmatdoost, and F. Azizi. 2008. "Effect of 
nutrition intervention on non-communicable disease risk factors among 
Tehranian adults: Tehran Lipid and Glucose Study."  Annals of nutrition & 
metabolism 52 (2):91-5. doi: 10.1159/000121364. 
Misra, A., P. Nigam, A. P. Hills, D. S. Chadha, V. Sharma, K. K. Deepak, N. K. 
Vikram, et al. 2012. "Consensus physical activity guidelines for Asian 
Indians."  Diabetes technology & therapeutics 14 (1):83-98. doi: 
10.1089/dia.2011.0111. 
Misra, A., and N. K. Vikram. 2004. "Insulin resistance syndrome (metabolic 
syndrome) and obesity in Asian Indians: evidence and implications."  
Nutrition 20 (5):482-91. 
Misra, A., N. K. Vikram, S. Arya, R. M. Pandey, V. Dhingra, A. Chatterjee, M. 
Dwivedi, et al. 2004. "High prevalence of insulin resistance in postpubertal 
Asian Indian children is associated with adverse truncal body fat patterning, 
171 
 
abdominal adiposity and excess body fat."  International journal of obesity 
and related metabolic disorders : journal of the International Association for 
the Study of Obesity 28 (10):1217-26. doi: 10.1038/sj.ijo.0802704. 
Misra, A., N. K. Vikram, R. Gupta, R. M. Pandey, J. S. Wasir, and V. P. Gupta. 
2006. "Waist circumference cutoff points and action levels for Asian Indians 
for identification of abdominal obesity."  International journal of obesity 30 
(1):106-11. doi: 10.1038/sj.ijo.0803111. 
Mohammadzadeh, G., and N. Zarghami. 2009. "Associations between single-
nucleotide polymorphisms of the adiponectin gene, serum adiponectin levels 
and increased risk of type 2 diabetes mellitus in Iranian obese individuals."  
Scand J Clin Lab Invest 69 (7):764-71. doi: 10.3109/00365510903137237. 
Molbak, A. G., B. Christau, B. Marner, K. Borch-Johnsen, and J. Nerup. 1994. 
"Incidence of insulin-dependent diabetes mellitus in age groups over 30 years 
in Denmark."  Diabetic medicine 11 (7):650-5. 
Molitch, M. E., R. A. DeFronzo, M. J. Franz, W. F. Keane, C. E. Mogensen, H. H. 
Parving, and M. W. Steffes. 2004. "Nephropathy in diabetes."  Diabetes Care 
27 Suppl 1:S79-83. 
Montague, C. T., I. S. Farooqi, J. P. Whitehead, M. A. Soos, H. Rau, N. J. Wareham, 
C. P. Sewter, et al. 1997. "Congenital leptin deficiency is associated with 
severe early-onset obesity in humans."  Nature 387 (6636):903-8. doi: 
10.1038/43185. 
Mooy, J. M., P. A. Grootenhuis, H. de Vries, H. A. Valkenburg, L. M. Bouter, P. J. 
Kostense, and R. J. Heine. 1995. "Prevalence and determinants of glucose 
intolerance in a Dutch caucasian population. The Hoorn Study."  Diabetes 
Care 18 (9):1270-3. 
Mozaffarian, D., M. Abdollahi, H. Campos, A. Houshiarrad, and W. C. Willett. 
2007. "Consumption of trans fats and estimated effects on coronary heart 
disease in Iran."  Eur J Clin Nutr 61 (8):1004-10. doi: 
10.1038/sj.ejcn.1602608. 
Mozumdar, A., and G. Liguori. 2011. "Persistent increase of prevalence of metabolic 
syndrome among U.S. adults: NHANES III to NHANES 1999-2006."  
Diabetes Care 34 (1):216-9. doi: 10.2337/dc10-0879. 
Murtola, T., T.A. Vuorela, M.T. Hyvönen, S.J. Marrink, M. Karttunen, and I. 
Vattulainen. 2011. "Low density lipoprotein: structure, dynamics, and 
interactions of apoB-100 with lipids."  Soft Matter 7 (18):8135-41. 
Nagle, C. A., E. L. Klett, and R. A. Coleman. 2009. "Hepatic triacylglycerol 
accumulation and insulin resistance."  Journal of lipid research 50 
Suppl:S74-9. doi: 10.1194/jlr.R800053-JLR200. 
Nagy, T. R., and A. L. Clair. 2000. "Precision and accuracy of dual-energy X-ray 
absorptiometry for determining in vivo body composition of mice."  Obes Res 
8 (5):392-8. doi: 10.1038/oby.2000.47. 
Nair, K. S., M. L. Bigelow, Y. W. Asmann, L. S. Chow, J. M. Coenen-Schimke, K. 
A. Klaus, Z. K. Guo, R. Sreekumar, and B. A. Irving. 2008. "Asian Indians 
have enhanced skeletal muscle mitochondrial capacity to produce ATP in 
association with severe insulin resistance."  Diabetes 57 (5):1166-75. doi: 
10.2337/db07-1556. 
Nakamura, T., K. Tokunaga, I. Shimomura, M. Nishida, S. Yoshida, K. Kotani, A. 
H. Islam, et al. 1994. "Contribution of visceral fat accumulation to the 




Nakamura, Y., K. Shimada, D. Fukuda, Y. Shimada, S. Ehara, M. Hirose, T. 
Kataoka, et al. 2004. "Implications of plasma concentrations of adiponectin in 
patients with coronary artery disease."  Heart 90 (5):528-33. 
National Health and Medical Research Council. "National evidence based guidelines 
for the management of type 2 diabetes mellitus. Part 3: Case detection and 
diagnosis of  type 2 diabetes." 
http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/di9.pdf. 
NCEP. 2002. "Third Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III) final report."  Circulation 
106 (25):3143-421. 
Nesto, R. W. 2003. "The relation of insulin resistance syndromes to risk of 
cardiovascular disease."  Rev Cardiovasc Med 4 Suppl 6:S11-8. 
Nguyen-Duy, T. B., M. Z. Nichaman, T. S. Church, S. N. Blair, and R. Ross. 2003. 
"Visceral fat and liver fat are independent predictors of metabolic risk factors 
in men."  American journal of physiology. Endocrinology and metabolism 
284 (6):E1065-71. doi: 10.1152/ajpendo.00442.2002. 
Nilsson, G., P. Hedberg, T. Jonason, I. Lonnberg, A. Tenerz, R. Forberg, and J. 
Ohrvik. 2008. "Waist circumference alone predicts insulin resistance as good 
as the metabolic syndrome in elderly women."  European journal of internal 
medicine 19 (7):520-6. doi: 10.1016/j.ejim.2008.01.018. 
Nothlings, U., M. B. Schulze, C. Weikert, H. Boeing, Y. T. van der Schouw, C. 
Bamia, V. Benetou, et al. 2008. "Intake of vegetables, legumes, and fruit, and 
risk for all-cause, cardiovascular, and cancer mortality in a European diabetic 
population."  Journal of Nutrition 138 (4):775-81. 
Ogden, C.L., M.D. Carroll, L.R. Curtin, M.M. Lamb, and K.M. Flegal. 2010. 
"Prevalence of high body mass index in US children and adolescents, 2007-
2008."  Journal of the American Medical Association 303 (3):242-9. 
Okafor, C. I. 2012. "The metabolic syndrome in Africa: Current trends."  Indian 
Journal of Endocrinology and Metabolism 16 (1):56-66. 
Olatunbosun, S., and DS Schade. 2002. "Insulin resistance." In.: EMedicine. 
Olatunji, L. A., and A. O. Soladoye. 2007. "Effect of increased magnesium intake on 
plasma cholesterol, triglyceride and oxidative stress in alloxan-diabetic rats."  
African journal of medicine and medical sciences 36 (2):155-61. 
Onat, A, H Uyarel, G HERGENC, A Karabulut, S Albayrak, and G Can. 2007. 
"Determinants and definition of abdominal obesity as related to risk of 
diabetes, metabolic syndrome and coronary disease in Turkish men: a 
prospective cohort study."  Atherosclerosis 191 (1):182-90. 
Ono, A., K. Ando, and T. Fujita. 1994. "High-calcium diet prevents salt-induced 
hypertension and impairment of renal hemodynamics in young spontaneously 
hypertensive rats."  Journal of cardiovascular pharmacology 23 (4):624-8. 
Packard, R. R., and P. Libby. 2008. "Inflammation in atherosclerosis: from vascular 
biology to biomarker discovery and risk prediction."  Clinical Chemistry 54 
(1):24-38. 
Pak, C. Y., H. M. Eun, R. G. McArthur, and J. W. Yoon. 1988. "Association of 
cytomegalovirus infection with autoimmune type 1 diabetes."  Lancet 2 
(8601):1-4. 
Palomo, I., P. Marin, M. Alarcon, G. Gubelin, X. Vinambre, E. Mora, and G. Icaza. 
2003. "Patients with essential hypertension present higher levels of sE-
173 
 
selectin and sVCAM-1 than normotensive volunteers."  Clinical and 
experimental hypertension 25 (8):517-23. 
Panagiotakos, D. B., C. Pitsavos, Y. Skoumas, and C. Stefanadis. 2007. "The 
association between food patterns and the metabolic syndrome using 
principal components analysis: The ATTICA Study."  Journal of the 
American Dietetic Association 107 (6):979-87; quiz 97. 
Papanikolaou, Y., and V. L. Fulgoni, 3rd. 2008. "Bean consumption is associated 
with greater nutrient intake, reduced systolic blood pressure, lower body 
weight, and a smaller waist circumference in adults: results from the National 
Health and Nutrition Examination Survey 1999-2002."  Journal of the 
American College of Nutrition 27 (5):569-76. 
Park, Y. W., S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon, and S. B. 
Heymsfield. 2003. "The metabolic syndrome: prevalence and associated risk 
factor findings in the US population from the Third National Health and 
Nutrition Examination Survey, 1988-1994."  Archives of Internal Medicine 
163 (4):427-36. doi: ioi20116 [pii]. 
Pearson, T. A., S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann, B. 
A. Franklin, et al. 2002. "AHA Guidelines for Primary Prevention of 
Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to 
Comprehensive Risk Reduction for Adult Patients Without Coronary or Other 
Atherosclerotic Vascular Diseases. American Heart Association Science 
Advisory and Coordinating Committee."  Circulation 106 (3):388-91. 
Pearson, T. A., G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon, 3rd, 
M. Criqui, Y. Y. Fadl, et al. 2003. "Markers of inflammation and 
cardiovascular disease: application to clinical and public health practice: A 
statement for healthcare professionals from the Centers for Disease Control 
and Prevention and the American Heart Association."  Circulation 107 
(3):499-511. 
Pereira, M. A., D. R. Jacobs, Jr., L. Van Horn, M. L. Slattery, A. I. Kartashov, and D. 
S. Ludwig. 2002. "Dairy consumption, obesity, and the insulin resistance 
syndrome in young adults: the CARDIA Study."  Journal of the American 
Medical Association 287 (16):2081-9. 
Perumal, L., S. Wells, S. Ameratunga, R. D. Pylypchuk, C. R. Elley, T. Riddell, A. 
Kerr, S. Crengle, D. Gentles, and R. Jackson. 2012. "Markedly different 
clustering of CVD risk factors in New Zealand Indian and European people 
but similar risk scores (PREDICT-14)."  Australian and New Zealand 
Journal of Public Health 36 (2):141-4. doi: 10.1111/j.1753-
6405.2011.00808.x. 
Pi-Sunyer, FX. 2000. "Obesity: criteria and classification."  The proceedings of the 
Nutrition Society 59 (4):505. 
Pischon, T., C. J. Girman, N. Rifai, G. S. Hotamisligil, and E. B. Rimm. 2005. 
"Association between dietary factors and plasma adiponectin concentrations 
in men."  Am J Clin Nutr 81 (4):780-6. 
Poirier, J. Y., N. Le Prieur, L. Campion, I. Guilhem, H. Allannic, and D. Maugendre. 
1998. "Clinical and statistical evaluation of self-monitoring blood glucose 
meters."  Diabetes Care 21 (11):1919-24. 
Prevention, Centers for Disease Control and. 2009. "Chronic Diseases 




Pueyo, M.E., W. Gonzalez, A. Nicoletti, F. Savoie, J.F. Arnal, and J.B. Michel. 
2000. "Angiotensin II stimulates endothelial vascular cell adhesion molecule-
1 via nuclear factor-κB activation induced by intracellular oxidative stress."  
Arteriosclerosis, thrombosis, and vascular biology 20 (3):645-51. 
Purnell, J.Q. 2011. "Definition of Obesity." 
Qasim, A. N., V. Budharaju, N. N. Mehta, C. St Clair, S. Farouk, S. Braunstein, M. 
Schutta, N. Iqbal, D. J. Rader, and M. P. Reilly. 2011. "Gender differences in 
the association of C-reactive protein with coronary artery calcium in type-2 
diabetes."  Clin Endocrinol (Oxf) 74 (1):44-50. doi: 10.1111/j.1365-
2265.2010.03879.x. 
Qatanani, M., and M. A. Lazar. 2007. "Mechanisms of obesity-associated insulin 
resistance: many choices on the menu."  Genes Dev 21 (12):1443-55. doi: 
10.1101/gad.1550907. 
Raban, M. Z., R. Dandona, and L. Dandona. 2012. "Availability of data for 
monitoring noncommunicable disease risk factors in India."  Bulletin of the 
World Health Organization 90 (1):20-9. doi: 10.2471/BLT.11.091041. 
Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat. 2009. 
"The role of reverse cholesterol transport in animals and humans and 
relationship to atherosclerosis."  Journal of lipid research 50 Suppl:S189-94. 
Raji, A., E. W. Seely, R. A. Arky, and D. C. Simonson. 2001. "Body fat distribution 
and insulin resistance in healthy Asian Indians and Caucasians."  J Clin 
Endocrinol Metab 86 (11):5366-71. 
Ramachandran, A., C. Snehalatha, K. Satyavani, S. Sivasankari, and V. Vijay. 2003. 
"Metabolic syndrome in urban Asian Indian adults--a population study using 
modified ATP III criteria."  Diabetes Res Clin Pract 60 (3):199-204. doi: 
S0168822703000603 [pii]. 
Randle, P. J., P. B. Garland, C. N. Hales, and E. A. Newsholme. 1963. "The glucose 
fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances 
of diabetes mellitus."  Lancet 1 (7285):785-9. 
Raymond, N. T., J. Paul O'Hare, S. Bellary, S. Kumar, A. Jones, and A. H. Barnett. 
2011. "Comparative risk of microalbuminuria and proteinuria in UK residents 
of south Asian and white European ethnic background with type 2 diabetes: a 
report from UKADS."  Current medical research and opinion 27 Suppl 3:47-
55. doi: 10.1185/03007995.2011.614937. 
Re, R. N. 2009. "Obesity-related hypertension."  Ochsner J 9 (3):133-6. 
Reaven, G. M. 1988. "Banting lecture 1988. Role of insulin resistance in human 
disease."  Diabetes 37 (12):1595-607. 
———. 2011. "Relationships among insulin resistance, type 2 diabetes, essential 
hypertension, and cardiovascular disease: similarities and differences."  J 
Clin Hypertens (Greenwich) 13 (4):238-43. doi: 10.1111/j.1751-
7176.2011.00439.x. 
Reaven, G. M., R. L. Lerner, M. P. Stern, and J. W. Farquhar. 1967. "Role of insulin 
in endogenous hypertriglyceridemia."  Journal of Clinical Investigation 46 
(11):1756-67. 
Reaven, P. 2004. "Metabolic syndrome."  Journal of insurance medicine 36 (2):132-
42. 
Reilly, JJ, and J Kelly. 2010. "Long-term impact of overweight and obesity in 
childhood and adolescence on morbidity and premature mortality in 
adulthood: systematic review."  International journal of obesity 35 (7):891-8. 
175 
 
Repas, T. 2011. "Obesity and dyslipidemia."  South Dakota Journal of Medicine 64 
(7):241-3, 5, 7 passim. 
Ridker, P. M., E. Danielson, F. A. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. 
Kastelein, W. Koenig, et al. 2008. "Rosuvastatin to prevent vascular events in 
men and women with elevated C-reactive protein."  N Engl J Med 359 
(21):2195-207. 
Ridker, P. M., C. H. Hennekens, J. E. Buring, and N. Rifai. 2000. "C-reactive protein 
and other markers of inflammation in the prediction of cardiovascular disease 
in women."  N Engl J Med 342 (12):836-43. 
Ridker, P. M., J. J. Kastelein, J. Genest, and W. Koenig. 2013. "C-reactive protein 
and cholesterol are equally strong predictors of cardiovascular risk and both 
are important for quality clinical care."  Eur Heart J 34 (17):1258-61. doi: 
10.1093/eurheartj/eht022. 
Ridker, P. M., N. Rifai, L. Rose, J. E. Buring, and N. R. Cook. 2002. "Comparison of 
C-reactive protein and low-density lipoprotein cholesterol levels in the 
prediction of first cardiovascular events."  N Engl J Med 347 (20):1557-65. 
Ritchie, SA, and JMC Connell. 2007. "The link between abdominal obesity, 
metabolic syndrome and cardiovascular disease."  Nutrition, metabolism and 
cardiovascular diseases 17 (4):319-26. 
Roden, M. 2004. "How free fatty acids inhibit glucose utilization in human skeletal 
muscle."  News in physiological sciences 19:92-6. 
Ross, R. 1993. "The pathogenesis of atherosclerosis: a perspective for the 1990s."  
Nature 362 (6423):801-9. doi: 10.1038/362801a0. 
Rothblat, G. H., and M. C. Phillips. 2010. "High-density lipoprotein heterogeneity 
and function in reverse cholesterol transport."  Current Opinion in Lipidology 
21 (3):229-38. 
Rotimi, S. O., I. Olayiwola, O. Ademuyiwa, and I. Adamson. 2010. "Inability of 
legumes to reverse diabetic-induced nephropathy in rats despite improvement 
in blood glucose and antioxidant status."  Journal of medicinal food 13 
(1):163-9. doi: 10.1089/jmf.2008.0293. 
Ruan, H., and H. F. Lodish. 2003. "Insulin resistance in adipose tissue: direct and 
indirect effects of tumor necrosis factor-alpha."  Cytokine Growth Factor Rev 
14 (5):447-55. 
Rui, L. 2014. "Energy metabolism in the liver."  Compr Physiol 4 (1):177-97. doi: 
10.1002/cphy.c130024. 
Rush, E. C., I. Freitas, and L. D. Plank. 2009. "Body size, body composition and fat 
distribution: comparative analysis of European, Maori, Pacific Island and 
Asian Indian adults."  British Journal of Nutrition 102 (4):632-41. doi: 
10.1017/S0007114508207221. 
Rush, E. C., J. H. Goedecke, C. Jennings, L. Micklesfield, L. Dugas, E. V. Lambert, 
and L. D. Plank. 2007. "BMI, fat and muscle differences in urban women of 
five ethnicities from two countries."  International journal of obesity 31 
(8):1232-9. doi: 10.1038/sj.ijo.0803576. 
Sadur, C. N., and R. H. Eckel. 1982. "Insulin stimulation of adipose tissue 
lipoprotein lipase. Use of the euglycemic clamp technique."  Journal of 
Clinical Investigation 69 (5):1119-25. 
Sahyoun, N. R., P. F. Jacques, X. L. Zhang, W. Juan, and N. M. McKeown. 2006. 
"Whole-grain intake is inversely associated with the metabolic syndrome and 
mortality in older adults."  Am J Clin Nutr 83 (1):124-31. doi: 83/1/124 [pii]. 
176 
 
Santos, A. C., and H. Barros. 2003. "Prevalence and determinants of obesity in an 
urban sample of Portuguese adults."  Public health 117 (6):430-7. doi: 
10.1016/S0033-3506(03)00139-2. 
Schmidt, A. M., S. D. Yan, J. L. Wautier, and D. Stern. 1999. "Activation of receptor 
for advanced glycation end products: a mechanism for chronic vascular 
dysfunction in diabetic vasculopathy and atherosclerosis."  Circulation 
research 84 (5):489-97. 
Schwandt, P., R. Kelishadi, and G. M. Haas. 2010. "Ethnic disparities of the 
metabolic syndrome in population-based samples of german and Iranian 
adolescents."  Metabolic Syndrome and Related Disorders 8 (2):189-92. doi: 
10.1089/met.2009.0054. 
Seidell, J.C. 2010. "Prevalence and trends in adult obesity in affluent countries."  
Obesity Epidemiology: From Aetiology to Public Health:17. 
Seino, Y., K. Nanjo, N. Tajima, T. Kadowaki, A. Kashiwagi, E. Araki, C. Ito, N. 
Inagaki, Y. Iwamoto, and M. Kasuga. 2010. "Report of the committee on the 
classification and diagnostic criteria of diabetes mellitus."  Journal of 
Diabetes Investigation 1 (5):212-28. 
Sesti, G. 2006. "Pathophysiology of insulin resistance."  Best Practice & Research 
Clinical Endocrinology & Metabolism 20 (4):665-79. 
Shabnam, A. A., K. Homa, M. T. Reza, L. Bagher, F. M. Hossein, and A. 
Hamidreza. 2012. "Cut-off points of waist circumference and body mass 
index for detecting diabetes, hypercholesterolemia and hypertension 
according to National Non-Communicable Disease Risk Factors Surveillance 
in Iran."  Archives of Medical Science 8 (4):614-21. doi: 
10.5114/aoms.2012.30284. 
Sharifi, F., S. N. Mousavinasab, R. Soruri, M. Saeini, and M. Dinmohammadi. 2008. 
"High prevalence of low high-density lipoprotein cholesterol concentrations 
and other dyslipidemic phenotypes in an Iranian population."  Metabolic 
Syndrome and Related Disorders 6 (3):187-95. doi: 10.1089/met.2008.0007. 
Shaw, JE, RA Sicree, and PZ Zimmet. 2010. "Global estimates of the prevalence of 
diabetes for 2010 and 2030."  Diabetes Res Clin Pract 87 (1):4-14. 
Shen, D. C., S. M. Shieh, M. M. Fuh, D. A. Wu, Y. D. Chen, and G. M. Reaven. 
1988. "Resistance to insulin-stimulated-glucose uptake in patients with 
hypertension."  J Clin Endocrinol Metab 66 (3):580-3. 
Sherwood, L. 2009. Human physiology: from cells to systems: Brooks/Cole Pub Co. 
Shiwaku, K., A. Nogi, K. Kitajima, E. Anuurad, B. Enkhmaa, M. Yamasaki, J. M. 
Kim, et al. 2005. "Prevalence of the metabolic syndrome using the modified 
ATP III definitions for workers in Japan, Korea and Mongolia."  J Occup 
Health 47 (2):126-35. 
Shojaie, M., A. Sotoodah, and G. Shafaie. 2009. "Is adiponectin associated with 
acute myocardial infarction in Iranian non obese patients?"  Lipids in Health 
and Disease 8:17. doi: 10.1186/1476-511X-8-17. 
Shulman, G. I. 2000. "Cellular mechanisms of insulin resistance."  Journal of 
Clinical Investigation 106 (2):171-6. doi: 10.1172/JCI10583. 
Skoumas, J., L. Papadimitriou, C. Pitsavos, C. Masoura, N. Giotsas, C. Chrysohoou, 
M. Toutouza, D. Panagiotakos, and C. Stefanadis. 2007. "Metabolic 
syndrome prevalence and characteristics in Greek adults with familial 




Smiley, D., P. Chandra, and G.E. Umpierrez. 2011. "Update on diagnosis, 
pathogenesis and management of ketosis-prone Type 2 diabetes mellitus."  
Diabetes 1 (6):589-600. 
Smith, J., M. Al-Amri, A. Sniderman, and K. Cianflone. 2006. "Leptin and 
adiponectin in relation to body fat percentage, waist to hip ratio and the 
apoB/apoA1 ratio in Asian Indian and Caucasian men and women."  
Nutrition & Metabolism 3:18. doi: 10.1186/1743-7075-3-18. 
Snijder, M. B., A. A. van der Heijden, R. M. van Dam, C. D. Stehouwer, G. J. 
Hiddink, G. Nijpels, R. J. Heine, L. M. Bouter, and J. M. Dekker. 2007. "Is 
higher dairy consumption associated with lower body weight and fewer 
metabolic disturbances? The Hoorn Study."  Am J Clin Nutr 85 (4):989-95. 
Song, Y., J. E. Manson, L. Tinker, N. Rifai, N. R. Cook, F. B. Hu, G. S. 
Hotamisligil, et al. 2007. "Circulating levels of endothelial adhesion 
molecules and risk of diabetes in an ethnically diverse cohort of women."  
Diabetes 56 (7):1898-904. doi: 10.2337/db07-0250. 
Sonnenberg, L., M. Pencina, R. Kimokoti, P. Quatromoni, B. H. Nam, R. 
D'Agostino, J. B. Meigs, J. Ordovas, M. Cobain, and B. Millen. 2005. 
"Dietary patterns and the metabolic syndrome in obese and non-obese 
Framingham women."  Obes Res 13 (1):153-62. 
Sorensen, T.I., and A.J. Stunkard. 1994. "Overview of adoption studies." In The 
Genetics of Obesity, edited by C. Bouchard, 49–62. Ann Arbor : CRC Press. 
Sorrentino, M. J. 2005. "Implications of the metabolic syndrome: the new epidemic."  
American Journal of Cardiology 96 (4A):3E-7E. 
Staehr, P., O. Hother-Nielsen, B. R. Landau, V. Chandramouli, J. J. Holst, and H. 
Beck-Nielsen. 2003. "Effects of free fatty acids per se on glucose production, 
gluconeogenesis, and glycogenolysis."  Diabetes 52 (2):260-7. 
Staiger, H., O. Tschritter, J. Machann, C. Thamer, A. Fritsche, E. Maerker, F. 
Schick, H. U. Haring, and M. Stumvoll. 2003. "Relationship of serum 
adiponectin and leptin concentrations with body fat distribution in humans."  
Obes Res 11 (3):368-72. doi: 10.1038/oby.2003.48. 
Stralfors, P., and R. C. Honnor. 1989. "Insulin-induced dephosphorylation of 
hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent 
protein kinase activity."  European Journal of Biochemistry 182 (2):379-85. 
Swaminathan, R. 2003. "Magnesium metabolism and its disorders."  The Clinical 
biochemist. Reviews / Australian Association of Clinical Biochemists 24 
(2):47-66. 
Swinburn, B.A., G. Sacks, K.D. Hall, K. McPherson, D.T. Finegood, M.L. Moodie, 
and S.L. Gortmaker. 2011. "The global obesity pandemic: shaped by global 
drivers and local environments."  The Lancet 378 (9793):804-14. 
Tanko, L. B., Y. Z. Bagger, P. Alexandersen, P. J. Larsen, and C. Christiansen. 2003. 
"Peripheral adiposity exhibits an independent dominant antiatherogenic effect 
in elderly women."  Circulation 107 (12):1626-31. doi: 
10.1161/01.CIR.0000057974.74060.68. 
Taylor, R., P. Ram, P. Zimmet, L. R. Raper, and H. Ringrose. 1984. "Physical 
activity and prevalence of diabetes in Melanesian and Indian men in Fiji."  
Diabetologia 27 (6):578-82. 
Taylor, S. I. 1992. "Lilly Lecture: molecular mechanisms of insulin resistance. 




Thogersen, A. M., J. H. Jansson, K. Boman, T. K. Nilsson, L. Weinehall, F. 
Huhtasaari, and G. Hallmans. 1998. "High plasminogen activator inhibitor 
and tissue plasminogen activator levels in plasma precede a first acute 
myocardial infarction in both men and women: evidence for the fibrinolytic 
system as an independent primary risk factor."  Circulation 98 (21):2241-7. 
Tillin, T., N. Forouhi, D. G. Johnston, P. M. McKeigue, N. Chaturvedi, and I. F. 
Godsland. 2005. "Metabolic syndrome and coronary heart disease in South 
Asians, African-Caribbeans and white Europeans: a UK population-based 
cross-sectional study."  Diabetologia 48 (4):649-56. doi: 10.1007/s00125-
005-1689-3. 
Tobey, T. A., M. Greenfield, F. Kraemer, and G. M. Reaven. 1981. "Relationship 
between insulin resistance, insulin secretion, very low density lipoprotein 
kinetics, and plasma triglyceride levels in normotriglyceridemic man."  
Metabolism 30 (2):165-71. 
Trinidad, T. P., A. C. Mallillin, A. S. Loyola, R. S. Sagum, and R. R. Encabo. 2010. 
"The potential health benefits of legumes as a good source of dietary fibre."  
British Journal of Nutrition 103 (4):569-74. 
Tummala, P. E., X. L. Chen, C. L. Sundell, J. B. Laursen, C. P. Hammes, R. W. 
Alexander, D. G. Harrison, and R. M. Medford. 1999. "Angiotensin II 
induces vascular cell adhesion molecule-1 expression in rat vasculature: A 
potential link between the renin-angiotensin system and atherosclerosis."  
Circulation 100 (11):1223-9. 
Umpierrez, G. E., M. M. Casals, S. P. Gebhart, P. S. Mixon, W. S. Clark, and L. S. 
Phillips. 1995. "Diabetic ketoacidosis in obese African-Americans."  
Diabetes 44 (7):790-5. 
Vakkilainen, J., G. Steiner, J. C. Ansquer, F. Aubin, S. Rattier, C. Foucher, A. 
Hamsten, and M. R. Taskinen. 2003. "Relationships between low-density 
lipoprotein particle size, plasma lipoproteins, and progression of coronary 
artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)."  
Circulation 107 (13):1733-7. 
Valsamakis, G., R. Chetty, A. Anwar, A. K. Banerjee, A. Barnett, and S. Kumar. 
2004. "Association of simple anthropometric measures of obesity with 
visceral fat and the metabolic syndrome in male Caucasian and Indo-Asian 
subjects."  Diabetic medicine 21 (12):1339-45. doi: 10.1111/j.1464-
5491.2004.01361.x. 
Van Loan, M. D., and P. L. Mayclin. 1992. "Body composition assessment: dual-
energy X-ray absorptiometry (DEXA) compared to reference methods."  Eur 
J Clin Nutr 46 (2):125-30. 
van Vark, L. C., M. Bertrand, K. M. Akkerhuis, J. J. Brugts, K. Fox, J. J. Mourad, 
and E. Boersma. 2012. "Angiotensin-converting enzyme inhibitors reduce 
mortality in hypertension: a meta-analysis of randomized clinical trials of 
renin-angiotensin-aldosterone system inhibitors involving 158,998 patients."  
European Heart Journal 33 (16):2088-97. doi: 10.1093/eurheartj/ehs075. 
Vasudev, S., A. Mohan, D. Mohan, S. Farooq, D. Raj, and V. Mohan. 2004. 
"Validation of body fat measurement by skinfolds and two bioelectric 
impedance methods with DEXA--the Chennai Urban Rural Epidemiology 
Study [CURES-3]."  J Assoc Physicians India 52:877-81. 
Veghari GR, Mansourian AR. 2007. "The Comparative Study of Obesity among 
Mothers with Different Ethnic Groups in Northern IRAN."  Iranian Journal 
of Public Health 36 (3):71-6. 
179 
 
Venn, B. J., and J. I. Mann. 2004. "Cereal grains, legumes and diabetes."  Eur J Clin 
Nutr 58 (11):1443-61. 
Ventura, E., J. Davis, C. Byrd-Williams, K. Alexander, A. McClain, C. J. Lane, D. 
Spruijt-Metz, M. Weigensberg, and M. Goran. 2009. "Reduction in risk 
factors for type 2 diabetes mellitus in response to a low-sugar, high-fiber 
dietary intervention in overweight Latino adolescents."  Archives of 
Pediatrics and Adolescent Medicine 163 (4):320-7. 
Villegas, R., Y. T. Gao, G. Yang, H. L. Li, T. A. Elasy, W. Zheng, and X. O. Shu. 
2008. "Legume and soy food intake and the incidence of type 2 diabetes in 
the Shanghai Women's Health Study."  Am J Clin Nutr 87 (1):162-7. doi: 
87/1/162 [pii]. 
Vuksan, V., A. Rogovik, A. Jenkins, V. Peeva, U. Beljan-Zdravkovic, M. Stavro, C. 
Fairgrieve, S. Devanesen, A. Hanna, and W. Watson. 2012. "Cardiovascular 
risk factors, diet and lifestyle among European, South Asian and Chinese 
adolescents in Canada."  Paediatrics & child health 17 (1):e1-6. 
Walls, H.L., D.J. Magliano, C.E. Stevenson, K. Backholer, H.R. Mannan, J.E. Shaw, 
and A. Peeters. 2011. "Projected progression of the prevalence of obesity in 
Australia."  Obesity. 
Wannamethee, S. G., A. G. Shaper, M. Walker, and S. Ebrahim. 1998. "Lifestyle and 
15-year survival free of heart attack, stroke, and diabetes in middle-aged 
British men."  Archives of Internal Medicine 158 (22):2433-40. 
Warram, J. H., B. C. Martin, A. S. Krolewski, J. S. Soeldner, and C. R. Kahn. 1990. 
"Slow glucose removal rate and hyperinsulinemia precede the development 
of type II diabetes in the offspring of diabetic parents."  Annals of Internal 
Medicine 113 (12):909-15. 
Whincup, P. H., J. A. Gilg, O. Papacosta, C. Seymour, G. J. Miller, K. G. Alberti, 
and D. G. Cook. 2002. "Early evidence of ethnic differences in 
cardiovascular risk: cross sectional comparison of British South Asian and 
white children."  British Medical Journal 324 (7338):635. 
WHO. 1999. "Definition, diagnosis and classification of diabetes mellitus and its 
complications."  Diagnosis and classification of diabetes mellitus 99 (2). 
———. 2005. "WHO STEPS Surveillance Manual." In The WHO STEPwise 
approach to chronic disease risk factor surveillance. WHO press. 
———. 2009. "Fact sheet No. 312: Diabetes."  Geneva: WHO. 
———. 2011a. "Global status report on noncommunicable diseases 2010." In. 
Geneva. 
———. 2011b. "Hypertension." 
———. 2011c. "Noncommunicable diseases country profiles 2011." In, 209. 
———. 2011d. "Obesity and overweight  " In. 
———. "Global database on body mass index." World Health Organization, 
Accessed 2012. http://apps.who.int/bmi/index.jsp. 
———. 2013. "A comprehensive global monitoring framework, including indicators, 
and a set of voluntary global targets for the prevention and control of 
noncommunicable diseases." In. 
Williams, E. D., E. Stamatakis, T. Chandola, and M. Hamer. 2011. "Assessment of 
physical activity levels in South Asians in the UK: findings from the Health 
Survey for England."  Journal of Epidemiology & Community Health 65 
(6):517-21. 
Williamson, J. R., R. A. Kreisberg, and P. W. Felts. 1966. "Mechanism for the 
stimulation of gluconeogenesis by fatty acids in perfused rat liver."  
180 
 
Proceedings of the National Academy of Sciences of the United States of 
America 56 (1):247-54. 
World Health Organization. "WHO expert committee on diabetes mellitus. Second 
report.Technical report series 646." 
http://whqlibdoc.who.int/trs/WHO_TRS_646.pdf. 
———. 1985. "Diabetes mellitus: Report of a WHO study group. Technical report 
series 727." In. Geneva: World Health Organization,. 
———. 1999. "Report of a WHO consultation: definition of metabolic syndrome in 
definition, diagnosis, and classification of diabetes mellitus and its 
complications. I. Diagnosis and classification of diabetes mellitus." In, edited 
by Department of Noncommunicable Diseae Surveillance. Geneva: World 
Health Organization. 
———. "Definition and diagnosis of diabetes mellitus and intermediate 
hyperglycemia: report of a WHO/IDF consultation." World Health 
Organization,, Accessed 2008 Jun 11. 
www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%
20diabetes_new.pdf. 
Woywodt, A., F. H. Bahlmann, K. De Groot, H. Haller, and M. Haubitz. 2002. 
"Circulating endothelial cells: life, death, detachment and repair of the 
endothelial cell layer."  Nephrology Dialysis Transplantation 17 (10):1728-
30. 
Wu, C. H., S. Heshka, J. Wang, R. N. Pierson, Jr., S. B. Heymsfield, B. Laferrere, Z. 
Wang, J. B. Albu, X. Pi-Sunyer, and D. Gallagher. 2007. "Truncal fat in 
relation to total body fat: influences of age, sex, ethnicity and fatness."  
International Journal of Obesity (Lond) 31 (9):1384-91. 
Wyszynski, D.F., D.M. Waterworth, P.J. Barter, J. Cohen, Y.A. Kesäniemi, R.W. 
Mahley, R. McPherson, G. Waeber, T.P. Bersot, and S.S. Sharma. 2005. 
"Relation between atherogenic dyslipidemia and the Adult Treatment 
Program-III definition of metabolic syndrome (Genetic Epidemiology of 
Metabolic Syndrome Project)."  American Journal of Cardiology 95 (2):194-
8. 
Xu, A., K. W. Chan, R. L. Hoo, Y. Wang, K. C. Tan, J. Zhang, B. Chen, et al. 2005. 
"Testosterone selectively reduces the high molecular weight form of 
adiponectin by inhibiting its secretion from adipocytes."  The Journal of 
biological chemistry 280 (18):18073-80. doi: 10.1074/jbc.M414231200. 
Yang, W., J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, and Q. Ji. 
2010. "Prevalence of diabetes among men and women in China."  New 
England Journal of Medicine 362 (12):1090-101. 
Yasojima, K., C. Schwab, E. G. McGeer, and P. L. McGeer. 2001. "Generation of C-
reactive protein and complement components in atherosclerotic plaques."  
American Journal of Pathology 158 (3):1039-51. doi: 10.1016/S0002-
9440(10)64051-5. 
Yeh, E. T., and J. T. Willerson. 2003. "Coming of age of C-reactive protein: using 
inflammation markers in cardiology."  Circulation 107 (3):370-1. 
Yeh, E.T.H. 2005. "A new perspective on the biology of C-reactive protein."  
Circulation research 97 (7):609-11. 
Yudkin, J. S., C. D. Stehouwer, J. J. Emeis, and S. W. Coppack. 1999. "C-reactive 
protein in healthy subjects: associations with obesity, insulin resistance, and 
endothelial dysfunction: a potential role for cytokines originating from 
181 
 
adipose tissue?"  Arteriosclerosis Thrombosis and Vascular Biology 19 
(4):972-8. 
Zainuddin, L. R., N. Isa, W. M. Muda, and H. J. Mohamed. 2011. "The prevalence of 
metabolic syndrome according to various definitions and 
hypertriglyceridemic-waist in malaysian adults."  International journal of 
preventive medicine 2 (4):229-37. 
Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman. 
1994. "Positional cloning of the mouse obese gene and its human 
homologue."  Nature 372 (6505):425-32. doi: 10.1038/372425a0. 
Zimmet, P. Z. 1992. "Kelly West Lecture 1991. Challenges in diabetes 
epidemiology--from West to the rest."  Diabetes Care 15 (2):232-52. 
———. 1995. "The pathogenesis and prevention of diabetes in adults. Genes, 
autoimmunity, and demography."  Diabetes Care 18 (7):1050-64. 
Zimmet, P. Z., D. J. McCarty, and M. P. de Courten. 1997. "The global 
epidemiology of non-insulin-dependent diabetes mellitus and the metabolic 
syndrome."  Journal of Diabetes and its Complications 11 (2):60-8. 
Zinman, B. 2011. "Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It 
Ready for Prime Time?"  American Journal of Medicine 124 (1):S19-S34. 
Zuliani, G., S. Volpato, M. Galvani, A. Ble, S. Bandinelli, A. M. Corsi, F. Lauretani, 
et al. 2009. "Elevated C-reactive protein levels and metabolic syndrome in 
the elderly: The role of central obesity data from the InChianti study."  
Atherosclerosis 203 (2):626-32. 
Zwaka, T. P., V. Hombach, and J. Torzewski. 2001. "C-reactive protein-mediated 
low density lipoprotein uptake by macrophages: implications for 
atherosclerosis."  Circulation 103 (9):1194-7. 
 
Every reasonable effort has been made to acknowledge the owners of copyright 
material. I would be pleased to hear from any copyright owner who has been omitted 
or incorrectly acknowledged. 
 

























Screening Checklist  
 
 
Name: ……………………….   ID:           Sex: Male      Female 
 
Address:………………………………………………………………………………. 
                     
Your country background: ………………….. 
 
The main language you spoken at your home: …………………………………….. 
 
Phone No.: H: …………….......…W:………………...…. Mobile: .......….………… 
 
EMail: ...……………………………………… DOB: ………………. Age: …...…... 
 
Weight: ……..... Height: ……... W/H circumference: ……………… BP: ….…… 
 
Medical History Yes No Details 
Are you a Smoker    
Females: Pregnancy, lactating, post-
menopausal, gestational diabetes 
   
Have you had your glucose or insulin, 
cholesterol, TG, measured recently?  
Can you remember the results? 
   
Have you had, or have, a history of diabetes 
in your family? 
   
Medications    
Supplements    
Major operations    
Major illnesses/diseases: Do you have 
 Diabetes &High BP 
 Kidney disease (renal problems) 
 Liver disease &Hepatitis 
 HIV& Blood diseases 
 Heart disease& GI problems 
   
Did you have faints or blackouts?    
Do you have any allergies?     
What type of alcoholic drink do you usually 
drink? 
   
How many standard alcoholic drinks do you 
drink per day? How many days per week? 
   
Do you exercise regularly?    
Can we keep your contact details for future 
reference in clinical research? 
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Participation Information sheet 
 
A comparison of overall health between migrants of Asian and European 
background: A West Australian study of Chronic Disease, Diet & Metabolic 
Syndrome Risk Factors 
 
The following document provides some information regarding to a medical research 
with the title above and carrying out at Curtin University. Please feel free to ask any 




This project evaluates the relationship between health risk factors and ethnic groups 
in Western Australia. The researchers are Associate Professor Jaya Earnest, 
Professor Moyez Jiwa and Dr Majid Meshkini. The study explores different risk 
factors among people of European, Chines, Indians and Iranian ethnicity. The 
reasons these groups are selected is because Europeans and Chinese are the 
largest group of migrants in Australia and there has been previous research on 
Indian and Iranian migrants. 
 
The study will involve one clinical visit to Curtin University and two questionnaires to 
be completed by the participants because there is a need to show the biophysical 
and biochemical differences between the four different ethnic groups. More details 




In recent decades, evidence of chronic disease such as heart disease, cancer and 
diabetes have risen significantly and has now reached epidemic proportions 
worldwide. These diseases are cause an estimated 35 million deaths annually - 60% 
of all deaths globally. Similarly, the rise of obesity as one of the most important 
causes of chronic disease, is affecting approximately 1.6 billion adults globally. In 
the stages before developing chronic diseases, there are some known signs called 
metabolic syndrome. Metabolic syndrome is a collection of disorders and conditions 
that develop into a wide range of life threatening diseases. Factors affecting 
metabolic syndrome include body specification like height, weight, waist 
circumference and other criteria such as blood pressure and blood fat including 
triglycerides and cholesterol.  According to recent studies the prevalence of 
metabolic syndrome in Australia is 30.7%. This study aims to find out more details 
about risk factors beween ethnicity and chronic disease among the 4 migrant groups 
that will be studies. 
 










The first part of clinical visit will be a primary visit of 1 hour which will do at Health 
Service Centre. The procedures will be explained and primary measurements 
including body weight, height, waist circumference and blood pressure will be 
recorded. If participants meet the inclusion criteria, a written consent of each 
volunteer will be obtained. Approved participants will fill in two questionnaires: the 
Dietary Questionnaire and Physical Activity Survey, then a blood sample will be 
taken by a qualified nurse. Participants will be required to fast overnight for about 
10-14 hours. 
The second part of clinical visit will take 20 minutes. The DEXA test (Dual Energy X-
ray Absorptiometry) (a safe test) to measure the body composition, will also be 
taken in the School of Physiotherapy. 
Inclusion criteria: 
 Aged 18 or more 
 Parents of the volunteers must be from one of the countries mentioned 
below  
o European countries 
o China   
o India  
o Iran  
 Participants have lived in Australia for at least 5 years 
 Have working knowledge of written and spoken English 
 
 Plus one or more criteria mentioned below: 
 Are Overweight: Body Mass Index of 25 or more (Weight Kg /Height
2
M) 






Possible adverse effects:  
The blood samples may cause minor discomfort and possible bruising for some 
participants. This bruising however is minor and will dissipate after a few days.  
 
General benefits & benefits to volunteers:  
 
This clinical study will be important to evaluate metabolic syndrome in individuals. 
The findings of this study will suggest a possible link to genetic factors and various 
ethnic groups and may play a critical role in the prevention of these chronic diseases 
for those who are at risk. Your involvement in this study will be useful to the health 
of the general population in Australia and specifically in the area of migrant health, 
chronic disease and metabolic syndrome.    
 
For your services as a volunteer in this study, you will receive copies of all your 
blood analyses results including Fasting Blood Sugar, Fat profile, Insulin, C-RP and 
DEXA test etc. We will advise you to refer to your GP if there is a finding of 






For your time in participating in the study, you will have the option or choice of:  
 
1. receiving a $50 gift card voucher for travelling and parking expenses or  
 
2. entering your name into a raffle for three $500 prizes which will be drawn at the 
end of study. 
 
You will be informed about the date and time via the contact details provided by you 
at registration time. All participants who choose to enter the raffle have an 
approximately 1 in 50 chance to win. Those who opt for the gift voucher option will 
not be included in the raffle and draw. 
 
Participants Privacy: 
Your participation in this study is completely voluntary and you are free to withdraw 
from the study at any time. All results and personal information are strictly 
confidential and are only accessible by the researchers. Participants' privacy is 
reserved during all procedures including during publication of results. Your individual 
results will be emailed or sent by registered post. 
 
Ethics Consideration: 
This study has been approved by the Curtin University Human Research Ethics 
Committee (Approval Number HR179/2008). The Committee is compromised of 
members of the public, academics, lawyers, doctors and pastoral carers.  It’s main 
role is to protect participants, if needed, verification of approval can be obtained 
either by writing to the Curtin University Human Research Ethics Committee, c/-
Office of Research and Development, Curtin University of Technology, GOP Box 
U1987, Perth, 6845 or by telephoning 9266 2784 or by emailing hrec@curtin.edu.au  
  
Any questions may be answered or clarified by contacting:  
 
1. Dr. Majid Meshkini on telephone no: 0413 246 859                                                                  
Email: majid.meshkini@postgrad.curtin.edu.au         
2. Associate Professor Jaya Earnest on telephone no: 9266 4151   
Email: J.Earnest@curtin.edu.au  
3. Professor Moyez Jiwa on telephone no: 9266 1768 






WRITTEN INFORMED CONSENT FORM 
 
Project Title: A comparison of overall health between Asians and 
Australians from European background: A West Australian study of 
Chronic Disease, Diet & Metabolic Syndrome Risk Factors 
 
I, ___________________________________ hereby consent to be a 
volunteer for the study “A comparison of overall health between Asians and 
Australians from European background: A West Australian study of Chronic 
Disease, Diet & Metabolic Syndrome Risk Factors”. I understand that the 
screening and examination process will involve: weight, height, waist/hip 
measurements, blood pressure, pulse wave analysis, DEXA (Dual Energy X-
Ray Absorptiometry), a safe method to determination of body composition, 
filling Dietary Questionnaire, Physical Activity Questionnaire and screening 
questionnaire, and blood samples for assessments. I consent to having a 
total of 18 ml of blood drawn by a trained phlebotomist in fasting condition on 
the assessment day, which will be assessed for various biochemical 
assessments. The potential risks of all the procedures have been explained 
to me. I understand that my participation in this project is voluntary and I can 
withdraw from the project at any time. 
 
Signature: _____________________________ 
Name:       _____________________________ 
Witness:    _____________________________ 
Date:         ___/___/___ 
 
 
Any questions or misunderstandings may be answered or clarified by contacting  
Dr. Majid Meshkini on telephone 9266 3226 or email:  
majid.meshkini@postgrad.curtin.edu.au  or  

























PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that 
people do as part of their everyday lives. The questions will ask you about 
the time you spent being physically active in the last 7 days. Please answer 
each question even if you do not consider yourself to be an active person. 
Please think about the activities you do at work, as part of your house and 
yard work, to get from place to place, and in your spare time for recreation, 
exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder than normal. Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
1.  During the last 7 days, on how many days did you do vigorous 
physical activities like heavy lifting, digging, aerobics, or fast bicycling? 
     
    _____ days per week 
  
     No vigorous physical activities → Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical 
activities on one of those days? 
 _____ hours per day 
 _____ minutes per day 
  
    Don’t know/Not sure 
 
Think about all the moderate activities that you did in the last 7 days. 
Moderate activities refer to activities that take moderate physical effort and 
make you breathe somewhat harder than normal. Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
3.  During the last 7 days, on how many days did you do moderate 
physical activities like carrying light loads, bicycling at a regular pace, 
or doubles tennis? 
 Do not include walking. 
  
 _____ days per week 
 







4.  How much time did you usually spend doing moderate physical 
activities on one of those days? 
  
 _____ hours per day 
 _____ minutes per day 
  
   Don’t know/Not sure 
 
Think about the time you spent walking in the last 7 days. This includes at 
work and at home, walking to travel from place to place, and any other 
walking that you might do solely for recreation, sport, exercise, or leisure. 
 
5.  During the last 7 days, on how many days did you walk for at least 10 
 minutes at a time? 
  
 _____ days per week 
 
   No walking → Skip to question 7 
 
6.  How much time did you usually spend walking on one of those days? 
  
 _____ hours per day 
 _____ minutes per day 
  
   Don’t know/Not sure 
 
The last question is about the time you spent sitting on weekdays during the 
last 7 days. Include time spent at work, at home, while doing course work 
and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading, or sitting or lying down to watch television. 
 
7.  During the last 7 days, how much time did you spend sitting on a 
week  day? 
  
 _____ hours per day 
 _____ minutes per day 
 
   Don’t know/Not sure 
 
This is the end of the questionnaire, thank you for 
participating. 
 
